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Abstract 
Recombinant therapeutic proteins have transformed the field of medicine since their 
advent more than twenty years ago, providing treatments for various refractory illnesses. 
Mammalian cells are the preferred hosts for the production of these therapeutics. 
However, a lack of understanding of the behavior of the cells results in numerous issues 
that affect the performance of process cultures including inefficient glucose metabolism 
and improper post-translational modification of the product proteins. With the advances 
in the knowledge of regulation of metabolism of mammalian cells and the availability of 
genomics and transcriptomics resources, systems biology approach combining kinetic 
model and “-omics” tools can now be used to address such issues. The work presented in 
this thesis employs such systems biology approach to better understand the metabolic 
behavior of the cells and devise strategies to enhance their performance in culture.  
Cultured mammalian cells consume huge amount of glucose and convert most of it 
towards lactate. The accumulation of lactate in culture adversely affects cell growth and 
productivity. The reliance of these cells on anaerobic glycolysis is also observed in 
proliferating cells such as cancer cells and embryonic stem cells. In contrast, quiescent 
cells metabolize glucose at slower rate and glucose is mostly oxidized to carbon dioxide. 
In the first part of this thesis, we attempt to unravel the regulation of glucose metabolism 
in proliferating and non-proliferating cells using a mechanistic model of glycolysis. We 
show that multiple allosteric regulations of glycolysis enzymes can act in synergy to 
confer bistable behavior to glycolysis activity: at a given glucose concentration, 
glycolysis can operate at either a high flux state or a low flux state. In proliferating cells, 
the default state of the cells is to operate at high glycolysis flux. However, it is possible to 
modulate factors extrinsic and intrinsic to the cells in order to make them switch to low 
flux state. 
In the late stages of fed-batch culture, mammalian cells have been observed to shift their 
metabolism from lactate production to lactate consumption. While it has been correlated 
with higher productivity, such metabolic shift is not a consistent occurrence as some 
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cultures continue to produce lactate. The metabolic model is used to explain the 
underlying mechanism behind the metabolic shift to lactate consumption in fed-batch 
culture. We show that the bistable behavior in glycolysis differs somewhat due to lactate 
inhibition and growth rate regulation on metabolism. As a result, the cells in culture may 
or may not shift their metabolism to consume lactate depending on the glucose, lactate 
and growth rate of the cells.  
In continuous culture, a similar metabolic behavior has been observed. With the same 
operating conditions of dilution rate and feed glucose concentration, some continuous 
cultures reach steady state with high glycolysis flux, while others reach steady state with 
low glycolysis. The two steady states are marked by distinct steady state cell 
concentrations. Using a multi-scale reactor model that combines the intracellular 
metabolism and macroscopic cell growth, we show that multiple steady states exist in 
continuous culture. At high flux steady state the vast majority of glucose is converted to 
lactate, whereas at low flux steady state most of the glucose consumed is converted to 
biomass. The two types of steady states thus have different metabolic efficiency, 
conferring different cell concentrations. 
In the final part of the thesis, RNA-seq and microarray are employed to survey the 
variability in CHO cell lines. We observe a wide range of transcript levels of glycolysis 
enzymes in CHO cell lines, potentially contributing to distinct metabolic characteristics 
in different cell lines. The extent of genetic variation in the protein coding regions of the 
growth signaling pathway genes in CHO cells are discussed. 
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Chapter 1 Introduction 
1.1 Mammalian Cell Culture 
The advent of recombinant protein therapeutics has transformed the field of medicine by 
providing treatments for various refractory diseases such as cancers, multiple sclerosis 
and arthritis. Ever since then, the proteins being produced have been increasing in 
structural complexity and many require post-translational modifications for their 
activities and efficacies. Proper protein folding and complex glycosylation modifications, 
for example, are carried out in the endoplasmic reticulum and Golgi of mammalian cells. 
Because of their capability to carry out these functions, mammalian cells have become 
the preferred hosts for recombinant protein production. 
A number of mammalian cells have been used for therapeutic protein production in the 
industry including Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) 
cells, myeloma (NS0, SP2/0), HeLa and Vero. In 2012, the total annual sales of biologics 
produced in mammalian cells surpassed US $63 billion in the United States and US $125 
billion globally [1,2]. Among all the mammalian cells used for production, CHO cells are 
indisputably the major workhorse, accounting for the production of an estimated 60% of 
the therapeutic proteins.  
Despite the importance of mammalian cells for protein production, a lack of 
understanding of their behavior in the cultivation process presents a huge challenge for 
developing robust process technologies. A typical process development is performed 
empirically and requires extensive optimization of parameters including nutrient levels, 
temperature and pH. These parameters, however, have limited control on the physiology 
of the cells. As a result, inefficient metabolism, low productivities, and undesired post 
translational modifications of the product proteins are still plaguing the process industry. 
To add further complication, the majority of mammalian cell lines are transformed cells 
that have been cultivated for a large number of generations and adapted to grow in 
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different culture modes. Accumulation of mutations in the genome and alteration in the 
gene expression of the cells can potentially influence their behavior in culture. 
In this study, we employ mathematical models of energy metabolism of mammalian cells 
using systems biology approach to provide a holistic understanding of the cells’ 
physiology. In addition, the availability of genomics and transcriptomics tools allows one 
to examine the genetic makeup of the cells and survey the global gene expression levels 
of the cells. We combine the modeling effort with the quantitative information gathered 
from these “-omics” tools to dissect the physiological function of the cells and conceive 
strategies for controlling their behavior and enhance their performance for protein 
production. 
1.2 Scope of the Thesis 
Mammalian cells used for protein production have inefficient metabolism. Under normal 
culture conditions, cells consume glucose at very high rate and a large proportion of the 
glucose consumed is converted towards lactate. Lactate produced by the cells is secreted 
outside and accumulates in the extracellular medium. The decrease in pH due to lactate 
accumulation in the medium is detrimental to both cell growth and productivity. Base is 
typically added to the culture to neutralize the pH. However, this results in increased 
culture osmolarity causing additional stress on the cells. Therefore, controlling the 
metabolism of the cells to reduce lactate production is critical for favorable process 
outcome. 
Industrially, the predominant cultivation method is fed-batch process, wherein glucose is 
fed regularly to the medium to sustain cell growth until the accumulation of lactate to 
high levels adversely affects cell growth and viability. In the later stages of this fed-batch 
process, sometimes a metabolic shift from a high lactate production state to a state of 
lactate consumption occurs. In other cases of seemingly identical culture conditions, cells 
continue to produce lactate. Cultures that exhibit metabolic shift to lactate consumption 
have been correlated with increased viability and higher productivity [3,4]. However, 
such metabolic shift is not a consistent occurrence and its underlying mechanism is not 
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well understood. Identifying the mechanism for such metabolic shift and the means to 
elicit it will be of crucial importance.  
Another cell cultivation method practiced in industry is continuous culture, wherein feed 
media is being added continuously while reactor content is withdrawn at equivalent flow 
rate, keeping the reactor volume constant. Under seemingly identical operating conditions 
of dilution rate and feed glucose concentration, some continuous cultures reach steady 
state with high glycolysis flux, while others reach steady state with low glycolysis. The 
two types of steady state have different metabolic efficiency. At high flux steady state the 
vast majority of glucose is converted to lactate, whereas at low flux steady state most of 
the glucose consumed is converted to biomass. Thus different steady states are marked by 
distinct steady state cell concentrations. Understanding the precise conditions that lead to 
steady state with low glycolysis flux and high cell concentration will be of great interest. 
In this study, we use a mechanistic kinetic modeling approach to unravel the regulation of 
energy metabolism in mammalian cells. We show that the synergistic action of enzyme 
regulations gives rise to steady state multiplicity in glycolysis. Within a range of glucose 
concentrations, two metabolic states corresponding to high glycolysis flux and low 
glycolysis flux exist for a given glucose concentration. We then use the metabolic model 
to explain the mechanism behind the metabolic shift to lactate consumption in fed-batch 
culture. Further, we also explain the nature of multiple steady states in continuous culture 
using a multi-scale model that incorporates the intracellular metabolism and macroscopic 
cell growth in the reactor. 
In the final part of this thesis, we explore the gene expression and genetic variations in 
CHO cell lines. Using genomics and transcriptomics tools, we assess the diversity in gene 
expression and the rate of mutation in CHO cell lines. Such variations at transcript and 
genomic levels potentially contribute to the diverse metabolic and growth behaviors of 
different CHO cell lines.  
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1.3 Thesis Organization 
This thesis is organized into eight chapters. Chapter 2 reviews the current knowledge of 
regulation of the central metabolic pathways in mammalian cells. Chapter 3 presents a 
summary of the methodology employed in cell cultures and analyses. Chapter 4 focuses 
on the modeling effort to study the effect of the allosteric regulations on the activity of 
the glycolysis pathway in proliferating and non-proliferating cells. Chapter 5 examines 
the mechanism of metabolic shift to lactate consumption in the fed-batch cultures of 
mammalian cells. The crucial parameters for inducing metabolic shift in fed-batch 
cultures are discussed. Chapter 6 focuses on the construction of a multi-scale kinetic 
model and the analysis of multiple steady states in continuous culture of mammalian 
cells. The steady state multiplicity behavior is harnessed to contrive strategies to achieve 
higher cell concentration in continuous culture of hybridoma cells. Chapter 7 presents the 
use of genomic and transcriptomic tools to examine gene expression and genetic 
variations in a number of CHO cell lines. The impact of such variations on the metabolic 
behavior of the cell lines is discussed. Chapter 8 summarizes the findings of this study 
and provides suggestions for future directions. 
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Chapter 2  Regulation of Energy Metabolism in 
Mammalian Cells 
2.1  Summary 
Energy metabolism of mammalian cells profoundly affects the performance of the 
culture. Cultured mammalian cells used in the industry exhibit wasteful metabolism 
characterized by the high rates of glucose consumption and lactate production. The 
accumulation of lactate in the extracellular medium adversely affects cell growth and 
productivity of the culture. Engineering the metabolism of the cell to be more efficient 
has therefore been the major focus of cell line and process optimization efforts in the 
industry. Recent research advances have increased our understanding of the regulation of 
glucose metabolism in mammalian cells and its link to the control of cell growth and 
proliferation. This chapter discusses the current understanding in this area of crucial 
importance to cell culture processes. 
2.2  Introduction 
Cultured mammalian cells are the workhorses for the production of recombinant 
therapeutic proteins. The majority of the cells used for manufacturing are continuous cell 
lines which have been cultivated for a large number of generations and are often 
aneuploid. Under normal culture conditions, these cells consume large quantity of 
glucose and convert the majority of it to lactate which is secreted into the extracellular 
medium. The hypermetabolic nature of the cells and their over reliance on aerobic 
glycolysis is referred to as the Warburg effect, and was first used to describe the contrast 
the metabolism of cancer cells and normal tissues. In industrial cell culture, lactate 
accumulation in the medium can reach levels of more than 100 mM which adversely 
affects cell growth and viability as well as productivity of the culture. A better 
understanding of metabolic regulation will allow for a better control of the metabolic 
state of the cell, which would lead to an increase in productivity. In recent years, much 
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progress has been made in elucidating the regulation of cell metabolism. This chapter 
presents some of the main findings relevant for process enhancement. 
2.3  Regulation of Enzyme Kinetics 
A host of enzymes in the central metabolism pathways are under allosteric regulations by 
metabolic intermediates or by various post translation modifications.  Such a regulation at 
the level of kinetics confers cells with an ability to modulate the flux in an acute manner 
to respond to the changing nutritional and energetic requirements of the cells.  
Furthermore, many enzymes exist as multiple isoforms (isozymes) which differ in their 
substrate affinities and the allosteric regulations they are subjected to. These isozymes are 
expressed in different proportions in different cells or tissues. Thus different cells exhibit 
different metabolic behaviors depending on the composition of isozymes being 
expressed.  
The key rate-controlling enzymes in the glycolysis pathway include hexokinase (HK), 
phosphofructokinase (PFK), 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 
(PFKFB) and pyruvate kinase (PK) among few others.  As stated earlier, allosteric 
regulations of enzyme kinetics are specific to the isozyme expressed.  For example, 
hexokinase isozymes HK1, 2 and 3 are inhibited by glucose 6-phosphate (G6P) whereas 
HK4 (also called as glucokinase) is devoid of the G6P inhibition (Figure 2.1).   Further, 
HK inhibition by G6P (or trehalose 6-phosphate in yeast) has been shown to be required 
for reaching a metabolic steady state [5].  Relieving this inhibition has been shown to 
result in an imbalanced state where cells accumulate glycolytic metabolites affecting their 
growth negatively.  
PFK is one of the flux controlling enzymes in the glycolysis pathway which is heavily 
regulated.  In mammalian cells, PFK exists in three different isoforms: the liver isozyme 
(PFKL), the muscle isozyme (PFKM) and the platelet isozyme (PFKP). The classic 
modulators of the PFK include fructose 6-phosphate (F6P), fructose 2,6-bisphosphate 
(F26BP), fructose 1,6-bisphosphate (F16BP), adenosine monophosphate (AMP), 
adenosine triphosphate (ATP), citrate and lactate among few others (Figure 2.1).  The 
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affinity of the enzyme PFK to these modulators is also isozyme dependent. For example, 
all three isoforms of PFK are activated by F6P and F26BP [6], but only PFKM and PFKL 
are activated by F16BP [7-9]. More recently, PFK kinetics has been shown to be 
regulated in a post-translational fashion.  O-GlcNAcylation at the Ser
529
 site was shown 
to interfere with the binding of F26BP molecule to PFK and thus decreases the allosteric 
activation of the PFK enzyme by F26BP [10]. Such an inhibitory effect reduces the flux 
through the glycolysis pathway and diverts it toward the pentose phosphate pathway for 
supplying carbon for biosynthetic needs of the cells. Further, this regulation is isozyme 
dependent with PFKL and PFKP being more sensitive to O-GlcNAcylation.   
PFKFB is a bifunctional enzyme whose kinase and bisphosphatase domains catalyze the 
formation and hydrolysis reaction of F26BP, respectively [11,12].  There are four 
mammalian PFKFB isozymes: PFKFB1, 2, 3 and 4. Isozymes of PFKFB differ in their 
relative ratio of kinase to phosphatase activities and thus give rise to different cellular 
F26BP concentrations [12]. F26BP is a very potent activator of the enzyme PFK. Thus, 
each isozyme of PFKFB has a distinct capacity in modulating PFK activity (and thereby 
glycolysis activity). The PFKFB3 isoform, which has the highest kinase to phosphatase 
ratio, is highly expressed in several tumor cells. 
Pyruvate kinase is another rate controlling enzyme which is expressed as four different 
isozymes in mammalian systems: M1, M2, L and R isozymes.  The L and R isoforms are 
spliced variants expressed by the same gene in liver and red blood cells, respectively. The 
M1 and M2 isoforms are spliced variants expressed by another gene. PKM2 is one of the 
most studied isozymes as it has been linked to rapid proliferation and nutrient sensing. 
The M2 isozyme is regulated at allosteric level by a number of intermediates, both from 
glycolysis and other metabolic pathways.  F16BP is the most well-known allosteric 
activator of PKM2 (Figure 2.1). Recently, succinylaminoimidazolecarboxamideribose-5′-
phosphate (SAICAR), an intermediate of de novo purine nucleotide biosynthetic 
pathway, was identified as another allosteric activator of PKM2 [13]. Under low glucose 
conditions (or starvation), SAICAR accumulates in the cells and induces PKM2 activity. 
Induction of PKM2 activity by SAICAR provides a way for the cells to maintain 
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glycolysis flux to be high for ATP synthesis under reduced glucose availability. Thus, 
SAICAR allows cells to fine-tune control of their metabolism under demanding 
conditions for energy production rather than diverting the flux towards the pentose 
phosphate pathway for de novo nucleotide biosynthesis [13].  PKM2 is also allosterically 
regulated by a number of amino acids including serine and phenylalanine. This allows 
PKM2 to operate as a nutrient sensor.  Positive regulation by serine gives the enzyme the 
ability to operate as a rheostat for maintaining the intracellular level of serine.  Under 
conditions of low serine, the activity of PKM2 drops resulting in a higher channeling of 
3-phosphoglycerate (3PG) toward serine biosynthesis (Figure 2.1) [14].  Conversely, 
when intracellular level of serine increase, PKM2 is activated and 3PG is channeled 
toward pyruvate for lactate production or energy synthesis.  In the case of essential amino 
acids such as phenylalanine, which acts as an allosteric inhibitor of PKM2, the regulation 
allows the cells to increase catabolic metabolism for ATP synthesis and repress cell 
proliferation under conditions of phenylalanine starvation [15].   
Furthermore, PKM2 has also been reported to respond to other physiological factors such 
as the tyroid hormone T3 and reactive oxygen species (ROS).  The T3 hormone, a pro-
growth hormone, has been shown to trap the M2 isoform in the monomeric state and 
thereby restraining the enzyme in its low activity state [15].  Similarly, oxidative stress 
has been demonstrated to reduce the isozyme activity through oxidation of the Cys
358
 
residue [16].  The reduction of PKM2 activity allows channeling of the glycolytic 
intermediates towards branching pathways to generate biosynthetic precursors such as 
NADPH and ribose nucleotides among others, required for cellular proliferation.  The 
reducing agents generated are also used to trigger the antioxidant response when cells 
undergo oxidative stress. 
9 
 
 
Figure 2.1: Regulation of glycolysis enzymes in proliferating cells. The rate-
controlling enzymes of glycolysis HK, PFK and PK are heavily regulated by a host of 
enzyme activity modulators.  
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2.4  Regulation of Glucose Metabolism by Signaling Pathways and 
Growth Control Elements 
Cells, in their native environments, adjust the rate at which they metabolize glucose and 
amino acids in response to external and internal signals. The external stimuli include 
metabolic hormones and growth factors, such as insulin, glucagon and epidermal growth 
factor, as well as cues from nutrient abundance or scarcity. An internal stimulus could be 
the energetic state of the cells or the growth conditions such as stress. At the core of the 
interface between energy metabolic pathways and those stimuli are signaling pathways 
that transduce the external cues to the internal regulators of energetic state and growth 
control elements that ultimately influence metabolic fluxes. When growth control goes 
awry, such as in cancer cells or continuous cell lines, a concomitant alteration in energy 
metabolism is observed, possibly through these coordinated regulations of growth and 
metabolism. 
2.4.1  AKT1 
AKT1 is a serine/threonine protein kinase that plays a key role in regulating a range of 
cellular processes such as glucose metabolism, apoptosis, cell growth and proliferation. 
Alterations that cause constitutive activation of AKT1, such as in cancer cells, result in 
dysregulation of these cellular functions. Activation of AKT1 is mediated by 
phosphoinositide 3-kinase (PI3K), a kinase downstream of the insulin receptor substrate 
(IRS) (Figure 2.2). The activated AKT1 stimulates glycolysis flux by increasing the 
transcription and plasma membrane localization of the glucose transporter, GLUT1 [17]. 
AKT1 also mediates the association of hexokinase 1 and 2 (HK1 and HK2) with outer 
mitochondrial membrane [18,19], providing direct access to ATP generated by 
mitochondria for increased activity of HK. In addition, activated AKT1 also increases the 
phosphorylation of PFKFB to shift its kinase/phosphatase ratio to increase the formation 
of F26BP [20-22], which in turn increases PFK activity and glycolysis flux. CHO and 
SP2/0 cells express high levels of AKT1, indicating the potential role it may play in 
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conferring high glycolytic nature of these cells. Interestingly, inhibition of AKT1 using 
LY294002 in SP2/0 cells caused a reduced phosphorylated (active) state of AKT1 and 
decreased glucose metabolism of the cells [23]. 
In addition, AKT1 also plays a role in coordinating glucose and lipid metabolism. Citrate 
generated in the mitochondrial TCA cycle is exported to the cytoplasm, where it is 
utilized for Acetyl CoA generation by the enzyme ATP-citrate lyase (ACL). ACL is 
directly phosphorylated and activated by AKT1 [24]. By increasing citrate utilization, 
AKT1 may help in driving the TCA cycle flux, in addition to providing precursors for 
lipid biosynthesis for new cell membrane generation. 
AKT1 is also linked to positive regulation of cell survival and proliferation through 
inhibition of several pro-apoptotic proteins by regulating their transcription or 
phosphorylation. AKT1 can phosphorylate the Bcl-2-associated death promoter (BAD) 
protein on Ser
136
 which leads to an inhibition of cytochrome c release in response to 
apoptotic stimuli [25,26]. Furthermore, AKT1 promotes cell growth by activating the 
global growth regulator mechanistic target of rapamycin complex 1 (mTORC1).   
2.4.2  mTORC1 
The mechanistic target of rapamycin (mTOR) is a serine/threonine protein kinase that 
integrates various upstream signals including stress, growth factors and nutrients 
availability and relay this information to control multiple cellular processes including 
growth, proliferation, survival, and protein synthesis. mTOR forms two structurally 
distinct complexes: mTOR complex 1 (mTORC1) and 2 (mTORC2). mTORC1 consists 
of mTOR, regulatory-associated protein of mTOR (Raptor) and other core and non-core 
components. mTORC1 functions as a nutrient, energy and redox sensor and controls 
protein synthesis. The activity of mTORC1 is stimulated by growth factors, amino acids 
and oxidative stress. mTORC2 consists of mTOR, rapamycin-insensitive companion of 
mTOR (Rictor) and other components. mTORC2 acts as a regulator of the cytoskeleton. 
In this review, our focus is strictly on mTORC1 regulations. 
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Activation of mTORC1 requires both growth factors and amino acids availability. Insulin 
and other growth factors signal through the PI3K/AKT signaling pathway (Figure 2.2). 
Activation of AKT1 inhibits the activity of the heterodimer consisting of tuberous 
sclerosis 1 and 2 (TSC1 and 2). The TSC1/TSC2 complex is a negative regulator of 
mTORC1. Inhibition of the TSC1/TSC2 complex by AKT, therefore results in the 
activation mTORC1. mTORC1 also requires amino acids, particularly leucine, for its 
activation. Activation of mTORC1 by amino acids is mediated by the Rag-GTPases 
(Figure 2.2). Intracellular nutrients only basally activate mTORC1, but are essential for 
robust stimulation of mTORC1 by growth factors.  
Global cellular protein synthesis is regulated by mTORC1 through direct phosphorylation 
of the eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and the p70-
S6 kinase 1 (S6K1). Phosphorylation of 4EBP1 releases the eukaryotic translation 
initiation factor 4E (eIF4E) allowing it to participate in the formation of the cap-
dependent translation initiation complex. Activation of S6K1 by mTORC1 stimulates 
protein synthesis through the activation of the S6 ribosomal protein and allowing its 
recruitment to the pre-initiation complex. Through 4EBP1 and S6K1, mTORC1 signaling 
can globally enhance protein synthesis in the cells. 
mTORC1 positively affects cellular metabolism and increases the flux of glycolysis. 
Activation of mTORC1 has been shown to globally upregulate the expression of the 
genes in the glycolysis, the lipid biosynthesis and the pentose phosphate pathways [27]. 
The action of mTORC1 is mediated by two major downstream effectors: the hypoxia-
inducible factor 1-alpha (HIF1α) protein and the sterol regulatory element-binding 
proteins (SREBPs). mTORC1 enhances the translation of HIF1α mRNA through 
phosphorylation of 4EBP1 [27,28]. The increase in HIF1α protein level results in the 
induction of glucose transporters and many glycolytic enzymes and promotes a switch 
from mitochondrial oxidative metabolism to glycolysis (to be described in a later 
section). mTORC1 activation also dramatically increases the processing of SREBPs to 
their active forms through the action of S6K1 [27,29,30]. Activation of SREBPs induces 
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global expression of genes involved in the oxidative branch of pentose phosphate 
pathway and lipid biosynthesis. 
2.4.3  AMPK 
AMP-activated protein kinase (AMPK) is an enzyme that plays a key role in sensing the 
cellular energy level. An increase in the cellular AMP and a decrease in the cellular ATP 
levels such as during nutrient deprivation and hypoxia result in the activation of AMPK. 
Upon activation, AMPK inhibits anabolic ATP-consuming processes such as fatty acid 
and protein synthesis, and initiates catabolic ATP-producing processes including glucose 
catabolism and fatty acid oxidation [31,32]. Critical to this is the role of AMPK as an 
antagonist of mTORC1. When ATP levels are low, AMPK activates TSC2 and 
inactivates Raptor through phosphorylation, resulting in the suppression of mTORC1 
activity (Figure 2.2) [33,34]. Suppression of mTORC1 activity by AMPK under low ATP 
levels thus results in the inhibition of anabolic processes including cell growth, protein 
synthesis and lipid synthesis.  
AMPK also functions independently of mTORC1. AMPK promotes glucose catabolism 
under low cellular ATP level by inducing the expression of the glucose transporters 
GLUT1 and GLUT4 and stimulating their translocation to the plasma membrane [35,36]. 
AMPK has also been shown to directly phosphorylate multiple isoforms of the glycolysis 
enzyme PFKFB [37,38]. Phosphorylation of PFKFB serves as a conduit for AMPK as a 
cellular energy sensor to modulate glycolysis flux. In addition, AMPK is capable of 
inhibiting ATP-consuming processes including fatty acid and cholesterol synthesis by 
phosphorylating the enzymes acetyl-CoA carboxylase (ACC1) [39] and HMG-CoA 
reductase (HMGCR) [40]. 
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Figure 2.2: Regulatory roles of the PI3K/AKT/mTORC1 and AMPK signaling 
pathways in mammalian cells. The receptor tyrosine kinases are stimulated upon 
association with their ligands (insulin/IGF). The activated receptors recruit IRS1 and 
IRS2 (not shown), which cross-phosphorylate each other and recruit PI3K. Subsequently, 
PI3K is activated, which catalyzes the synthesis of phosphatidylinositol (3,4,5)-
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triphosphate (PIP3) and recruits 3-phosphoinositide-dependent kinase 1 (PDK1) and 
AKT to the plasma membrane. Afterwards, PDK1 phosphorylates and activates AKT. 
Once active, AKT triggers pleiotropic effects, such as growth and protein translation. 
AKT phosphorylates TSC2 and inhibits its role as GTPase activating protein (GAP) for 
Rheb thereby increasing the levels of GTP-bound Rheb. Association of GTP-bound Rheb 
with mTORC1 stimulates its activity, which subsequently facilitates growth and protein 
translation through inhibition of 4EBP1 and activation of S6K1. AKT also stimulates 
glycolytic activity by increasing the transcription and membrane localization of GLUT1, 
increasing HK activity by mediating its association with outer mitochondrial membrane 
and increasing the activity of PFKFB. The figure also shows the regulatory roles of 
AMPK. AMPK is activated under the conditions of high levels of AMP and low levels of 
ATP such as during metabolic stresses by nutrients deprivation. Once activated, AMPK 
phosphorylates TSC2 to activate its GAP activity for Rheb thereby decreasing the levels 
of GTP-bound Rheb. AMPK also phosphorylates the Raptor component of mTORC1 
resulting in the inhibition of its activity. Altogether, they result in negative regulation of 
mTORC1 activity, which reduces growth and protein translation. Similar to AKT, AMPK 
promotes glycolysis activity through induction and translocation of GLUT4 to cell 
membrane and phosphorylation of PFKFB to increase its activity. AMPK also 
phosphorylates the enzymes ACC1 and HMGCR to inhibit the synthesis of lipid and 
cholesterol.   
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2.4.4  HIF1α 
The hypoxia-inducible factor (HIF) family consists of three members: HIF1, 2 and 3. 
HIF1 is ubiquitously expressed while HIF2 is expressed only in kidney, heart, lung and 
endothelial cells; HIF3 is poorly understood [41]. Each HIF is composed of a heterodimer 
of α and β subunits. HIF1β subunit is constitutively expressed in the cells while the level 
of HIF1α subunit is subject to cellular regulation. The protein level of HIF1α is regulated 
in oxygen dependent manner by prolyl hydroxylation. Under normal oxygen tension, 
HIF1α subunits are modified by prolyl hydroxylases (PHDs) which promotes their 
recognition by the von Hippel-Lindau (VHL) ligase resulting in the proteasomal 
degradation of HIF1α [42]. Under hypoxic conditions, where oxygen tensions are low, 
these PHDs are inhibited resulting in the stabilization of HIF1α protein level.  
HIF1α promotes aerobic glycolysis through increased transcription of many glycolysis 
genes and inhibition of mitochondrial oxidation. The transcription of specific isozymes in 
glycolysis LDHA, PFKL and PKM2 among many others are upregulated upon hypoxia 
(Figure 2.3) [43-45]. In addition, HIF1α induces the transcription of pyruvate 
dehydrogenase kinase 1 (PDK1), which represses the pyruvate dehydrogenase complex 
(PDH), leading to decreased flux to mitochondria [46]. Altogether, these results in the 
inhibition of glucose flux from entering mitochondria and diverting it towards lactate 
production. While HIF1α is mostly active in hypoxic conditions, cancers with VHL 
deficiency exhibit constitutive activation and stabilization of HIF1α even in oxygenated 
environments.  
Furthermore, the catabolic intermediates of glucose metabolism have also been shown to 
induce HIF1α stabilization in normoxic conditions. The intermediates mainly include the 
2-oxo acids including pyruvate and oxaloacetate, among few others.  The effect of 
pyruvate and oxaloacetate on HIF1α is attributed to the inactivation of the PHD enzymes. 
One hypothesis is that these metabolites render the state of the enzyme to be inactive by 
oxidizing a specific amino acid residue or by changing the oxidation state of the iron, a 
cosubstrate required for the hydroxylation reaction.  This inhibition of the PHDs has been 
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shown to be reversible and can be relieved when treated either with amino acids, 
including cysteine and histidine, or ferrous (Fe(II)) ion. In addition to the glucose 
intermediates, accumulation of succinate or fumarate has been shown to induce HIF1α 
stabilization [47,48]. These compounds inhibit PHDs by interacting directly with the 
substrate binding site of the enzyme. 
In fed-batch processes used for therapeutic protein production, typically the processes are 
designed such that the extracellular medium is replete of nutrients, including glucose and 
amino acids. However, depending on the feeding strategies employed and process 
parameters used, the nutrient levels in the medium can fluctuate across different 
processes. Such fluctuations can induce normoxic stabilization of HIF1α provided that 
the right nutrient conditions are met in the medium.  Of late it has been observed in some 
fed-batch processes that lactate is produced late in culture after a period of lactate 
consumption or low lactate production.  Such lactate production occurs upon increased 
feeding of nutrients.  Hence, the normoxic stabilization of HIF1α could be one of the 
potential causes of upregulation of glycolysis and lactate production in the late stages of 
these fed-batch processes. 
2.4.5  cMYC 
The cMYC proto-oncogene is a transcription factor that can activate a large number of 
genes through binding to the enhancer box (E-box) sequences. Activation of cMYC in the 
presence of mitogenic factors including Wnt and epidermal growth factor (EGF) affects 
myriad of cellular processes including proliferation, metabolism and apoptosis. In many 
cancer cells, mutations in the cMYC gene result in its constitutive activation independent 
of growth factors presence or unregulated expression that leads to very high cMYC 
transcript levels.  
cMYC has been shown to induce the expression of many glycolysis genes including 
LDHA, PFK, GLUT1, GPI, PGAM and ENO [49]. cMYC shares a large number of 
overlapping target genes with HIF1α due to the striking similarity in their binding motifs 
(Figure 2.3) [45,50,51]. The elevated expression of glycolysis genes in cells with 
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dysregulated cMYC or HIF1α further supports the notion of increased reliance on aerobic 
glycolysis in cancers. Induction of cMYC also results in the upregulation of the 
glutamine transporter ASCT2 and glutaminase (GLS), leading to increased consumption 
of glutamine in cancer cells [52]. 
2.4.6  p53 
p53 is a major tumor suppressor gene that plays a crucial role in regulating cell cycle. It is 
activated upon stimulation by numerous stressors including DNA damage, osmotic 
shock, oxidative stress, and deregulated oncogene expression. p53 also affects glucose 
metabolism. Increased expression of p53 reduces the transcription of GLUT1 and 
GLUT4 [53]. In addition, p53 also downregulates the activity and cellular protein level of 
the enzyme phosphoglycerate mutase (PGAM) [54]. Many tumor cells with dysfunctional 
p53 display elevated levels of PGAM, resulting in lower level of its substrate 3-
phosphoglycerate (3PG) and higher level of its reaction product 2-phosphoglycerate 
(2PG) (Figure 2.3) [55]. 3PG is an inhibitor of 6-phosphogluconate dehydrogenase 
(6PGD), the rate controlling enzyme in the pentose phosphate pathway. In addition, 2PG 
is an activator of 3-phosphoglycerate dehydrogenase (3PGDH), the first enzyme in the 
serine biosynthesis pathway. Accordingly, 6PGD and 3PGDH are stimulated in these 
tumors with elevated PGAM, resulting in the channeling of the glycolytic flux towards 
pentose phosphate pathway and serine biosynthesis [55].   
Furthermore, p53 has been shown to induce the expression of the protein TP53-induced 
glycolysis and apoptosis regulator (TIGAR). TIGAR has a high functional homology 
with the phosphatase domain of the enzyme PFKFB, which catalyzes the hydrolysis of 
F26BP [56]. Thus induction of TIGAR by p53 results in a decrease in the level of F26BP 
and leads to subsequent reduction in the activity of PFK and glycolysis flux. 
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Figure 2.3: Regulatory roles of HIF1α, cMYC and p53 in mammalian cells. HIF1α 
protein level is stabilized under hypoxic conditions resulting in the induction of the 
expression of most glycolysis genes and PDK1. PDK1 subsequently phosphorylates PDH 
resulting in its inhibition which prevents glucose flux from entering the mitochondrial 
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TCA cycle. Also shown in the figure are the regulations by cMYC and p53. cMYC also 
induces a large number of glycolysis genes. The similarity in the binding motifs of 
cMYC and HIF1α results in a huge overlap of target genes. cMYC also strongly regulates 
glutaminolysis through the upregulation of the expression of GLS and ASCT2. Unlike 
HIF1α and cMYC, p53 decreases the activity of glycolysis by suppressing the 
transcription of GLUT1, by decreasing the F26BP through upregulation of TIGAR and 
by downregulating the protein levels of PGM. 
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Chapter 3 Materials and Methods 
3.1  Mathematical Model of Central Metabolism Pathway 
A kinetic metabolic model of energy metabolism of mammalian cells that encompasses 
glycolysis, pentose phosphate pathway (PPP), tricarboxylic acid (TCA) cycle, malate-
aspartate shuttle and other inter-compartmental shuttles (between the cytosol and the 
mitochondria compartments) was constructed (Figure 3.1). The ordinary differential 
equation (ODE) model consists of mass balance equations for 40 reaction intermediates 
of the central metabolic pathways considered (Appendix Materials, Differential 
Equations section). The rate expressions for all enzymatic reactions were based on 
mechanistic derivation [57].  The rate expressions and the kinetic parameters along with 
their sources are listed in the Rate Equations section of the Appendix Materials. Many 
reactions are catalyzed by isozymes which differ not only in their rate constants but also 
in the type of the regulatory mechanisms they are subjected to. The allosteric regulations 
of these isozymes, specifically those of PFK, PFKFB and PK are considered in detail 
based on the Monod-Wyman-Changeaux method [58]. The levels of enzymes (or 
alternatively the Vmax) were obtained from their corresponding transcript levels in 
cultured cells, assuming that the protein level is proportional to the transcript [23] and are 
listed in the Rate Equations section of the Appendix Materials. 
In Chapter 4, the analyses focus on the allosteric regulations of glycolysis. A reduced 
model comprising of only the glycolysis pathway, the lactate production, and the 
pyruvate transport (Equations 1-13 in Appendix Materials, Differential Equations 
section) is therefore used in order to isolate the system.  
In Chapter 5, we examine the shift in the metabolism of cultured mammalian cells from 
lactate production to lactate consumption. The complete model is therefore used since it 
is necessary to consider the uptake of lactate from the extracellular medium and its 
further oxidation in the TCA cycle (Figure 3.1, also see Equations 1-40 in Appendix 
Materials, Differential Equations section). The complete model also takes into account 
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the malate-aspartate shuttle pathway which transfers the reducing potential of cytosolic 
NADH into mitochondria. The malate-aspartate shuttle pathway thus plays a crucial role 
in maintaining the balance of NAD/NADH in the cytosolic compartment and is especially 
critical for the switch of metabolic state. In addition, lactate consumption phase occurs in 
the late stage of fed-batch cultures when the growth rate of the cells has slowed down 
significantly. The regulation of glycolysis flux by growth control is thus modeled by an 
activation of the kinase activity of the bifunctional enzyme PFKFB using an empirical 
formulation depicting an increasing kinase activity with increasing pAKT in a saturation 
type of kinetics (Equation S4 in Appendix Materials, Rate Equations section). A similar 
expression has been used previously to describe the effect of AKT on glycolysis [59,60].  
In Chapter 6, we analyze the growth and metabolism of mammalian cells in the 
continuous culture. A multi-scale model is therefore constructed which incorporates the 
complete intracellular metabolic model described above and additional three mass 
balance equations describing cell growth, glucose and lactate concentrations in the 
bioreactor (Figure 3.2, also see Equations 1-44 in Appendix Materials, Differential 
Equations section). The rates of glucose consumption and lactate production are 
determined by the rates of intracellular metabolism of the cells (Equations 41 and 42 in 
Appendix Materials, Differential Equations section). The specific growth rate of the cells 
is assumed to follow Monod type kinetics with respect to glucose concentration and an 
inhibitory effect of lactate (Equation 44 in Appendix Materials, Differential Equations 
section) as described previously [61]. AKT activity is correlated to the growth rate of the 
cells. However, for the range of dilution rates considered in this study, growth rate is high 
and AKT is assumed to be fully active at all dilution rates.  
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Figure 3.1: Kinetic model of the central metabolic pathways. The pathways include 
glycolysis, TCA cycle, pentose phosphate pathway (PPP) and the NAD/NADH shuttles 
between cytosol and mitochondria.  
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Figure 3.2: Schematic of the multi-scale reactor model. The model takes into account 
the intracellular metabolism of the cell and substrate utilization for macroscopic cell 
growth in the reactor. Notations: V, reactor volume; F, volumetric flowrate; s, glucose; L, 
lactate; x, cell concentration. 
3.1.1  Steady State Solution 
An algebraic model consisting of the steady state mass balance equations for the 
intermediates of all the reactions considered was derived from the ODE model. The 
algebraic model was used to find all the possible steady states and the corresponding 
eigenvalues.  The inputs are the glucose concentration only for the reduced model; the 
glucose and lactate concentrations for the complete model; and the dilution rate and feed 
glucose concentration for the multi-scale model. In the simulations, intracellular 
concentrations of energy nucleotides (ATP, ADP, AMP) and metal ions influencing the 
kinetics of glycolytic enzymes (Mg
2+
, K
+
, Ca
2+
) were set to be constant in order to 
insulate the behavior of the system from the effect of their concentration fluctuations.  
The fixed concentrations of these cofactors are tabulated in Appendix Table 1. The steady 
state solutions were obtained using the numerical solver fsolve in Matlab (Mathworks, 
Inc.). Positive and real-valued steady state solutions were calculated using initial guesses, 
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which were pseudorandom values drawn from the standard uniform distribution. Stability 
analysis was performed using eigenvalue analysis on each of the steady state solution 
obtained. In addition, all the intracellular concentrations at steady state were verified to 
ensure that they are within the same order of magnitude as the physiological range. For 
simulations using the complete model, the lactate export flux at steady state is generated. 
However, the concentration of lactate in the extracellular medium is dependent on the 
reactor volume, the cell concentration achieved and the duration of time that lactate is 
allowed to accumulate. We thus simulated the condition that extracellular lactate level is 
fixed independent of the lactate export flux. 
3.1.2  Transient Simulation 
Transient simulations of the complete model, which are discussed in Chapter 5, were 
performed using the ODE solver ode15 in Matlab. The initial concentrations of 
extracellular glucose and lactate were 35 and 5 mM, respectively. The cell concentration 
was assumed to be constant at 2 x10
7
 cells/mL throughout the duration of the simulation. 
pAKT activity was held constant at 0.17 in order to confine the simulations to the 
moment when the metabolic fate starts to diverge. 
Transient simulations of the multi-scale model, which are discussed in Chapter 6, were 
performed using the ODE solver ode15 in Matlab. The initial cell and lactate 
concentrations were 1.5x10
5
 cells/mL and 0 mM, respectively. For the batch culture 
simulation, the dilution rate was set to zero and the initial glucose concentration used was 
15 mM. For the fed-batch culture, the dilution rate was set to zero and the extracellular 
glucose concentration was fixed at 0.5 mM by setting the right hand side of the 
differential equation for extracellular glucose (Equation 41 in Appendix Materials, 
Differential Equations section) to zero. Upon switching to continuous mode, the dilution 
rate was set at 0.033 h
-1
 and the feed glucose concentration was 7 mM. Changes in the 
extracellular concentrations of glucose, lactate and cell and the intracellular 
concentrations of all metabolites were followed.  
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3.1.3  Stability Analysis 
For a system of ordinary differential equation  
dx
f x
dt
 , where nx R and : n nf R R
, the Jacobian matrix, J  is the n n matrix defined by ij i jJ f x   . The local stability of 
a steady state was investigated using the standard approach of calculating the eigenvalues 
of the Jacobian evaluated at the steady state. If all the eigenvalues have negative real part, 
the steady state is stable, if not it is unstable. The Jacobian matrix was calculated as part 
of the output of Matlab’s fsolve function. The eigenvalues of the Jacobian matrix were 
evaluated using Matlab’s eig function.  
3.2  Single Nucleotide Variant Analysis 
The pipeline for identification of single nucleotide variants in RNA-seq reads, which are 
discussed in Chapter 7, and the programs used are shown in Figure 3.3. 
  
Figure 3.3: Workflow for single nucleotide variant detection. 
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3.2.1  Mapping and Local Realignment of Reads 
RNA-seq reads were mapped to the reference transcriptome using the gap-enabled 
aligner BWA v.0.5.9 [62] with a maximum of 3 mismatches allowed. The resulting 
alignments were processed using SAMtools (v.0.1.18) [63].  
BWA read alignments were refined by local realignment using GATK v. 1.5-20 [64].  A 
standard mapping algorithm takes each individual read and maps it to the reference.  
Such mapping is only optimal for each individual read, but may be sub-optimal when all 
of the reads are considered.  The local realignment process takes into account all the 
reads that are locally mapped together (as opposed to individual read mapping) to correct 
for sub-optimal alignments that may introduce an erroneously called variant due to its 
close proximity to an insertion or a deletion (Figure 3.4).   
 
Figure 3.4:  Variant call. (A) before and (B) after local realignment by GATK. 
A
B
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3.2.2  Transcript Level Quantification  
All the mapped reads were then piled up on top of each other as illustrated in Figure 3.3. 
The number of reads mapping to a contig were summed up to generate count for each 
contig. The counts were then normalized across all the sample libraries to adjust for 
variability in sequencing depth using the upper quantile normalization method [65].  The 
upper quantile normalized values were further adjusted to account for variation in the 
contig length.  
3.2.3  Identification of Single Nucleotide Variant 
An initial single nucleotide variant (SNV) detection was made using Varscan v.2.3.4 [66] 
which employs the following heuristic approach: a minimum depth of 8 at the variant 
position; at least 3 reads at that position must support the variant call; and the variant call 
must constitute > 1% of the total depth. Detected variants must have a base quality score 
> 30 and a mapping quality score > 20.  
A Poisson model was employed to distinguish potentially real variants from random 
errors. In the Poisson model, the number of variant reads observed at a particular site is 
compared to the probability that all of those variant reads occurred due to random error 
(estimated at a maximum rate of 1% according to Illumina).The significance level at each 
variant site is quantified by the calculated p-value. Multiple hypothesis testing is 
performed by controlling the family-wise error rate (FWER) at a significance level α of 
0.1 using the Bonferroni correction.  
Systematic sequencing errors may also occur in RNA-seq as a result of ambiguity in 
base-calling.  In particular, the spectra for the G and the T nucleotides are known to have 
significant overlap [67].  In addition, nucleotides in several specific sequence patterns, 
such as GGT, are prone to being misread.  In the majority of cases, the problems will 
occur only in one strand of the reads, while the complementary reads will not be affected.  
Since the Illumina protocol used in this study involves sequencing both strands of the 
cDNA, such systematic error will manifest itself in the form of an incorrect base call in 
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only one specific direction of the reads. To eliminate this type of systematic error, 
variants that are supported by reads in only a single read direction are filtered out. 
3.2.4  Phylogeny Analysis 
SNVs that have sufficient depth of coverage in all libraries (depth > 8 in all libraries) 
were used to construct a phylogeny tree using the DNA parsimony package in Mobyle 
[68].  
3.2.5  Variant Verification by Sanger Sequencing 
RNA was reverse transcribed using the Moloney Murine Leukemia Virus Reverse 
Transcriptase (M-MuLV RT) (New England Biolabs) with gene specific primers. cDNA 
was amplified with gene specific primers targeting the candidate variant-containing 
regions using the Phusion High-Fidelity DNA polymerase (New England Biolabs). PCR 
products were gel-purified using the QIAquick Gel Extraction kit (Qiagen), cloned into 
the TOPO-vector (Invitrogen), and transformed into One Shot TOP10 E. coli cells. 
Following transformation, the cells were spread on agar plates with 50 μg/mL kanamycin 
selection. The colonies were individually picked and expanded in LB broth containing 50 
μg/mL kanamycin. The plasmids were purified using the Qiaprep Spin Miniprep kit 
(Qiagen) and subsequently, subjected to Sanger sequencing. 
3.3  Cell Lines and Cell Culture 
3.3.1  HeLa Cell Culture 
The setup described here was used to perform the experiment demonstrating the existence 
of multiple steady states in the glycolysis of fast proliferating cells, and are discussed in 
detail in Chapter 4. HeLa cell line, originally obtained from ATCC (Manassas, VA) was 
a generous gift from Professor Kim Do-Hyung and has been reported previously [20]. 
HeLa cells were cultured in DMEM medium (Invitrogen, 11995-065) supplemented with 
4% fetal bovine serum at 37 
o
C in 5% CO2. 100 mL culture with 5 g/L of Cytodex 1 
microcarriers (GE Healthcare, 17-0448-01) was carried out in a 250 mL spinner flask. 
30 
 
HeLa cells were inoculated at 2 × 10
5
 cells/mL on Day 0. The procedure for microcarrier 
culture has been described previously [69]. On Day 5, cells on microcarriers were washed 
and re-suspended at 1 × 10
5
 cells/mL in DMEM medium containing either 0.6 mM (LG) 
or 25 mM (HG) of glucose. The cell concentration was intentionally kept low such that 
the glucose concentration in the culture could be maintained at a relatively constant level 
without getting depleted. The two flasks were then maintained for a further 12 hours to 
allow the cells in LG condition to reach a low flux state and those in HG condition to 
reach a high flux state.  Subsequently, the cells from each flask were washed twice with 
PBS and transferred to the wells of a 12-well plate containing 1 mL of medium with 
varying glucose concentration. Cells were inoculated at a high enough concentration (2 × 
10
6
 cells/mL) to allow measurable changes in the medium glucose concentration due to 
cellular glucose uptake. Supernatants were collected at time 0, 2, 4, and 6 hours which 
were then assessed for glucose and lactate levels using the Infinity Glucose reagent 
(Thermo Scientific, TR15421) and YSI 2700 SELECT industrial analyzer (YSI Inc.), 
respectively. Subsequently, using linear regression, specific rates of glucose uptake and 
lactate production were calculated from the glucose/lactate measurement data. 
3.3.2  CHO Cell Culture 
The setup described here was used to perform the experiments demonstrating the effect 
of initial lactate concentration and culture history on the metabolic state of CHO cells in 
fed-batch culture, and are discussed in detail in Chapter 5. Recombinant CHO cells 
producing an immunoglobulin were grown in shake flasks at 36.5 
o
C and 5% CO2 
environment. The medium and the culture conditions used have been previously reported 
[15,22].  Cells were inoculated at 6x10
5
 viable cells/mL.  Starting on Day 3, the cultures 
were fed with feed medium equivalent to 1.8% of the initial culture volume. pH was 
measured daily using a blood gas analyzer and adjusted to 7.2 using 1.0 M sodium 
carbonate (Na2CO3).  Samples were taken daily for measurements of cell density, 
viability, glucose and lactate concentrations using a Nova Bioprofile instrument. 500 g/L 
glucose solution was used to supplement the cultures with glucose as and when required 
to maintain the glucose levels above 1.5g/L.  
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3.3.3  MAK Cell Culture 
The setup described here was used to perform the experiments demonstrating an 
approach to direct a continuous culture toward a steady state with high cell concentration 
and low metabolic flux, and are discussed in detail in Chapter 6. A mouse-mouse 
hybridoma cell line, MAK, and its defined, serum-free medium have been described 
before [70]. All experiments were performed in a 750 mL glass bioreactor with a working 
volume of 550 mL. 
Fed-batch cultures were initiated using cells in the exponential growth phase at a 
concentration of 1.5x10
5
 cells/mL. The medium used was the same as that used for cell 
maintenance except for the initial glucose and glutamine concentrations which were at 
0.55 mM and 0.17 mM, respectively. Oxygen Uptake Rate (OUR) was measured every 
five minutes and the cumulative oxygen consumption was calculated on-line. Using a 
previously established glucose and oxygen stoichiometric ratio [70], the amount of 
glucose consumed was calculated and the amount of feed medium required to maintain 
glucose at the set point was added. The culture was operated in batch mode until glucose 
concentration reached 0.28 mM as estimated by on-line calculation at which point 
concentrated nutrient feeding was initiated. The nutrient concentration in the feed was ten 
times higher than the maintenance medium, except for glucose which was at 66.7 mM. 
During the cultivation, glucose was measured off-line and if necessary the stoichiometric 
ratio used for estimating the on-line feeding rate to maintain the set point was adjusted.   
Continuous cultures were initiated from either batch or fed-batch cultures. At the time 
point of switch, feed was added and culture fluid from the reactor was withdrawn at equal 
rate as dictated by the desired dilution rate. The feed for the continuous cultures had the 
same nutrient concentrations as that used for cell maintenance except for glucose (5.3 
mM), glutamine (2.9 mM) and other amino acids (1.6x the concentration of maintenance 
medium).   
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Chapter 4 Bistability in Glycolysis as a Robust 
Biological Switch in Energy Metabolism  
4.1  Summary 
This chapter explores the effect of allosteric regulations on the behavior of glycolysis. 
The enzymes of glycolysis are tightly controlled by allosteric regulations by the 
intermediates upstream and downstream of the pathway. The literature is rife with in vitro 
studies assessing the effect of allosteric regulations on virtually all metabolic enzymes. 
However, such studies were performed often at single or few enzyme steps level. The 
holistic effect on the complete metabolic pathway level is not known. In this chapter, 
using a mathematical model based on reported mechanisms for the allosteric regulations 
of the enzymes, we show that the synergistic action of these regulations can confer 
glycolysis with novel, previously undiscovered behavior in mammalian cells. Two 
regulatory loops centering on the enzymes phosphofructokinase and pyruvate kinase each 
gives rise to multiple steady state behavior, segregating glucose metabolism into high 
flux and low flux states. The steady state multiplicity is observed only when specific 
combinations of isozymes are expressed. Distinct combination of isozymes in glycolysis 
gives different cell types the versatility in their responses to different energetic needs. 
Steady state multiplicity endows glycolysis with a robust switch to transit between the 
two flux states.  Under physiological glucose levels, the glycolysis flux does not switch 
between the states easily without an external stimulus such as hormonal, signaling or 
oncogenic cues.  
4.2  Introduction 
Glycolysis is the conduit of glucose metabolism for generating energy and providing 
biosynthetic precursors for cellular materials. The flux of glycolysis in cancer cells is 
high compared to normal adult tissues and a vast amount of the glucose consumed is 
diverted towards lactate production; a phenomenon known as the Warburg effect [71].  
This behavior is also typical of highly proliferative tissues such as fetal tissues and stem 
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cells [72,73].  In contrast, quiescent cells transport glucose at low rates and catabolize 
most glucose to carbon dioxide [74,75]. The Warburg effect was previously attributed to 
defective oxidative phosphorylation [71,76] until it was realized that the pathway was not 
impaired in most tumor cells (see review [77]).   
The differences in glycolysis activity observed across various cell types are accomplished 
through different levels of regulation [78]. At one such level is the allosteric feed-back 
and feed-forward regulations exerted by the intermediate metabolites on its enzymes. 
Pivotal roles are played by three enzymes, (phosphofructokinase (PFK), pyruvate kinase 
(PK) and phosphofructokinase /fructose-2,6-bisphosphatase (PFKFB)) through their 
inhibition or activation by three reaction intermediates (fructose-1,6-bisphosphate 
(F16BP), fructose-2,6-bisphosphate (F26BP), and phosphoenolpyruvate (PEP)) in 
glycolysis. These enzymes have multiple isoforms (PFKL/M/P, PKM1/M2/L/R and 
PFKFB1-4) which are subjected to contrasting allosteric regulations [12,79,80].  Each 
isoform, therefore, affects the glycolytic activity in a distinct manner.    
All three isoforms of PFK are activated by F6P and F26BP [6], but only PFKM and 
PFKL are activated by F16BP [7-9].  PFKFB is a bifunctional enzyme whose kinase and 
bisphosphatase domains catalyze the formation and hydrolysis reaction of F26BP, 
respectively [11,12].  Isozymes of PFKFB differ in their kinase and phosphatase activities 
as well as in their sensitivity to feedback inhibition by phosphoenolpyruvate (PEP) [81-
83].  Thus, each isozyme of PFKFB has a profoundly distinct capacity in modulating 
PFK activity. Pyruvate kinase (PK) in mammalian systems is encoded by two genes that 
can produce two isoforms each. Except for the PKM1 isoform, the other three isoforms 
of PK, PKM2, PKL and PKR, are activated by F16BP to varying extents [80]. The 
sensitivity of the M2 isoform to such wide ranging modulators allows it to act, in-part, as 
the cell’s nutrient sensing machinery [15].  Different tissues and cell types express 
different isoform combinations of these enzymes, thus giving rise to a suitable glycolytic 
flux behavior that caters to the biosynthetic and energetic needs of the cell type in 
question.  
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The expression of the isoforms of glycolytic enzymes and their regulation is tightly 
linked to the control of cell growth [84]. The make-up of the glycolytic isoforms in 
quiescent tissues strictly restrains its flux, thus restricting the provision of the carbon for 
growth and proliferation. There is increasing evidence that loss of the growth control as 
in the case of tumor formation caused by mutations in proto-oncogenes and tumor 
suppressors, is accompanied by alteration in the expression of specific glycolytic 
isozymes leading to metabolic reprogramming [85,86]. For example, HK2 is only 
expressed in limited number of adult tissues but is expressed at high levels in cancer 
cells. HK2 binds to the outer mitochondrial membrane and inhibits the release of 
cytochrome c to suppress apoptosis and promotes cell survival in cancer cells [19,87]. 
Analogously, the embryonic isoform of pyruvate kinase, PKM2, is found to be expressed 
in few adult tissues, but is known to be highly expressed across wide range of tumor 
cells.  Interestingly, knockdown of PKM2 in cancer cells, such as the human lung cancer 
cell line H1299, and replacing it with PKM1 was demonstrated to result in a metabolic 
phenotype change involving decreased glucose uptake and increased oxidative 
phosphorylation [88]. Further, reprogramming of somatic cells to induced pluripotent 
stem cells (iPSCs) has also been shown to incur metabolic reprogramming; the change 
from a low glycolytic flux state of somatic cells to a high flux state of rapidly dividing 
iPSC cells is accompanied by a switch in the isozyme expression of HK and PFK 
enzymes [74].  
The composition of isozymes in glycolysis, through these regulations, is therefore pivotal 
to the flux control and plays a key role in growth control and physiological balance. Over 
the last four decades, the kinetic behavior of isoforms of individual glycolytic enzymes 
has been examined in detail.  However, a holistic understanding of the effect of different 
combinations of such isoforms on the flux behavior of the complete glycolysis pathway is 
yet to be attained.  We have taken a systems biology approach to study the flux states of 
glycolysis pathway.  Using a mathematical model that employs mechanistic rate 
equations for glycolysis enzymes, we demonstrate that glycolysis exhibits a classical 
multiple steady state behavior in terms of its flux with respect to the glucose 
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concentration. The multiplicity of steady states segregate cell metabolism into distinct 
states: high glycolytic flux states and low glycolytic flux states.  Such bistable behavior is 
an output of complex allosteric regulations which in turn depend on the type of glycolytic 
isozymes expressed. We show that the presence of the muscle or the liver isozyme of 
PFK or/and the L, R or M2 isoform of PK is necessary for multistability in glycolytic 
flux.  We substantiated the modeling insights with gene expression data from various 
tissues as well as experimental data from HeLa cells.  Further, we discuss the factors that 
affect the bistable nature of the glycolysis such as the expression of different isozymes at 
different proportions.   
Similar kinds of bistable behavior have been shown to act like a robust switch in many 
regulatory circuits including oocyte cell maturation [89], transition from quiescent to 
proliferative modes in mammalian cells [90], transition between multiple phospho-form 
stable states in multisite phosphorylation systems [91], among many others.  The 
dissection of glycolytic flux as a bistable switch will provide new insights on the 
regulation of cell metabolism and possibly allow for a new perspective in identifying 
ways to modulate metabolic activities for therapeutic purposes.  
4.3  Results 
In the following sections we will first present the steady state behavior of the F6P-node, 
and then discuss the effect of the regulatory behavior of F6P-node on the glycolysis flux. 
This is followed by description and analysis of the effect of a second regulatory loop 
acting on the glycolysis pathway.  Lastly, the combined effect of the two loops will be 
discussed. 
4.3.1  Bistability in the F6P-node 
PFK is a pivotal enzyme in glycolysis and exists in three distinct isoforms. The muscle 
(PFKM) and the liver (PFKL) isozymes are under allosteric feedback activation by 
F16BP to a varying extent [7,8,92], whereas the platelet isozyme (PFKP) is not [93]. It is 
well known that feedback activation can give rise to ultrasensitivity and even bistability. 
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To assess the effect of the allosteric regulation of F16BP on the PFK flux, we constructed 
a mechanistic model around the F6P-node encompassing the reactions catalyzed by the 
enzymes PFK and aldolase (ALDO) (Figure 4.1A, also see Materials and Methods, 
Mathematical Model of Central Metabolism Pathway section). The values of kinetic 
parameters for each enzyme were obtained from various literatures in which the values 
have been experimentally determined [6,8,94]. The simulated steady state behavior is 
thus only affected by the relative abundance levels of the two enzymes involved. The 
relative enzyme levels were obtained from their corresponding transcript levels in 
cultured cells and assuming that the protein level is proportional to the transcript [23].  
 
Figure 4.1: Multiplicity of steady states in the kinetics of fructose-6-phosphate node 
(F6P-node).  (A) Feedback activation of phosphofructokinase (PFK) by fructose-1,6-
bisphosphate (F16BP)    (B) Bistability in the kinetics of PFK due to feedback regulation 
by F16BP. The simulation was performed using only two enzymes PFK and ALDO. F6P 
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was varied and the steady state PFK flux was solved algebraically. Activation of PFK by 
F16BP was set at KPFK,fbp = 0.65 mM. (C) Allosteric regulations in the F6P-node. (D) 
Modulation of bistability span by kinase to phosphatase ratio (K/P) of PFKFB. The 
bifunctional enzyme PFKFB was integrated with PFK and ALDO to construct a three 
enzyme system. Simulations were performed at varying K/P value of PFKFB while 
keeping all other conditions the same as in (B).   
In the absence of feedback activation by F16BP, as is the case for PFKP, the steady state 
flux resembles a Michaelis-Menten type of kinetics (Appendix Figure 1). In contrast, the 
activation by F16BP on PFK as in the case of the isozyme PFKL (or PFKM) [6,8], causes 
the steady state flux of PFK at different F6P concentrations (Figure 4.1B) to bear the 
hallmark of bistability. In the region bound by F6P concentrations from 0.09 mM to 0.3 
mM, three types of steady state can be seen, two of which are stable (low flux states and 
high flux states) and the ones in the middle are unstable. The physiological concentration 
of F6P in rat liver tissue has been reported to be ~0.1 mM [95].  Outside the region, only 
one steady state for a given F6P concentration is observed; below 0.09 mM the PFK 
steady state flux exists only in the low state, whereas above 0.3 mM it exists only at the 
high state.  Eigenvalue analysis confirmed the stability of each steady state. It should be 
noted that the above specified concentration ranges for bistable behavior are subject to 
the model parameters (kinetic constants and enzyme levels) of the F6P-node. 
In the bistable region, the flux can be either at a low or a high state depending on the 
previous state of the system. The in-between states are unstable in nature; these states are 
never realized experimentally. When the concentration of F6P is varied slowly, the PFK 
flux changes along the stable steady state lines.  Starting at a low flux state, as the F6P 
concentration increases, the flux increases along the low flux steady state line until the 
F6P concentration reaches 0.3 mM (“switch-up” concentration, Figure 4.1B), and then 
the system undergoes a sharp transition to a high flux state.  Further increase in F6P 
moves the system farther up along the high flux steady state line.  Conversely, if the 
system is initially at a high flux state, as the F6P concentration decreases, the flux 
remains at the high state until the F6P concentration decreases to 0.09 mM (“switch-
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down” concentration, Figure 4.1B) where it rapidly descends to the low state.  Once the 
system is switched from the low flux state to the high flux state, or vice versa, it does not 
switch back to the original state by small fluctuations of F6P concentration at the switch-
concentration.  The system is thus marked by well separated high flux and low flux 
states, and very distinctive “switch-up” and “switch-down” F6P concentrations.  
All three isozymes of PFK are activated by F26BP.  The bi-functional enzyme PFKFB 
catalyzes both the formation and degradation of F26BP (Figure 4.1C). The steady state 
concentration of F26BP is thus not affected by the expression level of PFKFB but by the 
balance between the relative activities of the kinase (K) and the bisphosphatase (P) 
domains of PFKFB. Thus, the flux through PFK is indirectly influenced by the K to P 
activity ratio of PFKFB, also termed as the K/P ratio.  We examined the regulation of the 
PFK flux by incorporating PFKFB into the model of the F6P-node. The experimentally 
determined values of kinetic parameters for PFKFB were also obtained from literature 
[96,97]. The K/P ratio of PFKFB alters the steady state behavior of PFK flux as shown in 
Figure 4.1D. Bistability is present for a wide range of K/P ratios. However, at a very high 
level of K/P ratios (>10), the bistable behavior disappears and the PFK flux exhibits a 
saturation type of kinetics. Thus, changes in the K/P ratio of the PFKFB result in the 
modulation of the steady state PFK flux.  
Different isozymes of PFKFB have widely different K/P ratios [12], giving rise to 
different steady state behaviors of F6P-node. The brain isoform of PFKFB3 (with K/P ~ 
700) will have a lower switch-up F6P concentration than the muscle isoform PFKFB1 
(K/P ~ 0.4).  In addition, hormonal or growth factor mediated regulations can modulate 
the K/P ratio of PFKFB isozymes (see review [11]). Such a regulation thus equips cells 
with a way to modulate the F6P-node steady state behavior acutely, without undergoing a 
switch in their isozyme composition (chronic effect). 
4.3.2  Multiplicity of Steady States in Glycolysis 
In the following discussions, we extend our analysis to the entire glycolysis pathway 
(Materials and Methods, Mathematical Model of Central Metabolism Pathways section).  
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Figure 4.2: Multiplicity of steady states in the glycolysis flux. (A) Steady state 
glycolysis flux with neither Loop 1 nor Loop 2 active. The isozyme set consisting of 
PFKP (no activation by F16BP) and PKM1 (no activation by F16BP) were used in the 
simulation. The steady state flux exhibits classical Michaelis-Menten kinetics. (B) Steady 
state glycolysis flux with only Loop 1 active. When only Loop 1 is active, the glycolysis 
flux exhibits bistability. The isozyme set PFKL (KPFK,fbp = 0.65 mM) and PKM1 were 
used in the simulation.  (C) Steady state glycolysis flux with only Loop 2 active. When 
only Loop 2 is active, the glycolysis flux also exhibits bistability. The isozyme set PFKP 
and PKM2 (KPK,fbp = 0.04 mM) were used in the simulation. (D) Steady state glycolysis 
flux with both Loop 1 and Loop 2 active. The isozyme set PFKL and PKM2 were used in 
the simulation. When both Loop 1 and Loop 2 are active, multiplicity of steady states 
resembling superposition of (B) and (C) is observed. For A-D the K/P of PFKFB was set 
at 10. (E) The effect of modulation of the kinase to phosphatase ratio (K/P) of PFKFB on 
the multiplicity of steady states in glycolysis. In this simulation PFKL and PKM2 were 
used, while K/P was varied. 
For the purpose of this study, we will be focusing on the regulations of PFK, PFKFB and 
PK.  Feedback inhibition of HK by G6P and feed-forward activation of PFK by F26BP 
were considered and kept active in all the simulations discussed later. The known 
regulations for PFK, PFKFB and PK can be grouped into two regulatory loops: Loop 1 
and Loop 2 (Figure 4.2).  Loop 1 consists of the feedback activation of PFK by F16BP 
and activation of PFK by F26BP.  Loop 2 entails three regulations consisting of the feed-
forward activation of PK by F16BP, the feed-back inhibition of PFKFB by PEP and 
activation of PFK by F26BP. The three regulations in Loop 2, when active 
simultaneously, yield feedback activation effect on the activity of the glycolysis pathway. 
The presence or absence of the allosteric regulations considered in Loop 1 and Loop 2 is 
determined by the isozymes that constitute the pathway. Loop 1 is operational with the 
muscle or liver isoforms of PFK (PFKM or PFKL), but not with the platelet isoform 
(PFKP) as the latter lacks the feedback activation by F16BP.  Loop 2 is mainly seen with 
the expression of liver (PKL) or the red blood cell (PKR) or the M2 isoform of PK 
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(PKM2) which are strongly activated by F16BP, but not with the M1 isoform (PKM1). 
Depending on the make-up of the isozymes, the glycolysis pathway in a tissue or a cell 
may have allosteric regulations of Loop 1, Loop 2, both or neither. This is illustrated in 
the expression profile of glycolytic isozymes compiled from published RNAseq 
transcriptome data of developing human embryos [98], HeLa cells [99], mouse adult 
tissues and transformed cells [100] (Appendix Table 2 and Appendix Table 3).   
We will show that the bistable behavior imparted by the allosteric regulation at F6P-node 
is extended to glycolysis pathways through Loop 1. Subsequently, we will also show that 
the allosteric regulation of Loop 2 also gives rise to bistability. However, Loop 2 
encompasses a larger segment of glycolysis. Therefore the bistable behavior of Loop 2 
will only be shown as glycolysis flux, rather than as an isolated node.  
The glycolysis flux with neither Loop 1 nor Loop 2 regulation is shown in Figure 4.2A. 
This case reflects a combination of PFKP (thus Loop 1 inoperative) and PKM1 (Loop 2 
inactive), such as in oocyte or zygote in which PFKP and PKM1 are the dominant 
isozymes expressed (Appendix Table 2).  The simulation was performed by omitting both 
the terms corresponding to the F16BP feedback activation in the equation for PFK 
(KPFK,fbp) and the F16BP feed-forward activation in the equation for PK (KPK,fbp). In 
addition, the K/P ratio of PFKFB was set to 10. The simulated steady state glycolysis flux 
exhibits no bistability at any K/P ratio (Figure 4.2A and Appendix Figure 2); the steady 
state flux approaches its maximum level at a relatively low glucose concentration.  
The case that only Loop 1 is active occurs when either PFKL or PFKM and PKM1 are 
the dominant isoforms expressed.  Such a combination of isozymes is seen mainly in 
various sections of brain tissue including cerebellum, cortex and frontal lobe (Appendix 
Table 3).  The simulation was performed by setting KPFK,fbp = 0.65 mM (for PFKL [6,8] 
and omitting the F16BP feed-forward activation term in the rate equation for PK. The 
K/P ratio of PFKFB was set to 10. All the enzyme levels (including both PFK and PK) 
and all other kinetic constants were kept at the same values as in Figure 4.2A. As shown 
in Figure 4.2B, incorporation of Loop 1 (which is equivalent to introducing the F6P-node 
42 
 
to glycolysis), elevates the glycolysis flux to a much higher level and a region of 
bistability is seen.  
Similarly, the effect of the Loop 2 alone is shown in Figure 4.2C. This is the case when 
PFKP is the dominating PFK isozyme with PKL, PKR or PKM2 as the PK isozyme. 
Large and small intestine express such a combination of isozymes (Appendix Table 3). 
The simulation was performed by omitting the F16BP feedback activation term in the 
equation for PFK and setting KPK,fbp = 0.04 mM (for PKM2 [80]). The K/P ratio of 
PFKFB was set to 10. All the enzyme levels (including both PFK and PK) and all other 
kinetic constants were kept at the same values as in Figures 4.2A-B. In this case the 
extent of the maximal flux is somewhat lower than the case of Loop 1 alone.  A bistable 
region is seen with both the switch-up and the switch-down concentrations of glucose 
shifted toward a higher level of glucose. 
When both the loops are active, such as in case of hESCs, HeLa cells (Appendix Table 2) 
and mouse transformed cell lines (MEL and 10T1/2) (Appendix Table 3), the glycolysis 
flux has multi-stable behavior (Figure 4.2D). The simulation was performed by setting 
KPFK,fbp = 0.65 mM (for PFKL) and KPK,fbp = 0.04 mM (for PKM2). The K/P ratio of 
PFKFB was set to 10. All the enzyme levels (including both PFK and PK) and all other 
kinetic constants were kept at the same values as in Figures 4.2A-C. Three stable steady 
states and two unstable steady states can be seen for this case. The maximum flux is the 
same as that of Loop 1 alone while the multiple steady state region resembles the 
composite of the stability curves for Loop 1 and Loop 2 (Figures 4.2B and 4.2C).  
The results show that the steady state glycolytic flux may be at a high flux or a low flux 
state depending on the presence or absence of the regulatory Loop 1 and Loop 2.  
Without Loop 1 and Loop 2 active, in the physiological range of glucose concentration 
(5-10 mM) glycolysis flux is at a low flux state (Figure 4.2A). With Loop 1 active alone, 
it will be at a high flux state (Figure 4.2B).  To switch to a low flux state from a high flux 
state, the glucose concentration will need to decrease to a low level that is rarely seen 
physiologically; whereas if the initial flux is at a low state, as soon as the glucose level 
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reaches a physiological level of 5 mM the flux will switch to a high state. The steady 
state behavior with Loop 2 active alone is rather different from the case of Loop 1 active 
alone; the flux in the physiological glucose concentration range is at a low state with a 
switch up concentration at the high end edge of physiological concentration (Figure 
4.2C). Even if the flux is initially at a high state, it will switch to a low state when 
glucose decreases to a physiological level below 10 mM. 
With both Loop 1 and Loop 2 active, the flux is at a high state in the physiological range 
of glucose. Interestingly, from a high flux state the system can switch only to the low 
state, bypassing the intermediate stable steady states.  The intermediate stable steady 
states can be reached only from a low flux state by increasing glucose concentration.  The 
stability of those steady states was verified by eigenvalue analysis. 
In both the loops described above, F26BP plays a regulatory role through its allosteric 
control over PFK. The level of F26BP can be modulated by the K/P ratio of PFKFB. We 
have shown above that modulation of K/P affects the bistability behavior in the F6P-node 
alone (Figure 4.1D). This effect of flux modulation through K/P is also translated to the 
entire glycolysis flux (Figure 4.2E). The simulations were performed using exactly the 
same conditions as those used in Figure 4.2D, except for the K/P value which was varied. 
The multiple steady state region shifts as K/P ratio of PFKFB changes. At higher values 
the multiple steady state region is lost and the flux behaves like typical saturation type of 
kinetics. Reducing K/P has the effect of shifting the multiple steady state region to higher 
concentration range of glucose. At very low levels of K/P the multiple steady state region 
moves outside of the normal physiological range of glucose (> 10 mM). 
To evaluate the robustness of the multiple steady state behavior, sensitivity analysis on 
the multiplicity of steady states was performed by changing the levels of each enzyme 
(over a range of two orders of magnitude) while holding all the other kinetic parameter 
values constant. The results show that for all enzymes, the multiplicity of steady states 
can be seen to exist over a wide range of enzyme levels except for HK (Appendix Figure 
3). It has been reported that such a tight control of HK, either at enzyme level or through 
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allosteric regulation, is required in order for the glycolysis flux to reach a steady state [5]. 
Changing the concentration of the enzyme in the ranges shown in Appendix Figure 3 
maintains the presence of the bistable behavior but shifts the switch-up and the switch-
down concentrations. 
We further examined the sensitivity of the steady state behavior to a number of model 
parameters whose value was kept constant in this study, including the cellular redox state 
([NAD]/NADH]), the ratio of mitochondrial pyruvate and lactate concentrations 
([PYR]m/[LAC]) and the ratio of mitochondrial pyruvate and alanine concentrations 
([PYR]m/[ALA]).  For [NAD]/NADH], multiplicity of steady states was observed over a 
wide range of the ratio (0.5 to 700) (Appendix Figure 4A).  At very low [NAD]/[NADH] 
ratios (< 1), glycolytic flux has three steady states as compared to five steady states seen 
at higher [NAD]/NADH] ratios (> 9).  The data suggest that [NAD]/NADH] ratio has a 
marginal effect at very low values.  The effects of [PYR]m/[LAC] and [PYR]m/[ALA] 
were probed by maintaining [PYR]m constant (at 0.1 mM) and varying either [LAC] or 
[ALA] (Appendix Figure 4B and Appendix Figure 4C).  Multiplicity of steady states was 
observed across the range in which lactate and alanine were varied. No effect on the 
steady state flux profile was observed when lactate was varied.  Whereas, at higher 
concentrations of alanine, the switch-up concentration moves closer to upper bounds of 
(or in some cases beyond) the typical range of physiological glucose concentrations. 
4.3.3  Bistability in Cultured Cells 
We employed HeLa cells to examine the bistability in glycolysis flux. HeLa cells initially 
grown on microcarriers in high glucose (HG) medium were split into two cultures with 
either low glucose (LG) (0.6 mM) or high glucose (HG) (25 mM) (see Materials and 
Methods, HeLa Cell Culture section).  The cell concentration was kept low such that 
glucose would not be depleted in the LG condition due to the uptake by the cells. Cells 
were then allowed to reach steady states in LG and HG conditions, which were the low 
flux state (0.05 mmol/10
9 
cells/h) and high flux state (0.31 mmol/10
9 
cells/h), 
respectively.  Cells from both these conditions were then re-suspended in medium 
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containing varying glucose concentrations and the specific rates of glucose consumption 
and lactate production were monitored.  
When exposed to 25 mM glucose, cells showed high specific glucose consumption rate of 
~ 0.31 mmol/10
9 
cells/h regardless whether they were previously at a low flux or a high 
flux state (Figure 4.3A).  When exposed to 0.6 mM glucose, cells from both HG and LG 
showed low specific glucose consumption rate of 0.05 mmol/10
9 
cells/h. However, when 
exposed to intermediate glucose concentrations of 2 mM, 3 mM and 4.5 mM, contrasting 
specific rates were observed for the cells from HG and LG conditions. Cells that were 
previously cultured in HG maintained high specific glucose consumption rate (0.31 
mmol/10
9 
cells/h), whereas cells that were previously cultured in LG had low specific 
glucose consumption rate (0.05 mmol/10
9 
cells/h).  The flux in the intermediate glucose 
concentration range is thus dependent on the prior state or history of the cell.  Since a 
high flux of glucose is accompanied by a high lactate flux and vice versa, the bistable 
behavior of glucose flux should be reflected in lactate flux. This is indeed seen when 
lactate efflux was measured (Figure 4.3B). 
The experimental results thus show the characteristic of bistability in HeLa cell glucose 
metabolism: cells which were at a high flux state (previously in HG) have to experience 
glucose levels below the “switch-down” concentration to reach the low flux state while 
cells from a low flux state (previously in LG) have to experience glucose levels higher 
than the “switch-up” concentration to reach the high flux state.  
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Figure 4.3: Bistability in cultured HeLa cells. Cells initially cultured in high glucose 
(♦) or low glucose (□) exhibit different rates of (A) specific glucose consumption and 
(B) specific lactate production when exposed to varying glucose concentrations. 
4.3.4  Effect of Isozyme Composition on the Steady State Behavior 
Many isoforms of the same enzyme are expressed at different levels in the same tissue 
cell.  The presence of different isoforms with different allosteric regulations makes the 
steady state flux behavior deviate from that seen with a single isoform. We evaluated the 
effect of the isoform mixtures on the glycolytic flux.  In each case, the total level of the 
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isoform mix for each enzymatic step was kept at the same level as the one used in the 
original model (with single isoform for each enzymatic step). The steady state behaviors 
of single PFK isoforms (PFKM, PFKL or PFKP) as well as mixed expression of these 
isoforms, in conjunction with PKM2 are shown in Appendix Figure 5.   In all cases, the 
steady state behavior of the isoform mix takes the shape of that conferred by the 
mixture’s dominant isoform. As shown in Figures 4.2A-D, the presence of only a single 
isoform in any active Loop precisely fixes the switch-up and the switch-down glucose 
concentrations.  Interestingly, co-expression of the dominant isoform with smaller 
fractions of other isoforms allows for the movement of the switch-up and switch-down 
glucose concentrations within the physiological range, thus equipping cells with yet 
another way to control the span of the bistable region (Appendix Figure 5D-F).  
4.4  Discussion 
In this study we demonstrated that in the physiological range of glucose concentration the 
glycolysis flux exhibits multiple steady state behavior.  The multiple steady states arise 
from the regulatory loops centering at PFK and PK. The presence of M/L isoforms PFK 
and the M2 isoform of PK, which are all subjected to activation by their respective 
effectors, give rise to steady state multiplicity.  
The sets of isoforms, (PFKM/PFKL and PKM2) and (PFKP and PKM1), confer 
contrasting multiple steady state and the saturation type steady state behaviors to 
glycolysis flux, respectively (Figure 4.4). With the latter set of isozymes, the flux is at a 
low flux state under physiological glucose concentrations. In contrast, the bistable region 
conferred by the former set of isozymes can span the physiological concentration range 
of glucose. The model thus predicts that the flux will be at a high flux state under 
physiological conditions. Only upon a long period of exposure to a very low glucose 
concentration (< ~1 mM) will the glyolysis flux switch to a low flux state. A high flux 
state is also associated with a high lactate production as shown by the model simulation 
(Appendix Figure 6).   
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Figure 4.4: Glycolytic behaviors observed in mammalian cells.  Two types of 
glycolytic steady state kinetics were observed.  These include steady state behavior with 
no multiplicity of states or those with multiplicity of states.  The type of glycolytic 
isozymes expressed forms the basis for presence or absence of multiplicity of states in 
glycolysis activity. In case of non-proliferating cell, isozyme combination comprising of 
PFKP, PKM1 and PFKFB with K/P = 0.5 was used whereas in case of proliferating cell, 
isozyme combination including PFKM, PKM2 and PFKFB with K/P =10 was employed.   
In the bistable region, the stable steady state at which the glycolysis resides at a particular 
glucose concentration is dictated by the trajectory along which the system moves. Cells 
which are originally at a high flux state will remain at high flux state until the glucose 
concentration is reduced to a level below the switch-down concentration; whereas cells 
which are originally at a low flux state, will stay at low flux state until the glucose 
concentration is increased beyond the switch-up concentration. Using HeLa cells we 
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demonstrated this effect of cell’s “history” in terms of the fluxes of both glucose 
consumption and lactate production (Figure 4.3). 
Metabolic switch between low and high flux states to meet the changing bioenergetic 
demands caused by oncogenic or developmental events may be brought about by 
expression of a different set of isozymes (see review [72,73,77]).  Mature oocyte and 
zygote exhibit the oxidative type of metabolism [72].  As zygote differentiates and 
reaches the late blastocyst state, the metabolic phenotype changes to predominantly 
glycolytic.  Such a change in the metabolic phenotype from the oxidative state of 
quiescent oocyte and zygote to glycolytic state of the blastocyst is associated with 
changes in glycolytic isozymes from PKM1, PFKP and PFKFB2 to PKM2, PFKM/PFKL 
and PFKFB3/PFKFB4 isozymes (Appendix Table 2).  The concurrent switch in the 
isozyme pattern and the flux behavior observed in the above scenario matches that 
presented by our model simulations (Figure 4.4).  
It should be noted that most cells express a mixture of isoforms rather than a single one 
[101-106]. Such pattern is also observed in the tissues described above (oocyte, zygote 
and blastocyst), where other isoforms are also expressed in small fractions (Appendix 
Table 2).  We evaluated the effect of mixed expression of multiple isoforms of PFK on 
the multiple steady state behavior. When different isoforms of PFK are expressed, the 
isoforms which exhibit bistable behavior, namely PFKL and PFKM, dominate over 
PFKP unless PFKP is present in a much larger proportion than the other isoforms 
(Appendix Figure 5).  It is also worth noting that not all proliferating cells and quiescent 
cells have the same isozyme patterns.  However, it has been reported that fast 
proliferating cells typically express PFKM/PFKL, PKM2  and PFKFB3 as the major 
isoforms; whereas quiescent cells favor PFKP, PKM1 and other isoforms of PFKFB as 
the dominating isoforms [88,107,108].  
Metabolic shift may also come about by hormonal or signaling regulation, such as those 
that change the K/P ratio of PFKFB (Figure 4.2E).  For example, the K/P ratio of PFKFB 
in hepatocytes can be quickly modulated by glucagon-triggered cAMP signaling [12].  
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Furthermore, a number of factors that affect the allosteric state of PKM2 isozyme, 
including serine, SAICAR and phenylalanine, can influence the transition between the 
two metabolic states [13-15,109]. 
PFKFB affects the activity of PFK through its reaction product F26BP. Different 
isoforms of PFKFB have different K/P ratios that give rise to different steady state 
behavior of glycolysis (Figure 4.2E). An isoform with a high K/P ratio yields a higher 
level of F26BP at steady state, exerts a stronger activation of PFK and moves the switch-
up glucose concentration to lower levels. With hormonal actions that change the K/P of 
PFKFB, the steady state behavior of glycolysis can be altered quickly without resorting to 
changes in the isoform expression.  
The bistable behavior in glycolysis confers robustness to the response of glycolysis to 
changes in glucose concentration; within the physiological range of glucose concentration 
a change in the flux state is not readily realized unless via a regulatory action, 
differentiation or oncogenic event. In recent years there has been increasing interest in 
developing treatment strategies of suppressing hyperactive cellular metabolism to control 
cancer cell growth or diabetes development. The glycolysis flux behavior revealed in this 
study may be exploited to negatively manipulate the metabolism of tumor cells by 
rendering Loop 1 or Loop 2 inoperative.  Decreasing the activation of PFK by F16BP can 
make Loop 1 less active. Tumor cells typically express PKM2 as the dominant pyruvate 
kinase isozyme. Disrupting the allosteric regulations of PKM2 activity, such as by 
administering SAICAR [13], will make Loop 2 inactive. Further, suppressing the K/P 
ratio of PFKFB3 through expression of TIGAR [56] or by the use of small molecule 
modulators such as 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) can make Loop 
2 inoperative [21]. A mechanistic understanding of the regulation of glycolytic flux will 
have a positive impact on the advances of these metabolism-based therapeutic treatments. 
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Chapter 5 Regulatory Mechanism for Metabolic Shift 
to Lactate Consumption in Cultured Mammalian Cells 
5.1  Summary 
In the industrial bioprocesses for therapeutic protein production, glucose is fed regularly 
to the medium to sustain cell growth until the accumulation of lactate to high levels 
adversely affects cell growth and viability. In such fed-batch processes, glucose and 
lactate concentrations in the culture reach levels that are far beyond the physiological 
ranges. In the later stages of those cultures, sometimes a metabolic shift from a metabolic 
state of high glycolysis flux and high lactate production to a state of low glycolysis flux 
and lactate consumption is observed. While in other cases of very similar culture 
conditions with the same cell line and medium, cells continue to produce lactate. The 
occurrence of the metabolic shift to lactate consumption has been correlated to the 
productivity of the process. However, the cause that triggers lactate consumption is yet to 
be identified. We have previously shown that the glycolysis of proliferating cells can 
exhibit bistability with well-segregated high flux and low flux states. The cells can only 
transit from a high flux state to a low flux state when glucose is at very low levels. 
However, metabolic shift to lactate consumption observed in industrial fed-batch cultures 
often occurs when glucose is still available at high levels.  In this chapter, using the 
complete mathematical model we demonstrate that inhibition by high lactate 
concentration coupled with AKT regulation on glycolysis enzymes can profoundly 
influence the bistable behavior resulting in a complex steady-state topology. The 
transition from the high flux to the low flux state can only occur in certain regions of the 
steady state topology determined by the glucose, lactate and AKT. Consequently, the 
metabolic fate of the cells depends on the culture trajectory encountering the regions that 
allow such metabolic state switch.  
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5.2  Introduction 
Glucose metabolism plays a central role in supplying cellular needs of energy and 
precursors for many cellular materials. Cancer cells have elevated glucose consumption 
and glycolytic flux in ways similar to the response of tissues to growth promoting signals 
[71]. Cellular glucose metabolism is subjected to vast interacting regulations exerted at 
various levels [78,86,110]. The regulatory effectors and control action on the enzyme 
kinetics differ for different isozymes catalyzing the same reaction step. Cells in different 
tissues and even cells at different disease or development stage, may express different 
isozymes to meet their cellular needs [72,74]. Additionally, through signaling pathways, 
glycolysis activity is tied to growth control [78,110].  
The high rates of glucose consumption and lactate production seen in cancer cells are also 
observed in other fast proliferating cells such as the cultured mammalian cell lines. In the 
past two decades, fed-batch cultures have become extensively used in cell culture 
bioprocessing. In such cultures, concentrated feed medium is fed intermittently to the 
culture to make up for the consumed nutrients. The volume of the reactor increases 
through the culture duration. The total amount of glucose added and the resulting glucose 
concentration in the culture are far higher than the range commonly seen in typical 
culture media. Lactate accumulation seen in culture also greatly exceeds the 
physiological levels. The accumulation of lactate in culture has long been recognized as 
an inhibitory factor for cell growth and recombinant protein production [70,111]. The 
viability of the cells in the culture eventually drops and the culture is terminated.  
Cells in the later stages of their growth in a fed-batch culture sometimes switch their 
metabolism from lactate production to consuming lactate [23]. However, such metabolic 
shift is elusive; under seemingly similar conditions, some cultures switch their 
metabolism and consume lactate while others continue to produce lactate. The metabolic 
shift to lactate consumption has been shown to positively correlate to higher productivity 
[3,4]. Thus, a better understanding of the lactate consumption phenomena will help 
contrive strategies for robust control of cell metabolism and higher protein yields.  
53 
 
We have previously demonstrated that the combination of isoforms of glycolytic 
enzymes commonly seen in many rapidly growing cells give rise to bistable behavior in 
glycolysis activity [112]. Under physiological glucose concentrations, the steady state 
glycolysis flux may be at a high state or a low state. Although cells may switch their 
metabolism between the two flux states, the switching concentrations are outside the 
physiological range. This is consistent with the experimental observation that a shift from 
a high flux state to a low flux state was accomplished only by controlling glucose 
concentration at very low levels [70,111,112] . 
We hypothesize that the switch of metabolism in fed-batch culture is a reflection of the 
bistable behavior described above. The glucose and lactate concentrations in 
contemporary fed-batch processes often reach levels beyond 50 mM and 100 mM, 
respectively [3,4]. Such non-physiological conditions may elicit dynamic responses 
unseen in vivo. In particular the inhibitory effect of lactate on PFK that is relatively 
minor in most tissues in vivo may become prominent due to its high level of 
accumulation.    
In this work we extend our modeling explorations to the previously unexplored space of 
glucose and lactate concentrations that are non-physiological and yet important in 
biopharmaceutical manufacturing. Since lactate consumption occurs through its 
conversion to pyruvate and oxidation in the tricarboxylic acid (TCA) cycle, we extended 
our model to include the TCA cycle and the malate-aspartate shuttles (Figure 3.1 in 
Materials and Methods). Metabolic shift in cultured cells largely occurs after the rapid 
growth period is over. The link between metabolism and growth control has been a 
subject of intense research in the past decade.  
AKT is a serine/threonine kinase that plays a key role in multiple cellular processes 
including cell proliferation and glucose metabolism (for reviews, see [78,86,110]). AKT 
exists in an active/phosphorylated form and an inactive/unphosphorylated form. The 
AKT signaling cascade has been shown to activate the transcription of GLUT1 [17] and 
mediates the association of hexokinase 1 and 2 (HK1 and HK2) with outer mitochondrial 
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membrane [18,19]. In addition, the phosphorylated form of AKT (pAKT) can increase 
the phosphorylation of PFKFB to shift its kinase/phosphatase ratio to increase the 
formation of fructose 2,6-bisphosphate levels [20-22], which in turn increases PFK 
activity and glycolysis flux. A decrease in the growth rate of the cells observed during the 
course of the culture is accompanied by the decrease in the pAKT activity [23]. Thus, in 
the extended model the effect of cell growth rate on glycolysis flux is dealt with by a 
dependence of kinase activity of the bifunctional enzyme PFKFB activities on pAKT. We 
report herein that our extended model for cell metabolism reveals multiplicity of steady 
states of glycolysis activity, the topology of which is modulated by three culture 
parameters including glucose, lactate and growth rate. Such an understanding of the 
metabolic flux topology can help control the metabolic state and enhance process 
robustness. 
5.3  Results 
5.3.1  Bistability in Glucose Flux in Energy Metabolism 
In our previous study we have demonstrated that a combination of isozymes confers 
glycolysis flux with multiplicity of steady states. We showed that the presence of 
multiple steady states is the result of the regulatory action of two allosteric feedback 
loops [112].  Survey of transcriptome data of various CHO cell lines revealed that CHO 
cells typically express the same set of isozymes that confers glycolysis flux with the 
hallmarks of bistable behavior (Appendix Figure 7).  The glycolysis flux behavior of 
CHO cells was simulated using the metabolic model that incorporates the muscle 
isozyme of phosphofructokinase (PFKM), the M2 isozyme of pyruvate kinase (PKM2) 
and the brain isozyme of 6-phosphofructo-2-kinase/2,6-bisphosphatase (PFKFB3), which 
are the respective dominating isozymes observed to be expressed CHO cells.  The 
allosteric regulations which are active in CHO cells are shown in Figure 5.1A. The 
multiplicity of steady states of glycolysis flux is seen in CHO cells (Figure 5.1B). 
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Figure 5.1: Multiplicity of steady states in glycolytic activity of CHO cells. (A) 
Isozymes of glycolysis are subjected to multiple allosteric regulations (B) Bistability in 
glycolysis flux  
In the glucose concentration range of ~0.5 mM to ~2.2 mM, three types of steady states 
in glycolysis flux are seen: two are stable which represent the high and the low flux 
states, and the in-between steady states are the unstable states. The stability of each 
steady state was confirmed by eigenvalue analysis. Outside this region, only one steady 
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state is observed for a given glucose concentration; below 0.5 mM, glycolysis has only 
the low flux state, whereas above 2.2 mM, only the high flux state exists. In the high 
glycolysis flux state, glucose is consumed rapidly and lactate is produced at a high rate 
(Figure 5.1B). In the low glycolysis flux region, glucose consumption rate is low. The 
behavior of lactate in the low flux region varies somewhat; it is produced at a slow rate in 
the bistable region, but is consumed at a low rate as glucose concentration decreases 
further.  
In the bistable region, glycolysis can operate at either a high or a low state depending on 
the previous state of the system. The middle steady states being unstable cannot be 
realized experimentally. When the glucose concentration changes, the glycolysis flux 
changes along the stable steady state lines.  Starting from a high glucose concentration 
(thus the high flux state), as glucose concentration decreases the flux remains at the high 
state until the concentration decreases to 0.5 mM (“switch-down” concentration, Figure 
5.1B), where it decreases abruptly to a low state. Further decrease in glucose causes the 
system to travel farther down along the low flux steady state line. Once the system 
reaches a low state, it does not switch back to the high flux state at the “switch-down” 
concentration by a small perturbation (increase) in glucose level. In order to return to the 
high flux state, the system must now travel along a distinct trajectory. From a low flux 
state, glucose concentration must increase above 2.2 mM (“switch-up” concentration, 
Figure 5.1B), before it sharply transits to a high flux state. Further increase in glucose 
causes the system to travel farther up along the high flux steady state line. The system is 
thus marked by well separated high flux and low flux states and very distinct “switch-up” 
and “switch-down” glucose concentrations.  
Sensitivity analysis on the multiplicity of steady states was performed by varying the 
level of each enzyme over the range of two orders of magnitude while holding all the 
other kinetic parameter values constant. Exhaustive simulation for evaluation of steady 
state behavior on all possible enzyme level combinations is clearly not feasible. The 
results of the sensitivity analysis show that multiple steady states can be seen over a wide 
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range of enzyme levels for many enzymes except for HK and pyruvate dehydrogenase 
(PDHC) (Appendix Table 4).  
Altogether, these results indicate the potential for two systems to be at the same 
extracellular glucose concentration inside the bistable region, while showing different 
flux behaviors depending on their histories.   
5.3.2  Effect of Lactate Concentration on Bistability 
Lactate exerts an inhibitory effect on glycolysis flux through its feedback regulation on 
PFK (Fig 5.1A) [113,114].  The steady state behavior shown in Figure 5.1B was obtained 
at a constant extracellular lactate concentration of 0.4 mM.  In fed-batch cultures, lactate 
may accumulate to high levels that greatly exceed the physiological range [4].  We thus 
examined the effect of a wide range of lactate concentrations on the glycolysis flux.  The 
results are presented in a three-dimensional plot with the flux plotted against glucose and 
lactate concentrations (Figure 5.2).  The resulting plot shows a high and a low surfaces 
representing high and low fluxes, respectively.  The surfaces are colored in red, blue and 
yellow. The top (red) surface represents the plane of high flux steady states. The bottom 
(blue) surface represents the plane of low flux steady states and the yellow region 
represents the plane of unstable steady states. A slice of the plot at a fixed lactate 
concentration of 0.4 mM along the glucose axis yields the curve shown in Figure 5.1B.  
On this constant lactate plane the “switch-up” and “switch-down” points can be seen.  
With increasing levels of lactate, the “switch-up” glucose concentration shifts to higher 
glucose levels. At very high lactate concentrations (> 40 mM), the “switch-up” 
concentration will move to extremely high glucose concentrations that are not seen even 
in culture as they would represent near lethal high osmolality to cells.  Even in this region 
of very high lactate, switching down from high state to low state is feasible if glucose 
concentration falls to very low levels.  
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Figure 5.2: Effect of lactate on bistability. Effect of lactate on the multiplicity of states 
in glycolysis is probed by model simulation at various combinations of lactate (0-50 mM) 
and glucose (0-15 mM) concentrations typically seen in cell culture processes. The 
bistable behavior in glycolysis imparts more complex dynamics as lactate concentration 
is varied. 
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5.3.3  Effect of AKT on Bistability 
The AKT signaling pathway regulates growth and proliferation, and stimulates the 
activity of glycolysis [78,110]. The AKT signaling cascade induces the transcription of 
the glucose transporter GLUT1 and mediates the association of HK1 with outer 
mitochondrial membrane (Figure 5.3). The active form pAKT can also phosphorylate the 
enzyme PFKFB to enhance its kinase activity [20,21] resulting in an increase of F26BP 
production and thus increasing the flux of glycolysis.  In fed-batch cultures, cells grow to 
a maximum concentration after which they cease to proliferate.  As the growth rate of the 
cells slows down, simultaneous reduction in the pAKT level has been observed in the late 
stage of fed-batch cultures [23], causing glycolysis activity to also decrease.  Among the 
three enzymes regulated by AKT, PFKFB is stimulated at its activity level whereas the 
other two (GLUT1 and HK1) are regulated at the transcriptional or spatial level. For 
stability behavior our focus is on the system in which enzyme levels are kept constant 
and uniformly distributed inside the cells. Our investigation on the effect of growth on 
glycolysis flux thus focused on the regulation of AKT on PFKFB.  
The regulation of glycolysis flux by growth control is modeled by an activation of the 
kinase activity of the bifunctional enzyme PFKFB using an empirical formulation 
depicting an increasing kinase activity with increasing pAKT in a saturation type of 
kinetics (Eq. S4 in Appendix Materials, Rate Equations section). A similar expression has 
been used previously to describe the effect of AKT on glycolysis [59,60].  
Four discrete values of pAKT activity were examined and the steady-state behavior of 
glycolysis flux at various glucose and lactate concentrations are shown in Figure 5.4. At a 
high pAKT activity (pAKT = 1, Figure 5.4A), a shift from the high flux plane to the low 
flux plane can occur only at very low glucose concentrations (~1 mM) for the entire 
lactate concentration range examined.  However, with lower pAKT activities, a section of 
the top plane recedes towards higher glucose concentration such that a metabolic shift 
from the high flux plane to the low flux plane is possible at higher glucose concentrations 
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(Figure 5.4B-D).  The section of the top plane that regresses is confined to a small range 
of lactate concentration (~15-40 mM).   
 
Figure 5.3: Regulations of AKT on glycolysis. The metabolic control of the cells is 
tightly linked to growth control through signaling pathways such as AKT. The AKT 
signaling cascade has been shown to activate the transcription of GLUT1 and mediates 
the association of HK with outer mitochondrial membrane to provide direct access to 
ATP as a driving force for high rate of glycolysis. In addition, AKT can phosphorylate 
PFKFB to shift its kinase/phosphatase ratio to increase the formation of fructose 2,6-
bisphosphate levels which in turn increases PFK activity and glycolysis flux. 
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Figure 5.4:  Effect of AKT on the bistability in glycolysis activity. The red and blue 
surfaces are stable steady states representing the high and the low glycolytic flux states, 
respectively.  Yellow surfaces are unstable steady states.   
5.3.4  Trajectory of the Metabolic Shift  
In a fed-batch culture glucose is added intermittently to sustain its concentration within a 
range. Lactate is produced at a high specific rate in the growth phase, but its production 
rate is subject to variation when the growth rate decreases in the late stage of cell 
cultivation. In some cases the culture continues to consume glucose and produces lactate 
at high rates during the period when cell growth has ceased; while in other cases glucose 
consumption rate on a per cell basis becomes small and lactate production diminishes, or 
lactate is even consumed [4]. The phenomenon thus suggests that the two types of 
cultures differ in their trajectories while progressing on the high flux plane.  
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We performed a set of transient simulations to demonstrate different scenarios where 
cultures may have different metabolic fates.  Cells are initially at a position on the high 
flux plane of high pAKT activity in growth stage and move along a path with decreasing 
glucose concentration (due to glucose consumption) and increasing lactate concentration 
(due to lactate production). As the growth rate decreases in the later stages of the cell 
culture, the culture behavior is depicted by a line (line AB in Figure 5.5) in a surface plot 
resembling Figure 5.4C. In the first case the path encounters the receded section of the 
high flux plane leading to a switch down from the high flux plane to the low flux plane 
(line BC in Figure 5.5). In the other case, while moving along the path, glucose 
concentration is increased due to glucose feeding in fed-batch culture (line BF, Figure 
5.5). The feeding causes the path to shift and eventually leads to a trajectory that does not 
encounter the receded plane thus confining the cells to the high flux plane.  In the first 
case, upon switching to a low flux state, an addition of the same amount of glucose to the 
culture (line CD, Figure 5.5) will not cause the culture to switch back to a high flux state. 
Such a difference in the timing of glucose feeding is not uncommon in industrial 
manufacturing, as observed in the archived manufacturing data [3,4] and in laboratory 
practices.  Even cultures under the same conditions are not exact replicas.  Feeding of 
nutrient and glucose to a fed-batch culture is either prescribed as fixed time point or 
responding to a range of the controlled variable.  A small difference in the timing of 
glucose feeding may cause cultures with very similar metabolic behavior to diverge to 
different outcomes. 
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Figure 5.5:  Transient simulations of cultures with and without metabolic shift. Cells 
at exponential stage are initially cultured in high glucose and low lactate concentrations 
and exhibit high growth rate/AKT activity. (A-B) As the culture progresses, AKT activity 
decreases, glucose is consumed and lactate accumulates in the culture such that the 
trajectory follows the curve A-B in the top plane. (B-C) After certain time, the culture 
encounters a section of the top plane that regresses at slow growth phase. Such culture 
with slightly later glucose feeding time shows a metabolic shift. The cells have sufficient 
time to enter the regressed region and shift their metabolism from the high flux state to 
the low flux state. (C-D-E) After addition of glucose, cells remain at the low flux state 
and consume lactate.  (B-F) Culture with early glucose feeding time shows no metabolic 
shift behavior. Simulation shows that with early glucose feed the cells are able to avoid 
the regressed region of the top plane and continue their trajectory along the top plane, 
consuming huge amount of glucose and producing large amount of lactate (F-G).  
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5.3.5  Experimental Evidence of the Effect of Lactate  
A recombinant CHO cell line was grown in four fed-batch cultures with initial sodium 
lactate concentrations of 0, 10, 30 and 50 mM (Figure 5.6A, also see the CHO Cell 
Culture section of the Materials and Methods). Osmolarity at inoculation was adjusted to 
340 mOsm/kg in all four conditions, using appropriate amounts of sodium chloride.  In 
the culture without any initial lactate supplementation (0 mM), a metabolic shift to lactate 
consumption was seen after cell concentration peaked at 8x10
6
 cells/mL (Figure 5.6C). 
During the period of lactate consumption, glucose consumption is at a low flux state. A 
similar shift of metabolism was observed in the culture with 10 mM initial lactate 
supplementation. In contrast, the cultures initially at higher lactate levels of 30 and 50 
mM did not shift to lactate consumption (Figure 5.6A).  
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Figure 5.6: Effect of lactate on the metabolic fate of cell culture. Four fed-batch 
cultures of a recombinant CHO cell line were started with various amounts of initial 
lactate supplementation. The metabolic fate of a culture depends on the initial lactate 
concentration. (A) Lactate (B) Glucose (C) Viable cell concentration (D) Osmolarity  
Admittedly lactate concentration also exerted a significant effect of growth rate, thus the 
difference in the metabolism of the four cultures may not be solely attributable to lactate 
concentration. Nevertheless, the results are consistent with the model prediction shown in 
Figure 5.4 that a switch from the high flux state to the low flux state while glucose level 
is moderately high occurs only within a certain range of extracellular lactate 
concentrations.  At higher levels of lactate than the “switch-permissible” range, as in the 
cases of 30 and 50 mM, cells cannot switch to low flux state; whereas at lower levels of 
lactate the switch to low flux state, as indicated by lactate consumption, is observed.  
5.3.6  Experimental Evidence of the Effect of History on Metabolic Shift  
Cells were next cultivated in two fed-batch cultures supplemented with 30 mM of sodium 
lactate as described above. The two cultures were under identical treatment until in late 
exponential growth stage, when one of them received glucose feeding to maintain a high 
level of glucose (Figure 5.7A, open diamonds). For the other culture, glucose was 
allowed to decrease to a low level and was maintained at low levels for a period of time 
by intermittent glucose spiking (Figure 5.7A, open squares). In the first culture, glucose 
continued to be consumed at a high rate and lactate continued to accumulate until even 
after viable cell concentration decreased. The results for the first culture are the same as 
shown in Figure 5.6 where at high levels of lactate, a switch to a low glycolytic flux (or 
alternatively lactate consumption state) at moderately high level of glucose is not 
possible. This is in contrast to the second culture. By allowing glucose concentration to 
decrease to a very low level, metabolism switched to a low flux state as predicted in 
Figure 5.4. Upon switching to a low flux state with lactate consumption, the glucose level 
in the second culture was increased to high levels again at 230h. In this case glucose 
consumption continued to be low, a clear indication that once a low flux state is achieved 
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cell metabolism can be maintained at a low flux state even with an increase in glucose 
concentration, unless the glucose concentration is increased to a level beyond the switch-
up concentration. 
 
Figure 5.7: Memory of metabolic state. Two fed-batch cultures of a recombinant CHO 
cell line were run with different feeding strategy. (◊) Glucose was maintained at high 
levels. The culture continued to produce lactate. (□) Glucose was maintained at a low 
concentration for a period of time by intermittent glucose feeding. The cells shifted their 
metabolism to lactate consumption. Lactate continued to be consumed even after glucose 
was restored to a high concentration. 
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5.4  Discussion 
Using a mechanistic model we have shown previously that with the combination of 
isozymes typically seen in proliferating cells the glycolysis flux exhibits classical steady 
state multiplicity [112].  In the bistable region, high flux and low flux steady states 
coexist; at the edges of bistable region, the metabolism may shift-up or shift-down to a 
different flux state when glucose concentration is changed from the bistable region into 
regions in which only one steady state is possible. The glucose concentration for shift-
down from a high flux state to a low flux state is notably low and outside the 
physiological range. The model prediction of low “switch-down” glucose concentration 
is consistent with experimental observations reported in fed-batch cultures [70,111,115]. 
Using an on-line control system to deliver glucose and to control glucose concentration at 
low levels, the high glucose consumption rate and lactate production rate in hybridoma 
cells were switched to low levels. It was notable that in those studies the glucose 
concentration was controlled at very low levels in order for the switch to occur, akin to 
the model prediction. 
Lactate may also be consumed in the late stages of fed-batch culture when the cell 
concentration is high and the growth rate is decreasing [23].  In those cultures, cells 
switch from a lactate production state during the exponential growth to a lactate 
consumption state when the growth rate diminishes. The switch occurs only when 
glucose flux is low.  A prominent difference between the contemporary metabolic switch 
in the late stages of fed-batch culture and the earlier reports of metabolic shift through 
controlled glucose feeding is the glucose level at the point of metabolic switch.  While in 
the early studies it was necessary to control glucose at very low levels, in later stage fed-
batch cultures the glucose concentration can be high at the time of switching.  
In recent times much progress has been made in advancing our understanding of the 
interplay between energy metabolism and growth control and oncological transformation. 
Of particular relevance to cell culture bioprocessing is the influence of lactate levels and 
growth control on glycolysis. We incorporated the inhibitory effects of lactate and 
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regulatory role of growth (through AKT) in our mechanistic model of energy 
metabolism.  
Model simulation demonstrated that increasing lactate concentration increases the shift-
down glucose concentration, allowing the switch to low flux state at a higher level of 
glucose as seen in the late stage of culture. However, at a low AKT activation level, the 
effect of lactate is not monotonic (Figure 5.4). At low levels of lactate an increase of its 
concentration increases the “switch-down” glucose concentration, but beyond a point the 
trend is reversed; further increase of lactate concentration actually decreases the “switch-
down” glucose concentration. There is thus a window of lactate concentrations within 
which the “switch-down” glucose concentration is highest; at lactate concentrations 
higher or lower than that, the “switch-down” glucose concentration decreases again. This 
rather complex steady state behavior in response to lactate level is the result of the 
balance of two factors at play, the suppression effect on flux by lactate and the 
stimulatory effect on flux by F16BP.  As the growth rate decreases, the window widens 
and the “switch-down” glucose concentration becomes higher.  
In fed-batch cultures, even under seemingly identical culture conditions, the 
physiological trajectory of the culture may not be identical.  The different metabolic 
outcomes seen in industrial biomanufacturing processes might be the outcome of subtle 
differences in their operation. Using our model we demonstrated a scenario in which 
difference in the timing of glucose addition results in two different metabolic states 
(Figure 5.5). The experimental data presented in this study provide further evidence to 
support our model prediction. 
The steady state profile of glycolysis flux is affected by the isozymes that are expressed 
in the cell.  Most cells and tissues express a mixture of different isoforms of the same 
enzyme, although one isoform is often the dominant type. Different producing cell lines 
often have varying composition of isozymes in glycolysis.  Furthermore, the relative 
abundance levels of different enzymes are also somewhat different.  In our previous study 
we have shown that the expression of mixture of isozymes alters the switch-up and shift-
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down glucose concentrations [112].  It is likely that different cell lines will have 
somewhat different dynamic behaviors of glucose metabolism.  
Recently there has been increasing interest in employing continuous culture or 
continuous culture with cell recycle (perfusion culture) for cell cultivation. The rationale 
is that continuous processes minimize equipment down time and increase overall 
productivity. Since multiplicity of metabolic states occurs under some conditions, it is 
likely that those distinctive metabolic states will also lead to different steady states of the 
culture: at a high flux state, the vast majority of glucose is converted to lactate, hence a 
low cell concentration; conversely at a low flux state, little glucose is diverted to lactate, 
and a high cell concentration is achieved.  Published experimental results of continuous 
culture did suggest that difference in metabolism gave rise to different cell concentrations 
[61,116,117]. 
The mechanistic metabolic model presented above has provided insights into the possible 
cause of the somewhat erratic behavior of metabolic shift to a low flux and lactate 
consumption state often seen in cell culture bioprocessing. The experimental evidence 
supports the notion that the steady state multiplicity is at play, and may possibly be the 
root cause of this behavior. With a better understanding of the mechanistic cause of the 
lack of consistency of metabolic shift in culture, one can begin to explore the feasibility 
of controlling the metabolism and ensuring metabolic shift through external medium 
components such as enzyme inhibitors or through cell engineering.  
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Chapter 6  Multiplicity of Steady States with Distinct 
Cell Concentration in Continuous Culture of Mammalian 
Cells 
6.1  Summary 
In some cases of industrial bioprocessing, continuous mode of operation, wherein feed 
media is being added continuously while reactor content is withdrawn at equivalent flow 
rate, is used. The continuous removal of the reactor content is especially suitable for 
cases where the product is unstable such as Factor VIII. In addition, continuous culture 
offers great advantages including increased productivity, consistent product quality and 
longer culture duration. Accumulation of lactate produced by the cells, however, inhibits 
cells from growing to high concentration. Even when cell retention devices are employed 
such as in perfusion cultures, operation at high dilution rate is required to purge lactate 
from the reactor and sustain long culture duration. Under certain conditions, multiplicity 
of steady state in continuous culture has been observed. At seemingly identical dilution 
rate and feed glucose concentration, some continuous cultures reach steady state with 
high glycolysis flux and high lactate production, while others reach steady state with low 
glycolysis flux and low lactate production. The two kinds of steady states have different 
metabolic efficiency and thus exhibit distinct steady state cell concentrations. 
Understanding the precise conditions that lead to those steady states is therefore critical 
to achieve the desired cell density and productivity. We have previously demonstrated 
that cultured mammalian cells exhibit bistable behavior in glycolysis with distinct high 
flux and low flux states. In this study, we establish a multi-scale model taking into 
account the intracellular metabolism and macroscopic cell growth in the reactor. Using 
the model, we show that steady state multiplicity exists in a range of dilution rates in 
continuous culture as a result of the bistable behavior in glycolysis.  The actual steady 
state reached is dependent on the trajectory followed by the culture. 
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6.2  Introduction 
Mammalian cells are the predominant host cells for the production of therapeutic 
recombinant proteins. In the past two decades, fed-batch cultures, wherein feed 
containing nutrients including glucose and amino acids are regularly added to the culture 
to replenish the nutrients consumed to sustain a longer cell growth and production period, 
has become the prevailing form of process. The product accumulates to very high 
concentration in the reactor and is harvested at the end of the fed-batch culture. Another 
culture mode is continuous culture, wherein feed media is being added continuously 
while reactor content is withdrawn at equivalent flow rate simultaneously, keeping the 
reactor volume constant. The product is extracted from this efflux continuously. While 
continuous process has been explored as a process technology and for kinetic studies of 
cell growth and metabolism [118-127], its industrial applications are mostly in the case 
that the product is labile or is produced at a rather low concentration, such as Factor VIII 
and Protein C.  
A simple continuous culture is limited in its productivity because of the large amount of 
metabolites, including lactate and ammonia that accumulate in the culture from the 
catabolism of glucose and amino acids. The accumulation of those metabolites has 
adverse effects on cell growth [128,129] and productivity [130-132]. Such accumulation 
is detrimental for continuous cultures, as steady growth must be sustained for long culture 
duration. Typically the dilution rate that is needed to purge out the metabolites and to 
sustain cell growth is higher than the specific growth rate. As a consequence, a cell 
recycle stream is often employed to return a concentrated cell stream to the reactor and to 
avoid a wash-out of the culture [133-135]. This mode of operation, called perfusion 
culture, mitigates the accumulation of inhibitory metabolites and provides an 
environment favorable to the cells to grow to a much higher density compared to a simple 
continuous culture.  
A key factor for the successful implementation of a perfusion culture is the robustness of 
the cell separation device that takes the exhaust stream from the reactor and returns a 
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concentrated cell stream to the reactor. Various technologies such as spin filters 
[136,137], centrifuges [138,139], gravitational settlers [140,141], hollow-fiber separators 
[142,143], acoustic separators [133,144,145], microfiltration [146-148] and alternating 
tangential flow filters [149,150] among others have been employed in perfusion culture. 
In recent years the cell separation technologies have been refined to become more robust 
and the protein content of the medium employed in cell culture has been reduced to 
alleviate equipment fouling problems. Some industrial perfusion cultures are now 
practiced for as long as six months.  
The successful practice of perfusion culture for many products has spurred a renewed 
interest in continuous processes for biologics manufacturing. Continuous cell culture 
processes allow a very high cell concentration to be sustained in the reactor for an 
extended period. The increased productivity allows a small manufacturing facility to be 
used. Continuous cell culture processes also offer the advantage of a steady state 
operation and possibly allow for a better control of the cells’ physiological state, thereby 
enhancing our ability to control product quality. 
However, the growth and metabolic behavior of mammalian cells differ significantly 
from those of most microbial cells. While the growth of microorganisms can often be 
adequately described by a Monod growth model and be shown experimentally to have a 
unique stable steady state under a set of nutrient conditions and at a fixed dilution rate, 
the complex metabolism of cultured mammalian cells is known to utilize nutrients 
differently under different physiological states. Such capability was demonstrated in 
metabolic shift of glucose catabolism in many types of cultured cells [70,131]. Under 
those different metabolic states, the proportion of carbon source diverted to lactate 
changed from a very high value of over 90% of glucose being converted to lactate to less 
than 10%. Given the same input of carbon sources, the metabolic shift resulted in a 
higher proportion of carbon being directed toward cell mass. This rationale led to the 
attempts of altering cell metabolism to low lactate production by controlling glucose 
levels in a fed-batch culture prior to the initiation of continuous culture [116,117]. The 
culture reached a steady state with a higher cell concentration compared to the culture 
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started from batch mode without alteration in cell metabolism. Because the feed and the 
operating dilution rate are the same, these results suggest the existence of steady state 
multiplicity. Similar demonstrations of steady state multiplicity in continuous culture 
were reported in other studies [151,152]. Such steady state multiplicity was observed 
merely through conjecture based on metabolic observation and was only explored in a 
narrow range of dilution rate, as the true cause of multiplicity and the range of conditions 
that multiplicity exist are not known.  
We have previously shown that, with the combination of isozymes expressed in 
mammalian cell lines, the glycolysis flux exhibits multiple steady state behavior [153]. 
The glycolysis flux increases with increasing extracellular glucose concentration as in 
most metabolic pathways, but in a range of glucose concentrations multiple steady states 
exist for a given glucose concentration. Because of allosteric inhibition of the enzyme 
phosphofructokinase (PFK) by lactate, the bistable behavior differs somewhat at different 
lactate levels (see Chapter 5 of this thesis). In the bistable region, the glycolysis flux (i.e. 
the specific glucose consumption rate of the cell) may be at either a high flux state or a 
low flux state. At a high flux state, glucose is consumed rapidly and lactate is produced at 
a high rate. At a low flux state, glucose consumption rate is low and lactate is either 
produced at a slow rate or even consumed. In the late growth phase of a fed-batch culture, 
the culture can move into a region in the steady state space where it can transit from a 
high flux state to a low flux state (see Chapter 5 of this thesis). The metabolic model thus 
provides a mechanistic foundation for the metabolic shift seen in fed-batch cultures as 
well as in continuous cultures. 
In this study, we extend our exploration to continuous culture systems by constructing a 
multi-scale reactor model that incorporated the intracellular metabolism of the cells and 
the macroscopic evolutions of cell growth, glucose and lactate in the reactor. Through 
model simulations, we show that multiplicity of steady states is present in a range of 
dilution rates in continuous culture as a result of the bistable behavior in glycolysis, and 
that different metabolic states are marked by distinct steady state cell concentrations.  In 
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addition, the path followed by the culture dictates the actual steady state reached. 
Strategies to guide the culture towards a desired steady state are discussed. 
6.3  Results 
6.3.1  Multiplicity of Steady States in Continuous Culture 
The multi-scale model encompassing intracellular metabolism and macroscopic 
evolutions of cell growth and glucose and lactate concentrations in the reactor (Figure 3.2 
in Materials and Methods) was used to first find the steady state reached in continuous 
culture. The steady state concentrations of cells, glucose and lactate as well as the flux 
(i.e. specific consumption rate) of glucose and lactate at different dilution rates are shown 
in Figure 6.1.  The glucose concentration in the feed was fixed at 5 mM (Figures 6.1A-
C). The figures depict classical bistable behavior where two stable metabolic steady 
states exist in the dilution rate ranging from 0.029 to 0.039 h
-1
. The middle steady states 
are unstable ones which can never be realized in the culture. The glucose flux and lactate 
flux data in the bistable region indicate that a set of stable steady states corresponds to 
high flux state and the other set correspond to low flux state. At high flux states, glucose 
is mostly converted towards lactate as indicated by the ratio of lactate flux and glucose 
flux into glycolysis (JL/JG) which is in the range of 1.45-1.6 mol/mol. In contrast, the low 
flux states have (JL/JG) < 0.8 mol/mol. In addition, the high flux states have lower cell 
concentrations and higher lactate levels, while the low flux states have higher cell 
concentrations and lower lactate levels. Thus, glucose is more efficiently metabolized to 
support cell proliferation at low flux states. Outside of the bistable region, only one 
steady state exists for a given dilution rate: at dilution rate <0.029 h
-1
 only the low 
metabolic flux state (high cell concentration) exists whereas at dilution rate > 0.039 h
-1
 
only the high metabolic flux state (low cell concentration) exists.  
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Figure 6.1: Multiple steady states in continuous culture. Bistability is observed in the 
profiles of cell concentration (A,D,G), extracellular concentrations of glucose and lactate 
(B,E,H), rates of glucose consumption and lactate production and the ratio of the two 
rates (C,F,I). Feed glucose concentration was 5 mM (A-C), 8 mM (D-F) and 12 mM (G-
I), respectively. The steady states corresponding to low metabolic flux are in blue, while 
those corresponding to high metabolic flux are in red. The unstable steady states are in 
black. Note that the steady states with low metabolic flux confer high cell concentration 
and vice versa. 
The effect of increasing the feed glucose concentration on the steady state behavior was 
then investigated by varying the feed glucose concentrations from 5 mM to 8 mM 
(Figures 6.1D-F) and 12 mM (Figures 6.1G-I), respectively. At a low flux steady state 
increasing feed glucose concentration gives rise to a higher steady state cell 
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concentrations as well as somewhat elevated residual glucose and lactate concentrations 
(comparing Figures 6.1B,E,H), although the extent of cell concentration increase 
diminishes somewhat at the high dilution rate region at a feed glucose concentration of 12 
mM. This is due to the higher levels of residual glucose concentration (thus lower 
amounts of glucose taken up by cells) at those steady states. In contrast, increasing feed 
glucose concentration at high flux states does not increase the cell concentration 
substantially, rather the residual lactate concentration increases significantly. At the low 
feed glucose concentration of 5 mM, the high flux state extends only to a dilution rate of 
0.029 h
-1
, below that only the low flux state is observed. Whereas at higher feed glucose 
concentrations the high flux metabolic steady states reach into lower dilution rate range.  
6.3.2  Effect of Feed Lactate on Steady State 
Consumption of lactate typically occurs in the late stage of fed-batch cultures. It happens 
when the glycolysis flux is low [23]. In continuous culture, while steady states with low 
lactate production rate are possible under normal feed condition as shown in Figure 6.1, 
steady states with lactate consumption do not occur unless lactate is present in the feed.  
The steady state profiles of continuous cultures with a feed glucose concentration of 5 
mM and lactate supplemented at 2 mM and 5 mM are shown in Figure 6.2. In both cases, 
lactate consumption only occurs at dilution rate < 0.021 h
-1
. In this range of dilution rate 
in which lactate consumption is observed, cell concentration is hardly affected compared 
to the case of no lactate supplementation (comparing with Figure 6.1A). In the lactate 
consumption state a significant residual lactate concentration is present in order to drive 
lactate uptake by cells. At higher concentrations of lactate supplemented in the feed, the 
maximum achievable cell concentrations are reduced due to lactate inhibition on growth 
(data not shown).  
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Figure 6.2: Effect of feed lactate on the bistable behavior in continuous culture. 
Lactate concentration in the feed was 2 mM (A-C) and 5 mM (D-F), respectively. Lactate 
is consumed only at dilution rate <0.021 h
-1
.  
6.3.3  Trajectory to Steady State in Continuous Culture 
We next ask the question of how to direct a continuous culture to a different steady state 
in the bistable region. The key is to “guide” the cells to the desired flux state before the 
culture reaches steady state. For increasing the productivity, the desired steady state is the 
low flux state with a higher cell concentration compared to the high flux state. In a batch 
culture of mammalian cells the default steady state is always the high flux state as cells in 
culture, without intervention, always consume glucose at a high rate and convert a large 
portion of glucose to lactate. To “guide” the system toward a low flux steady state in 
continuous culture, one strategy is to first culture them in fed-batch with glucose 
maintained at low concentration. Such strategy allows the culture to move to a region in 
which only the low flux state exists (Appendix Figure 8). Once the metabolic state is at a 
low flux state one can switch the culture to a continuous mode.  
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This scenario is illustrated by two simulated cultures: in one case a batch culture is 
switched to a continuous mode without guiding cells to a low flux state (Figure 6.3A-B); 
in the other a low glucose concentration is imposed in fed-batch culture to first guide 
cells to a low flux state (Figure 6.3C-D). The initial conditions used are 1.5x10
5
 cells/mL 
and 0 mM lactate in both cases. Upon switching to continuous mode, the dilution rate is 
0.033 h
-1
 and feed glucose concentration is 7 mM in both. 
 
Figure 6.3: Transient simulations of continuous culture that reaches steady states 
with distinct cell concentration. (A-B) Culture started from batch mode exhibits high 
metabolic flux and remains at high flux state upon initiation of continuous culture. Such 
culture reaches steady state with high metabolic flux and lower cell concentration. (C-D) 
Culture started from fed-batch with glucose maintained at low level exhibits a metabolic 
shift to low flux state. Upon initiation of continuous mode, the culture remains at low 
flux state and reaches steady state with higher cell concentration. Arrow (↑) indicates the 
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time at which continuous mode is initiated. In the continuous mode, dilution rate and feed 
glucose concentration were fixed at 0.033 hr
-1
 and 7 mM, respectively. 
The batch culture is initiated with a glucose concentration of 15 mM. It consumes 
glucose and produces lactate at very high rates and reached 11.8 mM and 4.9 mM of 
glucose and lactate respectively at 50 h (Figures 6.3A-B). The ratio of glucose to lactate 
conversion (JL/JG)  is 1.55 mol/mol, indicating that the culture operates at high metabolic 
flux state. At this time, with a cell concentration of 1.3x10
6
 cells/mL, the culture is 
switched to a continuous mode. The culture continues at a high flux state (JL/JG is 1.53 
mol/mol) to reach a steady state with a relatively low cell concentration of 2.1x10
6
 
cells/mL.  
For the fed-batch culture, glucose concentration is maintained at 0.5 mM. Over time the 
culture undergoes metabolic shift to a low flux state. After 110 h (Figures 6.3C-D) JL/JG 
was 0.22 mol/mol indicating low metabolic state. Cell concentration reaches 5.1x10
6
 
cells/mL. At this point, the culture is switched to continuous mode, where it continues at 
a low flux state as indicated by the low JL/JG. Glucose and lactate concentrations settled 
down to 0.54 mM and 3.2 mM, respectively, and the cells continued to grow before 
reaching a final steady state concentration of 8.2x10
6
 cells/mL.  
6.3.4  Directing Continuous Culture to Steady State with Low Glycolysis 
Flux 
Continuous cultures of MAK hybridoma cells were initiated either from batch or fed-
batch mode (also see the MAK Cell Culture section of the Materials and Methods). A 
typical continuous culture, started from a batch culture, is shown in Figure 6.4 (solid 
squares). Cells were inoculated at a concentration of 1.5x10
5
 cells/mL using a medium 
identical to that used for cell maintenance except that the initial glucose concentration 
was 3 mM. After 45 hours, the cell concentration increased to 8x10
5
 cells/mL while 
lactate accumulated to 3.9 mM.  JL/JG is 1.44 mol/mol, which is in the range typically 
seen in batch cultures. At this point, the culture was switched to continuous mode. 
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Dilution rate of 0.033 h
-1
 and feed medium as described in the MAK Cell Culture section 
of the Materials and Methods were used. Steady state, as judged from the cell, glucose 
and lactate concentrations, was reached at approximately 200 h. The viable cell 
concentration at steady state was 3.6x10
6
 cells/mL, whereas glucose and lactate 
concentrations were 0.23 mM and 2.7 mM, respectively. JL/JG is approximately 1.30 
mol/mol at steady state. 
 
Figure 6.4: Directing continuous culture to steady state with low glycolysis flux by 
glucose control. Continuous cultures were started either from batch cultures (■ and ♦) or 
fed-batch cultures with glucose maintained at 0.3 mM (□ and ◊). Cultures initiated from 
batch mode reached steady states with lower cell concentrations while those started from 
fed-batch mode reached steady states with higher cell concentrations. Arrow (↑) indicates 
the time at which continuous mode is initiated. 
Cultures were also started from fed-batch mode. Cells were inoculated at a concentration 
of 1.5x10
5
 cells/mL using a medium identical to that used for maintenance except that the 
initial glucose concentration was 0.55 mM. Enriched medium with fortified nutrient 
concentrations was fed according to a strategy previously described [70] to maintain 
residual glucose concentration near a set point of 0.28 mM. Cell concentration increased 
steadily to 5x10
6
 cells/mL for 90 hr. During this time period, lactate accumulated to 2.8 
mM (Figure 6.4). At this point, JL/JG was 0.13 mol/mol, indicating a shift in metabolism 
towards low lactate production. The culture was then switched to continuous mode at 
dilution rate of 0.033 hr
-1
 and feed medium as described in the Materials and Methods 
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was used. Steady state was reached at approximately 250 hr. The steady state viable cell 
concentration was 5.4x10
6
 cells/mL, while glucose and lactate concentrations were 0.21 
mM and 1.2 mM, respectively. JL/JG is approximately 0.12 mol/mol at steady state. 
Consistent with the model prediction, these results show that guiding the metabolic state 
of the cells prior to initiation of the continuous culture can determine the actual steady 
state reached at identical operating conditions.  
6.4  Discussion 
We constructed a multi-scale model combining intracellular metabolic pathways with the 
macroscopic cell concentration in a continuous bioreactor. The steady state multiplicity 
predicted by the mechanistic metabolism model is manifested in the continuous 
bioreactor.  In the bistable region, for a given dilution rate, the culture can exist at either a 
high flux steady state or a low flux steady state. The two kinds of steady states have 
different metabolic efficiency. At a high flux state the vast majority of glucose is 
converted to lactate, whereas at a low flux state more glucose consumed is converted to 
biomass. Thus different steady states are marked by distinct steady state cell 
concentrations. With the feed glucose concentration used in the simulation, multiple 
steady states are observed only in a range of dilution rates. Outside of the bistable region, 
in the high dilution rate region only the high flux states are present whereas in the low 
dilution rate region only the low flux states exist. It is notable that the model predicts that 
in the range of lactate production rate to glucose consumption rate ratio (JL/JG) between 
0.8-1.45 no stable steady state exists. The experimental data in literature are in close 
agreement to this finding [126,127]. 
In the bistable region, which steady state (high flux state or low flux state) a culture will 
reside in is dependent on the history of the culture. One can thus influence the steady 
state to be reached by controlling the cell’s metabolic state before steady state is reached. 
Since the “default” state of cells in culture under typical culture conditions is a high flux 
state, at issue is thus “guiding” the cells to a low flux state before steady state is reached. 
This was illustrated by two approaches: one by eliciting a metabolic shift to a low flux 
82 
 
state in fed-batch culture via controlling glucose at low levels (Figure 6.3), and the other 
by operating at a low dilution rate region in which only the low flux steady state exists 
before gradually increasing the dilution rate to the bistable region (Figure 6.5). Indeed 
these two approaches were used to reach a low flux steady state in two experimental 
studies [117,151]. 
 
Figure 6.5: Directing continuous culture to steady state with a low glycolysis flux by 
controlling dilution rate. Culture was started in batch mode and exhibits high metabolic 
flux.  The culture is then switched to continuous mode with dilution rate of 0.021 h
-1
 and 
feed glucose concentration of 7 mM. By operating at a low dilution rate, the culture 
reaches a steady state with low metabolic flux. Incrementally increasing the dilution rate 
to a final rate of 0.033 h
-1
 allows the culture to remain at low flux and reaches a final 
steady state with higher cell concentration (compared to Figure 6.3A). Arrow (↑) 
indicates the time at which continuous mode is initiated. 
The bistable behavior observed in continuous culture is reminiscent of that observed in 
fed-batch cultures. Cells in the later stage of fed-batch cultures can switch their 
metabolism from high rate of lactate production to lactate consumption. Metabolic shift 
to lactate consumption in fed-batch cultures has been shown to be correlated with a 
higher productivity [3,4]. In continuous culture, steady state with lactate consumption 
does not exist without lactate supplementation in the feed. Addition of lactate to the feed 
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medium of a continuous culture may not be used in practice, but the result does show its 
feasibility as a steady state operation.  
There has been a resurgence of interest in using continuous culture for recombinant 
therapeutic protein production [154]. With the patent expiration of older generation of 
therapeutics, follow-on biologics, also called biosimilars, are entering the market creating 
a wave of generic drugs. The prospect of producing biosimilars in different regions in the 
world has provided incentives for constructing regional manufacturing facilities. Many 
new facilities will aim to be smaller and more flexible in terms of the product they 
produce while sustaining a high throughput similar to the facility designed for fed-batch 
manufacturing. Continuous processes are well suited to such purposes.  
Furthermore continuous processes offer the possibility of steady state operation in which 
the metabolic state of cells is kept relatively constant as opposed to constantly changing 
nature in fed-batch cultures. Increasingly biopharmaceutical production is focusing on 
controlling product quality in addition to the productivity. The glycosylation pattern of 
the product protein is a key product attribute that process engineers strive to control and 
is reported to be affected by many environmental factors that fluctuate in typical fed-
batch cultures [155-158]. Steady state operation of continuous cultures may minimize 
such culture variations and provides greater control of product quality.  
The multi-scale model presented demonstrates that multiple steady states exist under 
some culture conditions. Since those different steady states represent different metabolic 
states, they may also elicit different glycosylation patterns or other product quality 
attributes with some being the preferred. In view of such possibilities, controlling the 
culture condition to ensure it follows the trajectory to reach the desired steady state is 
thus critical. The model we established should provide mechanistic understanding to 
prescribe such trajectories to enhance process performance. 
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Chapter 7  Diversity of the Chinese Hamster Ovary Cell 
Line Transcriptomes 
7.1  Summary 
The metabolic behavior of mammalian cells in culture depends not only on the external 
cues such as glucose and growth factors availabilities but also on the intrinsic attributes 
of the cells including gene expression and genetic variations. Different cell lines may 
express different isoforms of metabolic enzymes in different proportions. Furthermore, 
their cultivation for a large number of generations may lead to accumulation of mutations 
in their genomes. These variations can potentially influence their behavior in culture. In 
this chapter, we unveil the transcript level and genetic diversities among different 
Chinese hamster ovary (CHO) cell lines using transcriptomics tools including RNA-seq 
and microarray. We find that CHO cells have the preference for glycolysis isozymes that 
confer high glycolytic flux, similar to proliferating cells such as cancers and embryonic stem 
cells. Among different CHO cell lines, the variability of transcript levels of glycolysis 
enzymes is high suggesting its crucial role in determining the metabolic characteristics of 
the cells. Using RNA-seq, we find that the number of sequence variants and the 
corresponding mutation rate in CHO cells does not appear to be alarmingly high, 
implying mutations in the gene coding regions may not be key to cell line variability. The 
knowledge of the variability in CHO cells will serve as tremendous resource in devising 
strategies to counter the variability in cell line development. 
7.2  Introduction 
Cultured mammalian cells are widely used for the production of recombinant 
therapeutic proteins. Because of their economic importance, much effort has been 
devoted to enhancing our understanding of the physiology of those cell lines. In recent 
years, global survey of the transcriptome using microarrays has been increasingly 
employed to better understand a number of producing cell lines and production processes 
[159-162]. With the rapid advances in sequencing technology, especially direct 
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sequencing of transcripts, or RNA-seq, the repertoire of CHO transcriptome data has 
been expanding [163-166]. These resources will usher the research in cell culture 
bioprocessing into a post-genomic era, increasingly using systems approaches and 
integrating data from various -omics based global surveys (reviewed in [167,168]). 
The use of genomics and transcriptomics tools holds great potential to advance the 
understanding of cellular behavior. It is well known that different production cell lines 
display different characteristics. These differences are not only in productivity but also in 
their growth rate, metabolic behavior and even in the post translational modification 
patterns of the product protein. Such cell line dependent characteristics are possibly 
linked to the variation in gene expression profile. For example, mammalian cells can 
express multiple isoforms of the same metabolic enzyme which catalyze the same 
reaction but have different kinetic properties and are subjected to contrasting regulations. 
The expression of these distinct glycolysis isozymes in different proportions may account 
for the different metabolic behaviors observed in different cell lines. An integrated 
transcriptome-based systems biology approach can be employed to provide insights into 
cell line selection for specific gene expression.  In this study, we survey the transcript 
expression data of the genes in CHO cell lines using microarray. We highlight the 
characteristic isoform expression of CHO cells and the variability among different CHO 
cell lines. The effect of the variation on the metabolic characteristics will be discussed. 
Another possible source of variability is genomic variation, especially in the gene coding 
regions. Cell lines have a propensity to accumulate single nucleotide mutations and copy 
number differences over the course of continual culture since their isolation almost six 
decades ago [169,170]. Accumulation of mutations in the genome can potentially dictate 
their behavior in culture. However, the fraction of the population harboring such 
mutations may remain low unless it offers some growth advantage or recurs repeatedly. A 
majority of such mutations in recombinant cell lines has gone unnoticed because few cell 
lines have been sequenced to adequate depth to detect such low-frequency mutations. 
Even with high-throughput genome sequencing, the depth of coverage employed is rarely 
more than 100. RNA-seq, on the other hand, sequences the transcripts of abundant genes 
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to much greater depth, sometimes to tens of thousands of reads per base. The high depth 
of RNA-seq data enables the detection of large number of low frequency single 
nucleotide variants in cultured cell lines with a high degree of confidence. We thus also 
analyzed the single nucleotide variants in the cell lines for which RNA-seq data are 
available. 
7.3  Results 
7.3.1  Analysis of Transcript Levels of Glycolysis Genes in CHO Cell Lines 
We quantified of the expression levels of genes in fourteen CHO cell lines using 
microarray (Appendix Table 5). The use of these diverse samples was intended to give a 
representative view of the range of transcript expression level for genes that are relevant 
for bioprocessing. The transcript levels of glycolysis enzymes in fourteen CHO cell lines 
are shown in Figure 7.1.  
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Figure 7.1: Gene expression levels of several glycolysis isozymes from microarray 
data of 14 CHO cell lines. The identity of the cell lines are given in Appendix Table 5. 
The hexokinase isozymes HK1 and HK2, are highly expressed in CHO cell lines. Both 
HK1 and HK2 have strong affinity to glucose (low Km) and can physically bind to the 
outer membrane of mitochondria (reviewed in [79]), giving them direct access to ATP 
generated by mitochondria for increased rate of glycolysis. 
CHO cell lines express predominantly the liver (PFKL) and the muscle (PFKM) forms of 
phosphofructokinase (PFK). Both PFKL and PFKM are subjected to activation by 
0
2000
4000
6000
8000
10000
1 2 3 4 5 6 7 8 9 10 11 12 13 14
M
ic
ro
a
rr
a
y
 I
n
te
n
s
it
y
Cell Line
Hk1
Hk2
Hk3
Glucose
Pyruvate
Fructose-1,6-
Bisphosphate
Fructose-2,6-
Bisphosphate
Glucose-6-Phosphate
Phosphoenol
Pyruvate
PK
PFKFB
…
Lactate
PFK
Fructose-6-Phosphate
HK
0
1000
2000
3000
4000
5000
1 2 3 4 5 6 7 8 9 10 11 12 13 14
M
ic
ro
a
rr
a
y
 In
te
n
s
it
y
Cell Line
PFKL
PFKM
PFKP
0
500
1000
1500
2000
2500
3000
1 2 3 4 5 6 7 8 9 10 11 12 13 14
M
ic
ro
a
rr
a
y
 In
te
n
s
it
y
Cell Line
PFKFB1
PFKFB2
PFKFB3
PFKFB4
0
4000
8000
12000
16000
1 2 3 4 5 6 7 8 9 10 11 12 13 14
M
ic
ro
a
rr
a
y
 In
te
n
s
it
y
Cell Line
PKLR
PKM2
0
2000
4000
6000
8000
10000
12000
1 2 3 4 5 6 7 8 9 10 11 12 13 14
M
ic
ro
a
rr
a
y
 In
te
n
s
it
y
Cell Line
LDHA
LDHB
LDHC
LDH
88 
 
fructose-1,6-bisphosphate (F16BP), however, this interaction is absent for PFKP. They 
thus confer a high glycolytic rate as a result of F16BP activation.  
PFKFB3 is the dominant isoform of 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase (PFKFB)  expressed in CHO cell lines. The balance between the activities 
of the kinase (K) and the bisphosphatase (P) domains of PFKFB controls the steady state 
concentration of fructose-2,6-bisphosphate (F26BP) [11,12].  F26BP is a very potent 
activator of the glycolysis enzyme PFK. The flux through glycolysis is, therefore, 
influenced by the K/P activity ratio of PFKFB. Isozymes of PFKFB differ in their K/P 
ratio [81-83]. The K/P ratio of PFKFB3 (~ 700) is the highest among all PFKFB 
isozymes, conferring very strong activation to the flux of glycolysis.  
CHO cell lines express PKM2 as the dominant pyruvate kinase isoform. PKM1 and 
PKM2 are alternatively spliced transcripts encoded by the Pkm gene, with a difference in 
23 amino acids from one alternatively spliced exon. PKM2, but not PKM1, is activated 
by F16BP. PKM2 is under the regulation by many allosteric modulators which is crucial 
for controlling the flux of glycolysis for ATP production and the channeling of the flux 
for biosynthetic needs of the cell. PKM1 is expressed in the majority of adult tissues, 
whereas PKM2 is restricted to embryonic tissues and transformed cells.  
The LDHA isozyme of lactate dehydrogenase isozyme is very highly expressed in CHO 
cell lines. Lactate dehydrogenase is a tetrameric enzyme that catalyzes the reversible 
conversion of pyruvate to lactate. LDHB and LDHC, which are found in heart and 
spermatozoa, respectively, convert lactate to pyruvate that is further oxidized. In contrast, 
LDHA, which is also predominantly expressed in skeletal muscle, kinetically favors the 
reverse conversion of pyruvate to lactate. Many cancers also express LDHA at higher 
levels compared to normal tissues [171]. 
All CHO cell lines express the same dominant isoforms but at different levels. They also 
express different proportions of isoforms of a given enzyme, including those which play 
major regulatory roles. PFKFB2 and PFKFB3 vary by 4-fold and 3-fold, respectively. 
Mulukutla et al. [153] showed that the level of PFKFB enzymes determine the response 
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rate of cells to changes in glucose concentration cells. Similarly, PFKL and PFKM, each 
vary by 3-fold among CHO cell lines. Such variation in the isozyme composition of PFK 
can affect the metabolic profile of cells (Appendix Figure 5) [153]. Other enzymes in 
glycolysis also show some degree of variations (Figure 7.2). The diversity in metabolic 
characteristics of CHO cells under identical culture conditions and/or treatments [172] 
may potentially be the result of such intrinsic variation in gene expression. 
 
Figure 7.2: Variation in glycolysis gene expression levels from 14 CHO cell lines. 
7.3.2  Sequence Variation in CHO Cell Lines 
In addition to the variation in the transcript level, genomic variation can confer distinct 
characteristics in mammalian cells. Typical mammalian diploid genomes harbor two 
copies of the same genes. While many genes are homozygous, some are heterozygous 
and have differences in the alleles. Cultured cells derived from a mammal retain those 
heterozygote sequences, and accumulate additional somatic mutations, including the 
single nucleotide mutations in their genomes. These heterozygous mutations are carried 
over when the gene is transcribed into RNA. The great sequencing depth provided by 
RNA-seq, especially for abundant transcripts, houses a trove of information on single 
nucleotide variants (SNVs). In RNA-seq, a SNV is characterized by a fraction of the 
reads with one base call and another fraction with a different base call at the same 
location (Appendix Figure 9). We identified these SNVs in the transcriptome of five 
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CHO cell lines and in tissue samples from RNA-seq data (Appendix Table 6). On an 
average, each cell line possesses approximately 4,000 SNVs which correspond to a rate 
of 1.6x10
-4
/bp (Figure 7.3A). This rate is substantially lower in liver and brain. 
 
Figure 7.3: Single nucleotide variants in the transcripts of five CHO cell lines and 
two Chinese hamster tissues. (A) Number of variants identified and (B) Distribution of 
variants according to the fraction of variant call at each location. The identity of the cell 
lines are given in Appendix Table 6. 
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These sequence variants occur at different frequencies. In a diploid cell or tissue, a 
variant that arises from heterozygocity will constitute close to 50% of all base calls at that 
particular location. Since CHO cell lines are aneuploid, it is possible that even a variant 
caused by heterozygocity may be present close to 30% or 25% depending on the number 
of that genomic segment in the genome. The recombinant cell lines used in the study 
have undergone single cell cloning at the time they were first derived. They have since 
been in culture for a large number of cell generations. A variant resulting from a mutation 
after single cell cloning will most likely occur in only a small portion of cells unless that 
mutation confers an advantage under some growth conditions to overtake the population. 
To analyze the source of the variants, we plotted the count of variants and the percentage 
of the variant call at each variant location for the five cell lines as well as the liver and 
brain tissues (Figure 7.3B).  A majority of the variants in cell lines were present at 40-
50% of all reads at that position, suggesting a strong possibility that they arose from 
heterozygocity of the tissue of their origin or from the mutation that occurred prior to the 
last single cell cloning. This is in contrast with the variants in tissues for which there is no 
strong presence of variants at 40-50%, possibly as a consequence of extensive inbreeding 
that leads to homozygocity from genetic drift. 
Comparisons were performed to identify sites with distinct nucleotide sequences between 
pairs of closely related cell lines. Each comparison indicates the presence of ~500 – 1,200 
such sites (Appendix Figure 10). Twenty one sites with distinct nucleotide sequence 
between DG44 and rDG_2 were selected to be examined at the cDNA and genomic DNA 
level using Sanger sequencing method. In both cDNA and gDNA (Appendix Figure 11), 
17 sites (71%) were confirmed while four others were false positive. 
7.3.3 Mutations in Growth Signaling Pathways 
We examined the sequences of the genes in the PI3K/AKT, mTOR, p53, cMYC and 
MAPK pathways for mutations that are present in all CHO cell lines compared to 
Chinese hamster tissues. A total of 61 potential sites were spread across 22 genes, 42 of 
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which are located in the protein coding regions.  Five of them cause amino acid changes 
in Pdpk1, Trp53, Map3k10, Mapk8ip3 and Taok2 (Table 7.1).  
Table 7.1: Potential mutations in the growth signaling pathways of CHO cell lines. 
Gene Nucleotide 
Position 
Feature Amino acid change Base call  
in tissues 
Base call  
in cell lines 
Trp53 783 Exon Thr -> Lys C A 
Pdpk1 1669 Exon His -> Gln C A 
Map3k10 864 Exon Glu -> Gln G C 
Mapk8ip3 1537 Exon Ile -> Val A G 
Taok2 1739 Exon Arg -> Arg/Leu G G/T 
 
Their positions relative to functional domains in those proteins are shown in Fig. S7. 
Except for those in Mapk8ip3, the mutations identified in Trp53, Pdpk1, Map3k10 and 
Taok2 are located in the function-related protein domain (Appendix Figure 12A-E). 
Many mutations in those genes have been reported in human cancer. A few mutations in 
human cancer that are located in close proximities/correspond to those in CHO cell lines 
are shown in Appendix Figure 12F-J. Except for Taok2, the other four mutations were 
homozygous in all cell lines. These same mutations were also observed at genome level 
in CHO K1 [173] and rDG_2 (unpublished data) cell lines compared to the Chinese 
hamster genome [174]. These mutations probably occurred very early in the 
establishment of CHO cell line. 
7.3.4  Variant in Product Gene Not Detected 
Protein sequence variants in the product may be caused by mutations in the product gene 
[175,176]. The presence of such variants, even at small levels, causes grave concern. The 
great depth of coverage of product transcript in high producing cells allows for the 
detection of low levels of SNVs at a high confidence level. Three high confidence 
variants in the IgG transcripts in rDG_2 (coverage depth > 20,000) were detected at a low 
frequency (< 4.5 %). All are located in the heavy chain of IgG. Sanger sequencing was 
performed on both cDNA and gDNA to verify the presence of variants. None of 103 
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cDNA and 110 gDNA E. coli clones sequenced revealed any variants (Appendix Table 
7). These variants, if indeed present, must be present only at very low levels. 
7.3.3  Clustering of Cell Lines by Single Nucleotide Variants 
The SNVs identified in all the cell lines were used to construct the phylogeny tree. The 
phylogeny tree generated from the SNV data grouped the cell lines derived from the same 
parent together (Figure 7.4). When a mutation first occurs, it is most likely to occur in 
one cell initially, and the vast majority of cells in the population retain the parental base 
unless the mutant cell somehow increases its representation in the population. The variant 
markers of distinct nucleotides at the same location are thus signatures of parental 
lineage.  It is interesting to see that the nucleotide variants accurately trace the lineage of 
cell lines. 
 
Figure 7.4: Lineage tracing of various CHO cell lines through sequence variant 
profiles identified using RNA-seq. 
7.4  Discussion 
In this study, vast microarray data from our previous studies were collected to provide a 
reference for transcriptome analysis. The transcript levels of genes in the central 
glycolysis pathway were compiled from fourteen CHO cell lines to allow for a handy 
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reference of “typical” expression levels and identity of isozymes involved. The 
composition of the enzymes in this pathway greatly influences cellular metabolism. 
The glycolytic isozyme profile of CHO cells was very similar to that reported for 
proliferating cells such as cancer or embryonic cells. Overall, the variability of gene 
expression level in glycolysis was high. PKM2 isoform of PK, the pivotal isozyme that 
gives fast growing cells their high flux glycolysis characteristics, was expressed at a very 
high level and varied across a wide range among different cell lines. The enzyme PFKFB, 
which plays an important role in regulating glycolysis flux, also showed variable 
expression among cell lines. How the knowledge of the expression profiles of PKM2 and 
PFKFB can be leveraged to exert better control of metabolic behavior, awaits further 
exploration.  
We took advantage of the very high level of IgG transcripts in the high producing cells 
and its great depth in RNA-seq to search for possible sequence variants at very low 
levels. Three SNVs identified in RNA-seq were either present at very low frequency that 
was not detected in our verification sequencing or false positives possibly caused by 
errors in reverse transcription or sequencing. 
The recombinant cell lines used in the study have undergone single cell cloning during 
cell line development. Upon single cell cloning, the mutations accumulated by the cloned 
cell will be present at 50% (for a heterozygous diploid cell) or at 100% for homozygous 
mutation. Excluding very low level variants, we estimated that about 4,000 sequence 
variants have accumulated in the transcripts analyzed in most cell lines. Most of those 
variants were present at or near 50% (Figure 7.3B). These SNVs include heterozygous 
base pairs originated from the animal from which CHO cells were first derived [169,170] 
or from the mutation accumulated prior to the last single cell cloning. The SNVs 
accumulated in producing cell lines at a lower frequency are likely to represent mutations 
accumulated after single cell cloning. The number is in the range of a few hundreds. 
Since those cell lines all have been passaged extensively (>> 60 generations), the 
mutation rate does not appear to be alarmingly high. This is also consistent with the fact 
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that no detectable mutation was seen in the IgG product transcript. In contrast to the cell 
line data, SNVs in the liver and brain of Chinese hamster were relatively evenly 
distributed over different frequencies. Since the animal we used to isolate liver and brain 
tissue were inbred animals for the past five decades, it is not surprising that little 
heterozygocity remains due to genetic drift in inbred animals. 
The accumulated experiences in cultivating numerous recombinant CHO cell lines have 
given us insights into their variability in growth, metabolism, and nutritional needs. The 
variability also affects the consistency of product quality produced in different clones. 
Understanding the cause of the variability and devising means to counter the variability 
will be a major step forward in cell line development. We reckon that the mutation 
frequency in the transcribed region in CHO cells is not alarmingly high, implying 
mutations in those regions may not be influential to cell line variability. It is possible that 
mutations in the intergenic regions and other epigenetic events play more significant roles 
in the variability of gene expression and the diversity of the behavior of CHO cells in 
culture. The transcriptome data can provide us with a range of expression levels that we 
can utilize to begin epigenetic exploration and to apply systems analysis to better model 
cellular processes for enhancing process robustness and product consistency. 
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Chapter 8  Concluding Remarks and Future Directions 
Energy metabolism of mammalian cells profoundly affects the performance of cell 
culture processes. Reducing the production of lactate is desirable for sustained viability 
and increased productivity of the cells in culture. The lack of understanding of the 
metabolism of the cells and ways to control it has led to inefficient processes. This thesis 
presents a systems biology approach that provides insights into cell physiology and its 
behavior in culture. Such knowledge can be used to control process culture for more 
consistent behavior.  
We showed using a mathematical model that bistability is at the heart of the glucose 
metabolism of proliferating cells including cultured mammalian cells. Such bistable 
behavior is the root cause of phenomena of metabolic shift to lactate consumption in fed-
batch culture and multiplicity of steady state in continuous culture. In fed-batch culture, 
inhibition of glycolysis by lactate accumulation and by growth rate affects the topology 
of steady state glycolysis flux. Using the model, strategies to direct the culture to desired 
metabolic fate were explored. Metabolic shift to lactate consumption in fed-batch culture 
can be robustly induced by controlling glucose at low levels, by suppressing growth rate 
of the cells, or by modulating lactate concentration in the culture. In continuous culture, 
the bistability in energy metabolism leads to distinct achievable steady state cell 
concentrations. The steady state with higher cell concentration can be reached by 
directing cells to low glycolysis flux by first cultivating the cells in fed-batch with 
glucose maintained at a low level. Alternatively, one can initially operate the continuous 
culture at low dilution rate before incrementally increasing it to higher dilution rate. 
Exploration of the model for further novel strategies to robustly control cell metabolism 
awaits.  
CHO cells exhibit a wide range of variability in gene expression of metabolic genes. 
Using such information, one can begin to use the model to predict the steady state or 
transient behavior of different CHO cell lines in culture. The insights obtained will be 
valuable for screening cell lines that can robustly shift metabolism to low glycolysis flux 
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or for selecting targets for cell line engineering. This can possibly be achieved by 
switching the isozymes of phosphofructokinase to platelet type or the isozyme of 
pyruvate kinase to M1. Alternatively one can overexpress the kinase-deficient PFKFB 
enzyme. Finally, one can consider altering the expression or modulating the activity of 
growth control genes that affect glucose metabolism such as mTOR, AMPK, and HIF1α.  
One of the biggest challenges in the process cell culture is to achieve proper and 
consistent glycosylation of the product which greatly affects its efficacy. It is known that 
glucose metabolism affects the glycosylation pattern of the product. Glucose 6-phosphate 
and fructose 6-phosphate are channeled from glycolysis to the nucleotide sugar 
biosynthesis pathways. The synthesized nucleotide sugar precursors are then transported 
to the golgi apparatus and participate in the glycosylation process. The metabolic model 
presented here can therefore be expanded to include the glycosylation pathway. The 
resulting model will be very useful for systematically studying the effect of perturbation 
in glucose metabolism and its intermediates on the glycoform profile. Importantly, the 
model can serve as a guide for future engineering of glycoproteins. 
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Chapter 10  Appendix 
10.1 Appendix Figures 
 
Appendix Figure 1: Steady state behavior of F6P-node with PFKP as the sole PFK 
isozyme expressed.  F6P-node was simulated using PFKP as the sole PFK isozyme, at 
different K/P ratios (range: 0.5-50).  In all the cases, the steady state flux of the system 
(JPFK) followed the Michaelis-Menten type of kinetics.  No multiplicity of states was 
observed in the range of K/P simulated. 
117 
 
 
Appendix Figure 2: Steady state behavior of the glycolysis flux with no loop active 
and with PFKP as the sole PFK isozyme expressed.  The steady state glycolysis flux 
was simulated using PFKP as the sole PFK isozyme, at different K/P ratios (range: 5-
100).  In all the cases, the steady state flux followed the Michaelis-Menten type of 
kinetics.  No multiplicity of states was observed in the range of K/P simulated. 
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Appendix Figure 3: Bounds of enzyme activity within which bistability in glycolysis 
is observed. Sensitivity analysis was performed on the glycolytic enzyme activity levels. 
Each enzyme level was varied individually while holding all other parameters constant. 
The values shown are normalized to the concentration of enzyme used in the original 
simulation (shown in Figure 4.2D). The range of enzyme activities in which bistability 
was observed for each enzyme are plotted. The majority of enzymes have a large range of 
enzyme activity in which bistable behavior is observed for complete glycolysis. Only few 
enzymes including HK, ALDO and GAPDH have small enzyme activity range for 
bistable behavior. 
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Appendix Figure 4: Sensitivity of the steady state behavior of glycolysis to the 
perturbations in: (A) NAD/NADH ratio (B) [Pyruvate]m/[Lactate] ratio and (C) 
[Pyruvate]m/[Alanine] ratio. 
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Appendix Figure 5: Effect of single or mixtures of PFK isozymes on the bistability in 
glycolysis. (A) Single PFKM isozyme (B) Single PFKL isozyme (C) Single PFKP 
isozyme (D) Mixtures of varying levels of PFKM and PFKP. (E) Mixtures of varying 
levels of PFKL and PFKP. (F) Mixtures of varying levels of PFKM and PFKL. 
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Appendix Figure 6: Experimental data of glycolysis rate at varying glucose 
concentration. Data from continuous culture of mouse hybridoma cells (reference [117] 
of the Supplementary Information) were used to plot the metabolic rates as a function of 
glucose concentration (A).  The continuous culture data were from a total of 14 runs and 
reported data were all from steady states with a dilution rate (or growth rate) in the range 
of 0.30 to 0.33 h
-1
.  (B) The ratio of lactate production (analogous to LDH rate) to 
glucose consumption (analogous to glycolysis rate) is shown as ∆L/∆G.  A sharp 
transition from high flux state to a low flux state can be seen (0.24 mM glucose). The 
overlapping region of high flux and low flux state resembles that of bistability (0.17-0.24 
mM).  The ∆L/∆G plot is consistent with that postulated in Warburg effect. (C-D) 
Simulation results corresponding to the glycolysis activity and ∆L/∆G shown in (A-B). 
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Appendix Figure 7: Expression levels of glycolytic isozymes across different types of 
CHO cells.  Transcript levels of isozymes of (A) PFKFB, (B) HK, (C) PFK and (D) PK 
were probed using CHO microarrays. 
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Appendix Figure 8: Strategies for guiding continuous culture to steady state with a 
low glycolysis flux. Two strategies for directing a continuous culture to low flux state are 
depicted. (A-D) Cells cultured in fed-batch with glucose maintained at 0.5 mM undergo a 
metabolic shift to low flux state. Once a low flux state is reached, the culture can be 
switched to continuous mode with a dilution rate located in the bistable region (0.033 h
-1 
in this example). The continuous culture will remain at low flux state and reaches steady 
state with a low metabolic flux and higher cell concentration. (E-D) Without controlling 
glucose at a low level, the continuous culture will reach steady state with low glycolysis 
flux only when it is operated at a low dilution rate (<0.021 h
-1
). In the low dilution rate 
region, the only existing steady states are those with low glycolysis flux. The dilution rate 
can then be incrementally increased to a final dilution rate that is located in the bistable 
region (0.033 h
-1 
in this example). The culture will remain at low flux state and settles to 
steady state with a low flux and higher cell concentration. 
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Appendix Figure 9: Schematic of single nucleotide variants in RNA Seq. 
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Appendix Figure 10: Number of mutations among CHO cell line pairs. 
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Appendix Figure 11: Chromatograms of confirmed mutations in various genes 
between DG44 and rDG_2. 
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Appendix Figure 11 (continued) 
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Appendix Figure 11 (continued) 
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Appendix Figure 12: Protein domain annotation and mutation loci of Trp53, Pdpk1, 
Map3k10, Mapk8ip3 and Taok2 in Chinese hamster (A-E) and human (F-J). 
Prediction of the protein domain was based on the NCBI conserved domain search using 
SMART protein domain analysis sever. The amino acid sequence is shown as a black 
horizontal line to the scale of protein length.  The length corresponding to 100-amino 
acid is indicated. The protein domains are annotated as rectangle or pentagon with its 
corresponding function. The mutations are annotated with red vertical lines. The 
corresponding protein alignment location of mutations in Chinese hamster cell line is 
shown with blue vertical line in the human counterpart. P53, P53 DNA-binding domain; 
STKc, catalytic domain of the protein serine/threonine kinase; PH, Pleckstrin homology-
like domain; SH3, Src Homology 3 domain of Mixed Lineage Kinases 1, 2, and 3; TKc, 
catalytic domain of protein tyrosine kinases; BAR, the Bin/Amphiphysin/Rvs  domain; 
Smc, structural maintenance of chromosomes protein domain; PARP, procyclic acidic 
repetitive protein; JNK/SAPK, Jun amino-terminal kinase/stress-activated protein kinase 
domain; PKK, polo kinase kinase domain; TM, transmembrane domain; SbcC, domain 
related in ATPase involved in DNA repair.  
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10.2 Appendix Tables 
Appendix Table 1: Fixed parameter values in the metabolic model 
Parameter 
Symbol 
Parameter Description Value Units 
Ccadp Cytosolic ADP concentration 0.54 mM 
Cmadp Mitochondrial ADP concentration 0.1 mM 
Ccatp Cytosolic ATP concentration 0.31 mM 
Cmatp Mitochondrial ATP concentration 0.1 mM 
Ccamp Cytosolic AMP concentration 0.03 mM 
Cmamp Mitochondrial AMP concentration 0.1 mM 
Cmgtp Mitochondrial GTP concentration 0.1 mM 
Cmgdp Mitochondrial GDP concentration 0.1 mM 
pHm Mitochondrial pH 8  
pHi Intracellular pH 7.3  
Mg Cytosolic magnesium concentration 0.7 mM 
MgADP Cytosolic MgADP concentration 0.46 mM 
MgATP Cytosolic MgATP concentration 2.69 mM 
Ncd Total cytosolic NAD concentration 0.32 mM 
Ndp Total cytosolic NADP concentration 0.065 mM 
Ccpi Cytosolic phosphate concentration 2.5 mM 
Cmpi Mitochondrial phosphate concentration 2.5 mM 
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Cc23p2g Cytosolic 2,3-bisphosphoglycerate concentration 3.1 mM 
Ccg16p Cytosolic glucose 1,6-bisphosphate concentration 0.1 mM 
Ccala Cytosolic alanine concentration 1 mM 
Cmcoq Mitochondrial oxidized ubiquinol concentration 1.08 mM 
Cmqh2 Mitochondrial reduced ubiquinol concentration 0.27 mM 
Ccco2 Cytosolic CO2 concentration 1.2 mM 
Cmco2 Mitochondrial CO2 concentration 21.4 mM 
Cccoash Cytosolic Coenzyme A concentration 0.02 mM 
Ccaccoa Cytosolic Acetyl-Coenzyme A concentration 0.001 mM 
Cmcoash Mitochondrial Coenzyme A concentration 0.04 mM 
Cmnad Mitochondrial NAD concentration 2.87 mM 
Cmnadh Mitochondrial NADH concentration 0.1 mM 
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Appendix Table 2: Composition of the transcript levels of several glycolysis 
isozymes at various stages of human embryonic development and cell lines. 
Enzyme Isozyme Oocyte Zygote 2cell 4cell 8cell Morula Blastocyst 
hESC 
p10 
HeLa 
           
H
e
xo
ki
n
as
e
 (
H
K
) %HK1 0 0 0 6 10 19 15 80 69 
%HK2 100 100 100 94 87 76 84 18 31 
%HK3 0 0 0 0 0 0 0 0 0 
%GCK 0 0 0 0 3 5 1 2 0 
 
          
6
-P
h
o
sp
h
o
fr
u
ct
o
-2
-
ki
n
as
e
/f
ru
ct
o
se
-2
,6
-
b
is
p
h
o
sp
h
at
as
e
 (
P
FK
FB
) %PFKFB1 9 2 0 0 0 0 0 6 0 
%PFKFB2 65 57 78 69 11 22 7 20 57 
%PFKFB3 9 7 7 9 87 65 0 12 17 
%PFKFB4 16 34 15 22 2 13 93 62 27 
 
          
P
h
o
sp
h
o
fr
u
ct
o
ki
n
as
e
 (
P
FK
) %PFKL 1 4 5 2 4 10 51 20 14 
%PFKM 9 5 6 4 17 42 9 50 52 
%PFKP 90 91 89 94 78 48 39 30 34 
 
          
P
yr
u
va
te
 k
in
as
e
 (
P
K
) 
%PKL 0 0 0 0 0 0 0 0 0 
%PKR 0 0 0 0 0 0 0 0 0 
%PKM1 67 64 63 50 17 12 4 6 11 
%PKM2 33 36 37 50 83 88 96 94 89 
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Appendix Table 3: Composition of transcript levels of glycolysis isozymes in various mouse organs and cell lines. 
  
 Bladder Cerebellum Cortex Frontal 
Lobe 
Colon Heart Large 
Intestine 
Lung Small 
Intestine 
Spleen Testis Thymus MEL 10T1/2 
%PKM1 60 89 87 84 11 92 12 21 6 8 75 94 22 13 
%PKM2 40 11 13 16 86 8 73 79 78 90 25 6 67 87 
%PKL 0 0 0 0 2 0 14 0 15 1 0 0 5 0 
%PKR 0 0 0 0 1 0 1 0 1 1 0 0 5 0 
               
%PFKL 21 12 20 22 70 12 22 46 33 62 8 43 40 68 
%PFKM 32 69 59 54 6 85 7 32 7 12 56 29 43 28 
%PFKP 47 19 21 24 24 4 71 22 61 26 36 28 17 4 
               
%PFKFB1 7 2 3 3 4 31 4 4 1 5 5 9 6 24 
%PFKFB2 21 25 30 37 11 40 6 12 4 5 12 8 34 2 
%PFKFB3 46 48 34 33 11 21 17 40 15 52 27 68 39 2 
%PFKFB4 25 26 33 28 74 9 73 44 80 38 55 16 21 73 
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Appendix Table 4: Bounds of enzyme activity within which bistability is observed. 
Enzyme Lower bound Upper bound 
Glycolysis   
HK 0.4 2 
GPI < 0.1 > 10 
PFK 0.4 > 10 
ALDO 0.2 > 10 
TPI < 0.1 > 10 
GAPDH 0.2 > 10 
PGK < 0.1 > 10 
PGM < 0.1 > 10 
ENO < 0.1 > 10 
PK < 0.1 > 10 
LDH < 0.1 > 10 
Pentose Phosphate Pathway   
G6PD < 0.1 > 10 
6PGD < 0.1 > 10 
EPI < 0.1 > 10 
RPI < 0.1 > 10 
TK1 < 0.1 > 10 
TK2 < 0.1 > 10 
TA < 0.1 > 10 
TCA Cycle   
PDHC 0.5 2 
CS < 0.1 > 10 
ACON < 0.1 > 10 
IDH < 0.1 > 10 
AKGD < 0.1 > 10 
SCOAS 0.4 > 10 
SDH < 0.1 > 10 
FUM < 0.1 > 10 
MDH2 < 0.1 > 10 
Malate-Aspartate Shuttle Cycle   
MDH1 < 0.1 > 10 
GOT1 < 0.1 > 10 
GOT2 < 0.1 > 10 
AKGMAL < 0.1 > 10 
ASPGLU < 0.1 > 10 
Transporters   
GLUT1 < 0.1 > 10 
PYRH < 0.1 > 10 
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GLUH < 0.1 > 10 
CITMAL < 0.1 > 10 
MALPi < 0.1 > 10 
Other reactions   
PC < 0.1 > 10 
CMALIC < 0.1 > 10 
MMALIC < 0.1 > 10 
GPT1 < 0.1 > 10 
GLS < 0.1 > 10 
GDH < 0.1 > 10 
CLY < 0.1 > 10 
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Appendix Table 5: Summary of fourteen CHO cell lines used for microarray gene 
expression analysis. 
Cell Line ID Description (mRNA Source) 
1 CHO-K1 Parental CHO-K1 
2 DG44 Parental DG44 
• Exponential growth phase, adherent culture 
• Serum containing medium 
3 DXB11 Parental DXB11 
4 rDG_1 Recombinant DG44 (IgG TNF-alpha fusion protein producer) 
• Exponential growth phase, suspension culture 
• Serum free medium 
5 rDG_2 Recombinant DG44 (IgG) 
• Exponential growth phase, suspension culture 
• Serum free medium 
6 rDG_2, 
Late 
Recombinant DG44 (IgG) 
• Late phase, suspension culture 
• Serum free medium 
7 rDG_2, 
NaBu 
Recombinant DG44 (IgG) 
• Late phase, 2mM butyrate for 24 hr 
• Serum free medium 
8 rDX_1 DXB11-derived recombinant IgG producer 1 
9 rDX_1M DXB11-derived recombinant IgG producer 1 
• 20 nM MTX treatment 
10 rDX_2 DXB11-derived recombinant DHFR 
11 rDX_2M DXB11-derived recombinant DHFR 
• 20 nM MTX treatment 
12 rDX_3 DXB11-derived recombinant IgG producer 3 
13 rDX_3M DXB11-derived recombinant IgG producer 3 
• 20 nM MTX treatment 
14 rDX_4 DXB11-derived recombinant IgG TNF-alpha fusion protein 
producer 
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Appendix Table 6: Summary of five CHO cell lines and two Chinese hamster tissues 
used for single nucleotide variant analysis. 
ID Description (mRNA Source) Total Output  
DG44 Parental DG44 
• Exponential growth phase, adherent culture 
• Serum containing medium 
3.32 Gbp 
rDG_2 Recombinant DG44 (IgG) 
• Exponential growth phase, suspension culture 
• Serum free medium 
2.57 Gbp 
rDG_3,Aza Recombinant DG44 (IgG)- High Producer 
• Exponential growth phase, suspension culture 
• Serum free medium 
• 5-azacytidine treatment 
4.47 Gbp 
rDG_4H Recombinant DG44 (EPO) 
• Exponential growth phase, suspension culture 
• Serum free medium 
3.94 Gbp 
rDG_4L Recombinant DG44 (EPO) 
• Exponential growth phase, suspension culture 
• Serum free medium 
4.29 Gbp 
Brain Chinese Hamster Brain Tissue 
Brain mRNA from one late adolescent virgin female 
hamster 
4.25 Gbp 
Liver Chinese Hamster Liver Tissue 
Liver mRNA from one late adolescent virgin female 
hamster 
6.59 Gbp 
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Appendix Table 7: No variants are observed in r-IgG heavy chain upon Sanger 
sequencing. cDNA or gDNA of r-IgG heavy chain was cloned into TOPO-vector and 
transformed into E. coli.  E. coli clones on agar plates were picked and plasmids were 
purified and subjected to Sanger sequencing.  
Transcript Nucleotide 
Position 
Base 
Change 
RNA-seq 
(#Variant Reads/ 
#Consensus 
Reads) 
cDNA Sanger 
(#Variant 
Clones/ 
#Total Clones) 
gDNA Sanger 
(#Variant 
Clones/ 
#Total Clones) 
Heavy Chain 708 A → C 1,461/44,814 0/103 0/110 
Heavy Chain 785 T → G 2,237/46,909 0/103 0/110 
Heavy Chain 905 A → G 1,343/73,924 0/103 0/110 
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10.3 Appendix Materials 
10.3.1  Rate Equations 
Glycolysis 
Hexokinase (HK):   The rate equation for HK was taken from Mulquiney et al. [94]. The 
kinetic constants which correspond to those of the isozyme HK2 were adopted from 
previous literature [177-181]. The rate equation employs the partial rapid equilibrium 
random bi bi mechanism with the assumption that all the steps in the mechanism, except 
for the reactive-ternary complexes, are fast reactions. The inhibitions by g6p, glucose-
1,6-phosphate (g16bp), 2,3-bisphosphoglycerate (2,3bpg) and glutathione (gsh) were 
modeled as mixed type of inhibition affecting both the activity (Vmax) as well as the 
affinity (KM) of the enzyme for glucose. 
Eq. S1:   
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Glucose Phosphate Isomerase (GPI): The rate equation for GPI was taken from 
Mulquiney et al. [94]. The kinetic constants were adopted from previous literature [182-
184]. The rate equation employs the steady state uni uni reaction kinetics. 
Eq. S2:   
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Phosphofructokinase (PFK): The rate equation for PFK was taken from Mulquiney et 
al. [94]. The kinetic constants were adopted from previous literature [185-189]. The rate 
kinetics was based on the two state allosteric model using ordered bi bi mechanism.  The 
two state model considers that the enzyme can exist in the active or the non-active state 
as determined by the levels of the activity modulators. These include activators (f16bp, 
f26bp, g16bp, AMP etc) and inhibitors (ATP, Mg etc).  These activity modulators are 
isozyme specific.  For example, f16bp only stimulates PFKM and PFKL. The fraction of 
enzyme in the active state is represented by the nonlinear term NPFK
 
which is a function of 
the levels of the activity modulators.  LPFK represents the equilibrium constant between 
the two states of the enzyme in the absence of any substrates.  The initial velocity 
expression for the enzyme fraction in the active state was modeled as partial rapid 
equilibrium random bi bi steady state equation similar to the HK kinetics. 
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Eq. S3: 
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6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase (PFKFB):  The rate equation 
for PFKFB and the kinetic constants were taken from previously reported studies [96,97]. 
PFKFB is a bi-functional enzyme with kinase and bisphosphatase activities, each 
localized to either terminals of the enzyme and are independent of each other’s activity.  
The kinase domain catalyzes the synthesis of fructose-2,6-bisphosphate (f26bp) from 
fructose-6-phoshate (f6p) and the bisphosphatase domain mediates the hydrolysis of 
f26bp to f6p.  The reaction kinetics for the kinase domain (rPFK2) follows the ordered bi bi 
steady state kinetics, with phosphoenolpyurvate (pep) inhibition of the kinase domain 
modeled as non-competitive inhibition.  The bisphosphatase reaction kinetics (rF2,6BPase) 
was modeled as simple Michaelis-Menten kinetics with non-competitive product 
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inhibition by f6p. Isozymes of PFKFB vary in their kinase to bisphosphatase activity 
(K/P) [12]. The effect of isozyme (or K/P) was modeled by changing the Vmax of rPFK2 
and holding rF2,6BPase constant. 
Eq. S4: 
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Aldolase (ALDO):  The rate equation for ALDO was taken from Mulquiney et al. [94]. 
The kinetic constants were adopted or estimated from previous literature [190-199]. The 
reaction kinetics of ALDO follows the ordered uni bi steady state kinetics.  Inhibition due 
to 2,3bpg as described in the original expression was retained in this study. However, 
since 2,3bpg is not a reaction intermediate considered in the model, its concentration was 
held constant for the purpose of this study. 
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Eq. S5: 
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Triose Phosphate Isomerase (TPI): The rate equation for TPI was taken from 
Mulquiney et al. [94]. The kinetic constants were adopted from previous literature 
[191,200-202]. The rate kinetics of TPI follows a simple steady state uni uni reaction 
kinetics. 
Eq. S6: 
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Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH): The rate equation for 
GAPDH was taken from Mulquiney et al. [94]. The kinetic constants were adopted from 
previous literature [203-206]. The rate kinetics of GAPDH follows the ter ter (bi uni uni 
bi ping pong) steady state kinetics. 
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Eq. S7: 
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Phosphoglycerate Kinase (PGK): The rate equation for PGK was taken from 
Mulquiney et al. [94]. The kinetic constants were adopted from previous literature [207-
210]. The rate kinetics of PGK follows the partial rapid equilibrium random bi bi steady 
state kinetics.  
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Eq. S8: 
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Phosphoglycerate Mutase (PGM): The rate equation for PGM was taken from 
Mulquiney et al. [94]. The kinetic constants were adopted from previous literature 
[211,212]. The rate kinetics of PGM follows the uni uni steady state kinetics. 
Eq. S9: 
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






 
Enolase (ENO): The rate equation for ENO was taken from Mulquiney et al. [94]. The 
kinetic constants were adopted from previous literature [213-215]. The rate kinetics of 
ENO follows the partial rapid equilibrium random bi bi steady state kinetics. 
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Eq. S10: 
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, ,, , , ,
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 
 

 
 
Pyruvate Kinase (PK): The rate equation for PK was taken from Mulquiney et al. [94]. 
The kinetic constants were adopted from previous literature [95,216-220]. Like PFK, the 
rate kinetics of PK was based on the two state allosteric model using the ordered bi bi 
mechanism.  The two state model considers that the enzyme can exist in active or non-
active state determined by the levels of the activity modulators. These include activators 
(f16bp, pep, pyr etc) and inhibitors (ATP, ala etc).  The fraction of the enzyme in the 
active state is represented by the nonlinear term NPK
 
which is a function of levels of 
activity modulators. LPK represents the equilibrium constant between enzymes at the two 
states in the absence of any substrates.  The initial velocity expression for the enzyme 
fraction in the active state is modeled as partial rapid equilibrium random bi bi steady 
state equation. 
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Eq. S11: 
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Lactate Dehydrogenase (LDH): The rate equation for LDH and the kinetic constants 
were adopted from previous literature [94,221-223]. The kinetics of LDH was modeled as 
ordered bi bi steady state kinetics, with substrate inhibition by pyruvate. 
Eq. S12: 
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Pentose Phosphate Pathway 
Glucose 6-phosphate Dehydrogenase (G6PD) 
G6PD is part of oxidative pentose phosphate pathway.  Kinetics of G6PD was modeled 
as ordered bi bi steady state kinetics [224]. The rate equation for G6PD was taken from 
[225]. The kinetic constants were adopted from previous literature [226,227]. 
Eq. S13: 
 
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mf NADP g p mr pg NADPH
G PD
G PD
c c
NADPH NADP
c c c
g p NADPH NADP
c c c
pg NADPH NADP g
D
V C C V C C
r
D
C C
C C C
C C C C
  
  


     29 276 1.10*10 8.65*10c c cp NADPH NADPC C
 
6 20 -1
6 19 -1
-1
-1
*
*
4.39 10
7.48 10
G PD
mf
G PD
mr
V mM h
V mM h

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6-Phosphogluconate Dehydrogenase (6PGD): 
6PGD is part of oxidative pentose phosphate pathway.  Kinetics of 6PGD was modeled 
as ordered sequential bi ter steady state kinetics [228]. The rate equation for 6PGD was 
taken from [225]. The kinetic constants were adopted from previous literature [229,230]. 
Eq. S14: 
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Ribulose Phosphate Epimerase (RPE)  
RPE is part of non-oxidative pentose phosphate pathway.  Kinetics of RPE was modeled 
as steady state uni uni mechanism. The kinetic constants were adopted from previous 
literature [231-234]. 
Eq. S15: 
5 5
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r
V mM h
V mM h
K mM
K mM

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Ribose Phosphate Isomerase (RPI)   
RPI is part of non-oxidative pentose phosphate pathway.  Kinetics of RPI was modeled as 
steady state uni uni mechanism. The kinetic constants were adopted from previous 
literature [231,232,235,236]. 
Eq. S16: 
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r
V mM h
V mM h
K mM
K mM

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
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Phosphoribosylpyrophosphate Synthetase (PRPPS)   
PRPPS channels ribose-5-phosphate (r5p) towards nucleotide synthesis. The rate is 
relatively small portion of total PPP flux.  Kinetics of PRPPS was modeled as rapid 
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equilibrium random bi reactant system. The kinetic constants were adopted from previous 
literature [237]. 
Eq. S17: 
  
5
5 5
c c
MgATP r pPRPPS
PRPPS m PRPPS c PRPPS c
MgATP MgATP r p r p
C C
r V
K C K C

 
                                  
-1
5
25.3  
0.01 
0.57 
PRPPS
m
PRPPS
MgATP
PRPPS
r p
V mM h
K mM
K mM



 
Transketolase1 (TK1)  
TK1 is part of non-oxidative pentose phosphate pathway.  Kinetics of TK1 was modeled 
as steady state bi bi ping pong mechanism. The kinetic constants were adopted from 
previous literature [231,232,238]. 
Eq. S18: 
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
  
Transaldolase (TA) 
TA is part of non-oxidative pentose phosphate pathway.  Kinetics of TA was modeled as 
steady state bi bi ping pong mechanism. The rate equation for TA was taken from [231]. 
The kinetic constants were adopted from previous literature [232,239-241]. 
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Eq. S19: 
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Transketolase2 (TK2)  
TK2 is part of non-oxidative pentose phosphate pathway.  Kinetics of TK2 was modeled 
as steady state bi bi ping pong mechanism. The kinetic constants were adopted from 
previous literature [231,232,238,242]. 
Eq. S20: 
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Glutathione Peroxidase (GPX)  
GPX oxidizes the reduced form of glutathione (gsh) into glutathione disulfide (gssg) 
while hydrogen peroxide (H2O2) is reduced into water. Thus this reaction plays an 
important role in preventing cells from oxidative stress. The kinetics of GPX was 
modeled as first order reaction kinetics. 
Eq. S21: 
GPX c
f gshGPX V Cr                               
4 -1-1
*1.56 10GPXfV mM h  
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Glutathione Reductase (GSSGR)  
The enzyme GSSGR converts gssg back into gsh while NADPH produced in the pentose 
phosphate pathway is oxidized into NADP. The kinetics of GSSGR was modeled as 
ordered sequential steady state kinetics [243]. The rate equation for GSSGR was taken 
from [225]. The kinetic constants were adopted from previous literature [244,245]. 
Eq. S22: 
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TCA Cycle 
Pyruvate Dehydrogenase (PDH) 
The rate equation for PDH was taken from [246].  The kinetics of PDH was modeled as 
hexa uni ping pong mechanism.The kinetic constants were adopted from previous 
literature [247,248].  
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Eq. S23: 
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Citrate Synthase (CS) 
The rate equation for CS was taken from [246]. The kinetic constants were adopted from 
previous literature [249-252]. The kinetics of CS was modeled as ordered bi bi 
mechanism. 
Eq. S24: 
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Aconitase (ACON)  
The rate equation for ACON was taken from [246].  The kinetics of ACON employs the 
steady state uni uni reaction kinetics. The kinetic constants were adopted from previous 
literature [249,250,253]. 
Eq. S25: 
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Isocitrate Dehydrogenase (IDH) 
The rate equation for IDH was taken from [246].  The kinetics of IDH was modeled as 
ordered bi ter mechanism. The kinetic constants were adopted from previous literature 
[249,250,254,255]. 
Eq. S26: 
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α-Ketoglutarate Dehydrogenase (AKGD) 
The rate equation for AKGD was taken from [246].  The kinetics of AKGD was modeled 
as hexa uni ping pong ter ter mechanism. The kinetic constants were adopted from 
previous literature [249,250,256,257]. 
Eq. S27: 
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f AKGD
8
eq AKGD
AKGD 3
m akg
AKGD 3
m CoaSH
AKGD 3
m NAD
AKGD 3
a ADP
AKGD 3
i ATP
AKGD 3
i SCoA
AKGD 3
i NADH
V 2495 mMh
K 1 66 10
K 120 10 mM
K 55 10 mM
K 21 10 mM
K 100 10 mM
K 50 10 mM
K 6 9 10 mM
K 0 60 10 mM


















 
 
 
Succinyl-CoA Synthetase (SCOAS) 
The rate equation for SCOAS was taken from [246].  The kinetics of SCOAS follows the 
ordered ter ter mechanism. The kinetic constants were adopted from previous literature 
[249,250,258]. 
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Eq. S28: 
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*
*
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f SCoAS
eq SCOAS
SCoAS 3
m GDP
SCoAS 3
m SCoA
SCoAS 3
m Pi
SCoAS 3
m CoaSH
SCoAS 3
m suc
V 362 mMh
K 7 43
K 16 10 mM
K 55 10 mM
K 660 0 10 mM
K 20 10 mM
K 880 10 mM






 






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. *
. *
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SCoAS 3
m GTP
SCoAS 3
i GDP
SCoAS 3
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SCoAS 3
i Pi
SCoAS 3
i CoaSH
SCoAS 3
i suc
SCoAS 3
i GTP
K 11 1 10 mM
K 5 5 10 mM
K 100 10 mM
K 2000 10 mM
K 20 10 mM
K 3000 10 mM
K 11 1 10 mM














 
  
Succinate Dehydrogenase (SDH) 
The rate equation for SDH was taken from [246].  The kinetics of SDH was modeled as 
Theorell-Chance bi bi mechanism. The kinetic constants were adopted from previous 
literature [249,250,259-261]. 
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Eq. S29: 
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i fum
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K 1 21
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K 2 45 10 mM
K 1200 10 mM
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

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
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
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
 
 
Fumarase (FUM) 
The rate equation for FUM was taken from [246].  The kinetics of FUM was modeled as 
ordered uni uni mechanism. The kinetic constants were adopted from previous literature 
[249,250,259,262,263]. 
Eq. S30: 
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, , 1
,
, 1
, , , , ,
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







 
 







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Malate Dehydrogenase 2 (MDH2) 
MDH2 is the isoform that is present in the mitochondria. The rate equation for MDH2 
was taken from [246].  The kinetics of MDH2 employs the ordered bi bi mechanism. The 
kinetic constants were adopted from previous literature [249,250,264,265]. 
Eq. S31: 
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


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
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
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NAD/NADH Shuttles 
Glutamate Oxaloacetate Transaminase 2 (GOT2) 
GOT2 is the isoform that is present in the mitochondria. The rate equation for GOT2 was 
taken from [246].  The kinetics of GOT2 is modeled as ping pong bi bi mechanism. The 
kinetic constants were adopted from previous literature [266]. 
Eq. S32: 
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

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 
 
 
Malate Dehydrogenase 1 (MDH1)  
MDH1 is the isoform that is present in the mitochondria. The rate equation and kinetic 
constants for MDH1 were taken from [267].  The kinetics of MDH1 was modeled as 
ordered bi bi mechanism. 
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Eq. S33: 
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Glutamate Oxaloacetate Transaminase 1 (GOT1)  
GOT1 is the isoform that is present in the cytosol. The rate equation for GOT1 was taken 
from [246].  The kinetics of GOT1 was modeled as ping pong bi bi mechanism. The 
kinetic constants were adopted from previous literature [266]. 
Eq. S34: 
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α-Ketoglutarate –Malate shuttle (AKGMAL) 
The rate equation for AKGMAL was taken from [246].  The kinetics of AKGMAL was 
modeled as rapid equilibrium random bi bi mechanism. The kinetic constants were 
adopted from previous literature [268]. 
Eq. S35: 
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Aspartate –Glutamate shuttle (ASPGLU) 
The rate equation for ASPGLU was taken from [246].  The kinetics of ASPGLU was 
modeled as rapid equilibrium random bi bi with charge translocation mechanism. The 
kinetic constants were adopted from previous literature [269]. 
Eq. S36: 
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Transporters 
Glucose Transporter (GLUT):  Glucose transporters mediate transport of glucose 
across plasma membranes.  Till date, fourteen glucose transporters (isozymes) have been 
identified which perform the same function but have very different kinetic properties 
[270]. Kinetics of the GLUT1 isozyme was considered in the model and was modeled as 
uni uni steady state kinetics. 
Eq. S37: 
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Pyruvate –Hydrogen shuttle (PYRH)  
PYRH was modeled as reversible mass action kinetics. The rate equation was taken from 
[246]. 
 
163 
 
Eq. S38: 
 , c c m mPYRH m PYRH pyr pyrH Hr V C C C C                                                             
-1
,
13=   1*10m PYRHV mM h  
Citrate –Malate shuttle (CITMAL)  
CITMAL was modeled as reversible mass action kinetics. The rate equation was taken 
from [246]. 
Eq. S39: 
 , c m m cCITMAL m CITMAL cit mal cit malr V C C C C                                                        -1, 296.6  m CITMALV mM h   
Malate-Phosphate shuttle (MALPi)  
MALPi was modeled as reversible mass action kinetics. The rate equation was taken 
from [246]. 
Eq. S40: 
 , c m m cMALPi m MALPi mal Pi mal Pir V C C C C                                                                -1, 17.3  m MALPiV mM h   
Glutamate-Hydrogen shuttle (GLUH)  
GLUH was modeled as reversible mass action kinetics. The rate equation was taken from 
[246]. 
Eq. S41: 
 , c c m mGLUH m GLUH glu gluH Hr V C C C C                                                      
8 -1
, 3.87*10  m GLUHV mM h   
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Other Reactions 
Glutaminase (GLS)  
The kinetics of GLS was modeled as simple Michaelis-Menten kinetics with non-
competitive inhibition by glutamate. The kinetic constants for GLS were taken from 
[271]. 
Eq. S42: 
       
,
,
,
,
1
m
gluc
m GLS gln
eq GLS
GLS m
gluGLS c
m gln glnGLS
i glu
C
V C
K
r
C
K C
K
 
  
 
 
   
 
                                                                  
-1
,
,
,
,
38.8  
1
12
55
m GLS
eq GLS
GLS
m gln
GLS
i glu
V mM h
K
K mM
K mM
 

 
 
 
Glutamate Dehydrogenase (GDH) 
The kinetic constants for GDH were taken from [272,273].  The kinetics of GDH was 
modeled as random bi bi mechanism.  
Eq. S43: 
3
,
,
, ,3
, , ,
, ,
, 3
, 3
m m m
m m AKG NADH NH
f GDH NAD Glu
eq GDH
GDH GDH GDH mm m m
GDH GDH GDH m GDH m m m i NAD m Glu NADHGlu NAD NH
i NAD Glu m Glu NAD m NAD Glu Glu NAD GDH GDH
i AKG i NADH
GDH m m
m Glu NAD NH
GDH
i NH
C C C
V C C
K
r
K K CC C C
K K K C K C C C
K K
K C C
K
 
  
 
    
  , , , 3 , 3
, 3 , , , , 3 ,
, , , 3
, 3 , ,
GDH GDH GDH m m GDH m m m m m m
i NAD m Glu m NADH AKG NH m NAD Glu NADH Glu AKG NAD NH
GDH GDH GDH GDH GDH GDH
m NH i AKG i NADH i NADH i NH i AKG
GDH GDH GDH m m
i NAD m Glu m AKG NADH NH
GDH GDH
m NH i AKG i NADH
K K K C C K C C C C C C
K K K K K K
K K K C C
K K K
 
 , , , 3
, 3 , , ,
, , , 3 , ,
, 3 , , ,
GDH GDH GDH m m m m m m
i NAD m Glu m AKG NH AKG NADH Glu NAD AKG
GDH GDH GDH GDH GDH
m NH i AKG i NADH i AKG
GDH GDH GDH m GDH GDH m m m
i NAD m Glu m AKG NH i NAD m Glu Glu NADH AKG
GDH GDH GDH
m NH i AKG i Glu i AK
K K K C C C C C C
K K K K
K K K C K K C C C
K K K K
 
  , ,
, , ,
, , 3 , , 3
, 3 , , , 3 , , ,
GDH GDH m m
i NAD m Glu AKG NADH
GDH GDH GDH GDH
G i NADH i AKG i NADH
GDH GDH m m m GDH GDH m m m m
m NADH m Glu NH AKG NAD i NAD m Glu Glu AKG NADH NH
GDH GDH GDH GDH GDH GDH
m NH i AKG i NADH m NH i Glu i AKG i NADH
K K C C
K K K
K K C C C K K C C C C
K K K K K K K

 
GDH
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3 -1 -1
,
,
,
,
, 3
,
5.55*10
3.5 
0.04 
1.1 
6 
0.25 
f GDH
GDH
m Glu
GDH
m NADH
GDH
m AKG
GDH
m NH
GDH
i AKG
V mM h
mM
mM
mM
mM
mM
K
K
K
K
K






       
,
, 3
,
,
,
6 
3.5 
0.004 
1 
0.003eq GDH
GDH
i NH
GDH
i Glu
GDH
i NADH
GDH
i NAD
mM
mM
mM
mM
K
K
K
K
K





 
 
ATP-Citrate Lyase (CLY)  
The kinetics of CLY was modeled as ordered bi bi mechanism. The kinetic constants 
were adopted from previous literature [274-277]. 
Eq. S44: 
 
,
,
, , , ,
, ,
, ,
,
, ,
c c
m CLY cit CoASH
CLY CLY c c c c c
CLY CLY CLY c CLY c c c m cit CoASH AcCoA cit CoASH OAA
i cit m CoASH m cit CoASH m AcCoA cit cit CoASH CLY CLY
i AcCoA i OAA
CLY CLY
i cit m CoASH
m AcCoCLY CLY
m OAA i AcCoA
V C C
r
K C C C C C
K K K C K C C C
K K
K K
K
K K

    
 ,,
, ,
CLY c c c c c
CLY c CLY c m AcCoA cit OAA c c CoASH OAA AcCoA
A OAA m OAA AcCoA OAA AcCoACLY CLY
i cit i CoASH
K C C C C C
C K C C C
K K
 
     
 
  
-1 -1
,
3
3
3
3
,
,
,
,
,
,
,
,
17.5 
0.0493 
0.0475 
4.4*10  
6.1*10  
0.177 
0.177 
9.8*10  
9.8*10  
m CLY
CLY
m cit
CLY
i cit
CLY
m CoASH
CLY
i CoASH
CLY
m OAA
CLY
i OAA
CLY
m AcCoA
CLY
i AcCoA
V mM h
mM
mM
mM
mM
mM
mM
mM
mM
K
K
K
K
K
K
K
K













 
 
Mitochondrial Malic Enzyme (MMALIC)  
The rate equation and kinetic constants for CMALIC were adopted from [278]. The 
kinetics of CMALIC was modeled as ordered bi ter mechanism. 
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Eq. S45: 
2
,
,
1
m m m
pyr NADH COm m
mmalic mal NAD
eq mmalic
mmalic m
mmalic m mmalic m mmalic mmalicATP
mal mal malmmalicNAD NAD NAD
i ATP
C C C
V C C
K
r
C
K C K C K K
K

  
 
 
 
 
 
   
 
                       
-1 -1
,
,
46.3 
34.4
1.7 
0.16 
0.5 
mmalic
eq mmalic
mmalic
mal
mmalic
NAD
mmalic
i ATP
V mM h
K
mM
mM
mM
K
K
K





 
 
Cytosolic Malic Enzyme (CMALIC)  
The rate equation and kinetic constants for CMALIC were taken from [279]. The kinetics 
of CMALIC was modeled as ordered bi ter mechanism. 
Eq. S46: 
2
2
2
,
,
, , ,
, , , ,
, ,
c c c
CO pyr NADPHc c
f cmalic mal NADP
eq cmalic
cmalic cmalic cmalic cmalic c
i NADP m mal m pyr COcmalic cmalic cmalic c cmalic c c c
i NADP m mal m mal NADP m NADP mal mal NADP cmalic
m CO i pyr
C C C
V C C
K
r
K K K C
K K K C K C C C
K K
 
  
 
   
2 2 2
2 2
,, ,, ,
, , , , , , ,
cmalic
c cmalic c c ccmalic cmalic c ccmalic cmalic c
CO i CO mal mal COm mal m NADPH NADP pyri NADP m mal NADPH
cmalic cmalic cmalic cmalic cmalic cmalic cmalic
i NADPH i pyr i NADPH m CO i mal m CO i mal
C K C C CK K C CK K C
K K K K K K K K
   
2
2
2
,
, , ,,
, , , , , , ,
1
cmalic
m CO
c cc cmalic cmalic cmalic c ccmalic c c
CO pyrpyr m mal i NADP m pyr NADPH pyrm NADP mal NADPH
cmalic cmalic cmalic cmalic cmalic cmalic
i NADPH i pyr i CO i pyr i pyr i NADPH m
C CC K K K C CK C C
K K K K K K K
 
  
 
 
     
 
2
2
2 2
2 2
,
, , , , ,
, , , , ,
1
c
CO
cmalic cmalic
pyr m CO
cmalic cmalic cmalic c c cmalic cmalic c cc
m mal i NADP m NADPH CO pyr m mal m pyr NADP CONADPH
cmalic cmalic cmalic cmalic cmal
m CO i pyr i NADPH m NADPH m CO
C
K
K K K C C K K C CC
K K K K K
 
  
 
 
    
  , ,
1
c
mal
ic cmalic cmalic
i pyr i mal
C
K K
 
  
 
    
                                                                                               
2
-1 -1
,
3
3
3
3
3
,
,
,
,
,
174 
120*10  
1.4*10  
13*10  
6.4*10  
2.1*10
f cmalic
cmalic
m mal
cmalic
m NADP
cmalic
m CO
cmalic
m pyr
cmalic
m NADPH
V mM h
mM
mM
mM
mM
mM
K
K
K
K
K











    
2
4
3
3
,
,
,
,
,
,
9.6*10  
0.22 
11.7*10  
7.8 
2*10  
34.4eq cmalic
cmalic
i NADP
cmalic
i mal
cmalic
i CO
cmalic
i pyr
cmalic
i NADPH
mM
mM
mM
mM
mM
K
K
K
K
K
K









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Glutamate Alanine Transaminase (GPT) 
The rate equation and kinetic constants for GPT were taken from [280].  The kinetics of 
GPT was modeled as ping pong bi bi mechanism.  
Eq. S47: 
,
,
,
,
, ,
m m
Pyr Glum m
f GPT Ala AKG
eq GPT
GPT GPT m m GPT m m GPT m m
GPT m GPT m m m Ala AKG Glu AKG Ala Ala AKG Ala Glu
Ala AKG AKG Ala AKG Ala GPT GPT GPT
i Glu IA RG
f GPT GPT m GPT
Pyr Glu Glu P
r GPT eq GPT
C C
V C C
K
r
K C C K C C K C C
K C K C C C
K K K
V
K C K C
V K
 
  
 
    
 
,
GPT m m GPT m m
AKG Ala Pyr Pyr Glu Glum m m
yr Pyr Glu GPT GPT
i Pyr IG
K C C K C C
C C
K K
 
    
 
   
-1 -1
,
7 -1 -1
,
,
,
,
66.4 
3.97*10  
3 
0.12 
0.23 
8.1 
0.23 
2.8 
470 
96 
79.16 
2.2
f GPT
r GPT
eq GPT
GPT
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GPT
AKG
GPT
Pyr
GPT
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GPT
i Pyr
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GPT
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GPT
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GPT
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K
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K
K
K
K
K
K
K


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
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

 
Pyruvate Carboxylase (PC)  
The kinetics of PC was modeled as bi uni mechanism. The kinetic constants for PC were 
taken from [281]. 
Eq. S48: 
 
2
2 2 2 2
,
, , , ,
m
m m OAA
PC pyr CO
eq PC
PC PC PC PC m PC m m m
m pyr m CO m pyr CO m CO pyr pyr CO
C
V C C
K
r
K K K C K C C C
 
  
 
  
                             
2
-1 -1
,
,
,
718.2 
0.22 
3.2 
1
PC
eq PC
PC
m pyr
PC
m CO
V mM h
mM
mM
K
K
K




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Mono Carboxylate Transporter (MCT)  
The kinetics of MCT was modeled as ordered bi bi mechanism. The kinetic constants for 
MCT were adopted from [282,283]. 
Eq. S49: 
 ,
, , ,, , ,
, ,
, , ,
c c e e
m MCT lac lacH H
MCT MCT MCT MCT c MCT c MCT e MCT e c c
m laci lac m laci lac m laci laci H m H H m H H H
MCT c e MCT e c c c e
lac lac lace e m H H m H H H H
lac MCT MCT MCTH
i H i H ii H
V C C C C
r
K K K C K C K C K C C C
K C C K C C C C C
C C
K K K
 
     
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
  

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,
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K
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

     
3 -1 -1
4
4
4
,
,
,
,
2.73*10  
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2*10  
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m laci
MCT
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

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
 
1
m m m
Mg KH
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HATP MgATP KATP
C C C
P
K K K

               
 
1
m m m
Mg KH
ADP
HADP MgADP KADP
C C C
P
K K K

     
 
1
m m m
Mg KH
AMP
HAMP MgAMP KAMP
C C C
P
K K K

     
GTP ATPP P  
GDP ADPP P  
1
m
H
CoASH
HCoASH
C
P
K

   
 
1
m m m
MgH K
cit
Hcit Mgcit Kcit
C C C
P
K K K

     
7
4
2
2.57*10
1.51*10
1.35*10
HATP
MgATP
KATP
K M
K M
K M






 
7
3
2
3.8*10
1.62*10
2.95*10
HADP
MgADP
KADP
K M
K M
K M






 
7
2
2
6.03*10
1.38*10
8.91*10
HAMP
MgAMP
KAMP
K M
K M
K M






 
 
 
 
97.41*10HCoASHK M
  
6
4
1
2.34*10
4.27*10
4.58*10
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K M
K M
K M
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

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
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1
m
H
scoa
Hscoa
C
P
K

   
1
m m
H K
fATP
HATP KATP
C C
P
K K
 
    
1
m m
H K
fADP
HADP KADP
C C
P
K K
 
    
1
m m
H K
fAMP
HAMP KAMP
C C
P
K K
 
    
fGTP fATPP P  
fGDP fGDPP P  
41.1*10HscoaK M
  
 
 
 
 
 
 
 
 
10.3.2  Differential Equations 
Glycolysis 
1. Glucose: 
c
glc
GlcTr HK
dC
r r
dt
   
2. Glucose 6-phosphate: 
6
6
c
g p
HK GPI G PD
dC
r r r
dt
    
3. Fructose 6-phosphate: 
6
2 2 2,6
c
f p
PGI TA TK PFK F BPase PFK
dC
r r r r r r
dt
       
4. Fructose 1,6-bisphosphate: 
16
c
f bp
PFK ALD
dC
r r
dt
   
5. Fructose 2,6-bisphosphate: 
26
2 2,6
c
f bp
PFK F BPase
dC
r r
dt
   
6. Dihydroxyacetone phosphate: 
c
dhap
ALD TPI
dC
r r
dt
   
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7. Glyceraldehyde 3-phosphate: 1 2
c
gap
ALD TPI TK TK TA GAPDH
dC
r r r r r r
dt
       
8. 1,3-bisphosphoglycerate: 
1,3
c
bpg
GAPDH PGK
dC
r r
dt
   
9. 3-phosphoglycerate:     
3
c
pg
PGK PGM
dC
r r
dt
   
10. 2-phosphoglycerate: 
2
c
pg
PGM EN
dC
r r
dt
   
11. Phosphoenolpyruvate: 
c
pep
EN PK
dC
r r
dt
   
12. Pyruvate: 
c
pyr
PK LDH PYRH CMALIC
dC
r r r r
dt
       
13. Lactate: 
c
lac
LDH MCT
dC
r r
dt
   
Pentose Phosphate Pathway 
14. 6-phosphogluconate: 
6
6 6
c
pg
G PD PGD
dC
r r
dt
   
15. Ribulose 5-phosphate:  
5
6
c
ru p
PGD RPE RPI
dC
r r r
dt
     
16. Xylulose 5-phosphate: 
5
1 2
c
xyl p
RPE TK TK
dC
r r r
dt
    
17. Ribose 5-phosphate: 
5
1
c
r p
RPI PRPPS TK
dC
r r r
dt
    
18. Erythrose 4-phospahte: 
4
2
c
e p
TA TK
dC
r r
dt
   
19. Sedoheptulose 7-phosphate: 
7
1
c
s p
TK TA
dC
r r
dt
   
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20. Glutathione: 
c
glutathione
GSSGR GSHOX
dC
r r
dt
   
TCA Cycle 
21. Mitochondrial pyruvate: 1
m
pyr c
PYRH PDH mmalic PC GPT
m
dC V
r r r r r
dt V
       
22. Mitochondrial Acetyl-CoA: 
m
AcCoA
PDH CS
dC
r r
dt
   
23. Mitochondrial Citrate: 
m
cit
CS ACON CITMAL
dC
r r r
dt
    
24. Mitochondrial Isocitrate: 
m
icit
ACON IDH
dC
r r
dt
   
25. Mitochondrial Alpha-ketoglutarate: 2 1
m
akg
IDH AKGD AKGMAL GOT GDH GPT
dC
r r r r r r
dt
       
26. Mitochondrial Succinyl-CoA: 
m
SCoA
AKGD SCOAS
dC
r r
dt
   
27. Mitochondrial Succinate: 
m
suc
SCOAS SDH
dC
r r
dt
   
28. Mitochondrial Fumarate: 
m
fum
SDH FUM
dC
r r
dt
   
29. Mitochondrial Malate: 2
m
mal
FUM mmalic MDH AKGMAL CITMAL MALPi
dC
r r r r r r
dt
       
30. Mitochondrial Oxaloacetate: 2 2
m
OAA
CS MDH GOT PC
dC
r r r r
dt
      
NAD/NADH Shuttles 
31. Mitochondrial Aspartate: 2
m
asp
ASPGLU GOT
dC
r r
dt
   
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32. Mitochondrial Glutamate: 2 1
m
glu
GOT ASPGLU GDH GLUH GPT
dC
r r r r r
dt
      
33. Aspartate: 1
c
asp m
GOT ASPGLU
c
dC V
r r
dt V
     
34. Glutamate: 1
c
glu m m
GOT ASPGLU GLUH GLS
c c
dC V V
r r r r
dt V V
       
35. Oxaloacetate: 1 1
c
OAA
GOT MDH CLY
dC
r r r
dt
    
36. Malate: 
1
c
mal m m m
MDH AKGMAL CITMAL MALPi cmalic
c c c
dC V V V
r r r r r
dt V V V
         
37. Alpha-ketoglutarate: 1
c
akg m
AKGMAL GOT
c
dC V
r r
dt V
     
Other Equations 
38. Citrate: 
c
cit m
CITMAL CLY
c
dC V
r r
dt V
     
39. NAD: 1
c
NAD
LDH GAPDH MDH
dC
r r r
dt
    
40. NADP: 6 6
c
NADP
GSSGR G PD PGD cmalic
dC
r r r r
dt
     
Macroscopic Balances 
41. Extracellular glucose:  
42. Extracellular lactate: 
 
 
43. Cell concentration:      
,
, ,( )
glc extracellular
glc feed glc extracellular GlcTr
dC
D C C r x
dt
   
,
,
lac extracellular
lac extracellular MCT
dC
D C r x
dt
    
( )
dx
D x
dt
  
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44. Growth rate:  
 
 
 
 
, ,
max 2
, , , ,
glc extracellular I lac
m Glc glc extracellular I lac lac extracellular
C K
K C K C
   
 
